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Chapter 1
Glycobiology in cellular function 
All living organisms in nature are composed of the same biological building blocks, 
i.e. nucleic acids (DNA/RNA), proteins, carbohydrates and lipids. Amongst these four 
classes, the central dogma dictates that biological information ﬂ ows from DNA to RNA 
to protein. Even though DNA, RNA and proteins are needed for cellular function, it 
cannot explain the enormous complexity of life, as the number of genes is relatively 
small (~30,000). Two major major classes of biomolecules are not taken into account 
in the central dogma, namely lipids and carbohydrates. Both of which, are essential 
for cell function. While lipids play an important role in cell membrane composition, 
especially carbohydrates increase the complexity of proteins and lipids necessary for 
living organisms. The complete set of glycans and glycoconjugates that are produced 
by a cell or organism, known as the glycome, is involved in many regulatory processes 
such as cell-cell contacts, protein folding and protein trafﬁ cking (1,2). Glycosylation 
is the most complex form of post-translational protein and lipid modiﬁ cation in nature. 
The theoretical number of all possible hexamers (i.e. consisting of 6 building units) 
for glycans is 1.44 × 1015 as a result of the different monosaccharides, the glycosidic 
linkage options and the possible anomeric conformations. The complexity of the glycans 
is several orders of magnitude higher than for oligonucleotides (4096 options for an 
hexamer) or peptides (6.4 × 106 options for an hexamer) (3). The enormous glycan 
diversity arises from the thirteen monosaccharide building blocks (Fig 1A, the seven 
most common saccharides are depicted). These monosaccharides can be connected 
via a range of glycosidic linkages, with one of the two possible anomeric conﬁ gurations 
and additional chemical modiﬁ cations (acetylation, sulfonation and phosphorylation) (4). 
Around 50% of the total cellular proteome and even >90% of the secreted proteome 
is glycosylated (5). Moreover, lipids, tRNA and many secondary metabolites can be 
glycosylated as well (6). Glycosylation of proteins leads to the generation of new binding 
sites, has crucial roles in recognition events and creates the diversity required to perform 
necessary physiological tasks. Malfunctions in the glycosylation pathway are often 
associated with diseases and a thorough understanding of the process of glycosylation 
has signiﬁ cant implications in the treatment of glycosylation-related diseases.
Glycosylation of proteins
The most prominent forms of eukaryotic glycosylation processes are O-linked 
and N-linked glycosylation. Other glycosylation forms such as proteoglycans, 
phosphoglycosylation, GPI-anchors or C-linked glycosylation are beyond the scope 
of this intorduction (6). This thesis focuses on the N-linked glycosylation, which has a 
multitude of biological functions including protection of the proteins against denaturation 
and proteolysis, enhance solubility, facilitate orientation of proteins on the cell plasma 
membrane, confer structural rigidity to proteins, regulate protein turnover, ﬁ ne-tune 
the charge and iso-electric point of proteins and mediate interactions with pathogens 
(4,7). Structurally, N-glycans are covalently linked to the side-chain aminogroup of an 
asparagine, which typically resides within a deﬁ ned N-X-S/T motif of the protein (or more 
rarely N-X-C, N-X-V, or N-G sequons), where X is any amino acid except proline (8).
 The biosynthesis of glycoproteins commences when proteins entering the 
endoplasmic reticulum (ER) are covalently modiﬁ ed on the asparagine aminogroup with 
a pre-assembled oligosaccharide (Glc3Man9GlcNAc2). This 14-mer glycan is transferred, 
as a whole, from a lipid donor (dolichol) onto the nascent protein by an enzyme named 
oligosaccharyltransferase. Next, the glycan is trimmed to Man9GlcNAc2 by a range of 
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enzymes, before the glycoprotein leaves the ER. If the protein is misfolded, trimming 
is compromised and a checkpoint protein called EDEM (ER degradation-enhancing 
α-mannosidase I-like protein) will target the glycoprotein for ER degradation (9). The 
hydrophilic character of the glycan increases the solubility and prevents cleavage 
by proteases. Moreover, addition of large polar groups can make the polypeptide 
chain more rigid, which increases the stability resulting in proper folding (10).
 After passing the ER, a series of reactions further trim the glycan until Man5GlcNAc2 
is formed in the cis-Golgi (7,9) and GlcNAcMan3GlcNAc2 in the medial-Golgi. Finally, 
maturation takes place in the trans-Golgi. Three different types of N-glycans are commonly 
present on proteins; high mannose, hybrid and complex type N-glycan. Especially 
complex type N-glycans can be very diverse, an example of each type is depicted in 
Fig 1B. Synthesis of complex and hybrid N-glycans is initiated in the medial-Golgi, and 
further processed in the trans-Golgi. Addition of fucose to the N-acetylglucosamine 
adjacent to the aminogroup in the core is a common modiﬁ cation in the trans-Golgi (7). 
Other important capping reactions are the addition of sialic acids (NeuAc), galactose, 
N-acetylgalactosamine and sulfate to the branches. These capping saccharides often 
facilitate the presentation of terminal sugars to glycan binding proteins and antibodies (7). 
Figure 1. General structures of natural linked N-glycans. 
A) Chemical structures of the most common saccharides expressed in N-glycans. 
B) Three examples of mature N-glycans. A high mannose, a hybrid and a complex 
type N-glycan is depicted from left to right. Figure is adapted from Varki et al. (7). 
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Once processed by the ER and Golgi, many glycoproteins are translocated towards the 
plasma membrane. Here, the glycans are exposed to the extracellular compartment as 
ﬂ exible, hydroﬁ le branches that can reach 3 nm or more into the extracellular ﬂ uid. X-ray 
crystal structures of glycoproteins and NMR studies indicate that the majority of glycans 
have only minor contact with the protein surface (11). Within the extracellular space, the 
glycan can interact with various glycan-binding proteins, known as lectins. These proteins 
without enzymatic activity have a high degree of heterogeneity in structure and function. 
Lectin-glycan interactions are involved in many biological cellular processes such as 
apoptosis, differentiation and proliferation (12). Changes in these interactions are often 
associated with tumor formation and metastasis, but also with other diseases like nephritis 
or increased susceptibility to infections (13-16). Lectins are divided into 14 different families 
based on their folding properties and capacity to bind sugars (3,7). Most mammalian lectins 
can be classiﬁ ed into ﬁ ve major groups based on the folding of the carbohydrate binding 
module: I-type lectins, C-type lectins, P-type lectins, L-type lectins and galectins (7,12).
 For the research performed in this thesis, only the interactions of galectins 
on speciﬁ c glycoproteins were evaluated. Galectins are a family of glycan-
binding proteins characterized by their afﬁ nity for β-galactose in a speciﬁ c 
reoccurring sequence of N-acetyllactosamine (LacNAc, Gal-(β-1,4)-GlcNAc) on 
branched N-glycans. However, some galectins have a relatively weak binding 
afﬁ nity to LacNAc repeats and bind more speciﬁ c to variants of this repeat (17).
Galectins
There are 15 galectins known, of which 11 are expressed in humans. The proteins 
can be classiﬁ ed into three main subgroups; the prototypical, the chimeric and the 
tandem-repeat galectins. Galectin-1 is part of the prototypical galectin group and acts 
as a homodimer with a single carbohydrate-recognition domain (CRD) in each subunit. 
Moreover, galectin-2, -7, -10, -13 and -14 are also human prototypical galectins. 
Galectin-3 is the only protein found in vertebrates belonging to the chimeric galectin 
group, characterized by a single CRD and a large amino-terminal domain. Finally, the 
tandem-repeat galectins, galectin-4, -8, -9 and -12, have two CRD’s linked by a small 
peptide (7,18,19). The function of galectins is diverse and they can even counteract 
each other in some systems. For example, galectins can mediate cell-cell interactions, 
cell-matrix interactions, protein-protein interactions, cross-linking of proteins or 
initiate signaling cascades (20). In the kidney, only galectin-1, -3, -7, -8 and -9 are 
expressed (21,22). From these galectins, galectin-1, -3, -8, and -9 are located in lipid 
rafts, and only galectin-3 and -9 are involved in cell trafﬁ cking and endocytosis (20). 
To enhance our knowledge on glycan structure and function, adequate 
labeling techniques are required, as the complexity of these glycans is enormous. 
The conventional toolbox to visualize and investigate glycans is relatively small. 
Lately, new techniques derived from various research ﬁ elds enable glycan labeling. 
Bioorthogonal glycan labeling reactions
Special chemical reactions are often used to study the glycosylation of cells in vitro and 
eventually in mammalians (23). Such reactions have to be suitable for application in 
biological systems, indicating they should proceed under aqueous, non-toxic conditions 
at physiological temperatures (4–37 °C). Another requirement is bioorthogonality, 
meaning that the chemical reaction must occur inside living cells or systems without 
interfering with native biochemical processes. Bioorthogonal reactions include amongst 
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others the so-called chemical reporter strategy which consists of the following two steps: 
1) the introduction of a reactive component such as an azide, an alkyne, a ketone or an 
aldehyde into a biomolecule by metabolic incorporation and 2) bioorthogonal conjugation 
with a molecule of interest to impart a speciﬁ c property onto the biomolecule, e.g. a 
ﬂ uorescent group or a radioisotope label (Fig 2A). A bioorthogonal reaction enabling 
glycan labeling implies that the mutually selective chemical reactivity of the two 
functional groups ensures speciﬁ c targeting of the metabolically labeled glycans. To 
insert the reactive component the introduction of non-natural monosaccharides, such 
as N-azidoacetylmannosamine (ManNAz), with unique chemical moieties is necessary. 
Presently used bioorthogonal reactions can be divided into two major groups, the 
polar reactions (reactions in which a nucleophile adds to an electrophile, with the 
formation of a covalent bond) and the cycloadditions (a reaction in which two or more 
unsaturated molecules combine with the formation of a cyclic adduct) (24) (Fig 2 B,C). 
i) Polar reactions
Aldehydes and ketones are susceptible to nucleophilic addition of amines, leading to 
a condensation reaction (formation of a new carbon-nitrogen bond with elimination of 
water). Ketones and aldehydes are not bioorthogonal, as they are present in hormones 
such as cortisone, progesterone and testosterone (25), in the citric acid cycle and in 
monosaccharides. Despite this, the carbonyl moiety is of sufﬁ cient uniqueness for 
extracellular labeling of glycans and proteins. Ketones and aldehydes displayed on 
the cell surface can react with hydrazide- and aminooxy-derivatized ligands (26). It 
has been demonstrated that an unnatural mannosamine derivative with a keto group, 
N-levulinoylmannosamine (ManLev), can compete with endogenous ManNAc (a natural 
NeuAc precursor). Subsequently, the saccharide derivative is implemented into the 
complex glycan and presented at the cell surface. At this stage, the ketone can react 
with a hydrazide to covalently attach a biotin tag (27). An alternative method to introduce 
an aldehyde in a glycan is via periodate oxidation of the diol present in endogenous 
sialic acids and galactose. Subsequently, via oxime ligation, aminooxy-biotin can 
form a covalent bond with the newly formed aldehyde on the sialic acids at the cell 
surface (28). The drawback of the ligation reactions between hydrazide or aminooxy 
with a carbonyl group is the need for acidic conditions (pH 5–6) and high reagent 
concentrations (2–5 mM) (26,29), a combination that is often toxic for the cells. In addition, 
the reaction products, hydrazones or oximes, respectively are susceptible to hydrolysis 
thereby giving the reverse reaction. One elegant solution to avoid the reversibility of 
the condensation is by using a Pictet-Spengler reaction between an aldehyde and a 
speciﬁ c tryptamine derivative, which will give a hydrolytically stable product (30).
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The Staudinger-Bertozzi reaction is another polar reaction frequently used for protein 
and glycan labeling (Fig 2B). The reaction between an azide moiety and a phosphine 
group adjacent to a methyl ester results in an amide linkage (31). Unlike aldehydes 
and ketones, azides are completely abiotic, small, stable in water and biocompatible, 
which makes them useful for bioorthogonal ligation reactions (33,34). Monosaccharide 
analogs functionalized with an azide moiety, such as ManNAz, SiaNAz, GalNAz, FucAz 
and GlcNAz, are often used for metabolic oligosaccharide engineering (23,35). However, 
monosaccharide analogs enter the cell inefﬁ ciently as a result of their hydrophilicity 
and the low level of adequate membrane transporters at the cell membrane. The 
incorporation of these modiﬁ ed monosaccharides can be improved by converting the 
alcohol-moieties into esters with short chain fatty acids, via acetylation for example, to 
increase the hydrophobicity. Peracetylation of sugar analogs increases the metabolic 
Figure 2. Metabolic incorporation of non-natural saccharide and examples of bioorthogonal reactions. 
A) 1. Cells incubated with an azido-saccharide such as ManNAz (purple) have this sugar incorporated into the 
N-glycan of membrane expressing proteins and into glycolipids. 2. This chemical handle is used to label the 
glycan with a tag (green). B) Example of a Staudinger-Bertozzi ligation to label azido-saccharides with a tag 
(31). C) SPAAC reaction between an azide and a strained alkyne (DIBAC), forming a stable triazole ring (32). 
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incorporation efﬁ ciency by 600-fold. One disadvantage of the peracetylated sugar 
analogs is that they are 2-3 orders of magnitude more cytotoxic compared to the non-
acetylated saccharide (36). The cellular uptake, incorporation and distribution of modiﬁ ed 
saccharides into glycoproteins are tissue-speciﬁ c, as a result of the differences in 
protein and transferase expression levels (36). Moreover, the reaction kinetics of the 
Staudinger-Bertozzi ligation is rather low and the technique is hampered by oxidation of 
the phosphane (31). Yet the remarkable selectivity of this reaction and the compatibility 
with cells, tissues and animals make this reaction a popular choice for in vivo studies (37). 
ii) Cycloadditions
Next to the polar reactions used for biochemical labeling, cycloadditions are often 
applied to label glycans. The previously described azide-moieties belong to the class 
of so-called 1,3-dipoles, which can be used for cycloaddition reactions. Previously, it 
was found that the reaction rate of azides with terminal alkynes is extremely enhanced 
by using copper(I) (Cu(I)) as a catalyst (38,39). Nowadays, the most commonly used 
cycloaddition in cellular systems is the copper(I)-catalyzed alkyne–azide 1,3-dipolar 
cycloaddition (CuAAC), also referred to as the ‘click reaction’, forming robust triazoles. 
Due to the high reaction rate and simplicity, this reaction is highly desirable for its use in 
biomolecular systems. The stable alkynes and azides are one of the smallest applicable 
groups with little interference in biological systems, which makes the click reaction suitable 
for in vitro glycan labeling. However, the required Cu(I) source used to catalyze this 
reaction is highly toxic, driving the need for elimination of Cu(I) in these cycloadditions. 
Two alternatives were developed, one of these was the application of a Cu(I) ligand 
(40). An example of a Cu(I) ligand is the water-soluble THPTA, which accelerates 
CuAAC and protects the cells from damage (41). The BTTES does not only prevent 
cytotoxicity of Cu(I), but also enhances the reaction rates in zebraﬁ sh (42). Furthermore, 
using BTTAA as a ligand increases labeling speciﬁ cities both in vitro and in vivo (43).
 Another  method  to  circumvent  the toxicity of Cu(I) is via the strain-promoted 
alkyne-azide cycloaddition (SPAAC), a reaction with good kinetics in the absence of 
the Cu(I) catalyst. A range of strained alkynes has been developed with improved 
speciﬁ city and reaction rates in the absence of Cu(I). By deﬁ nition, SPAAC involves 
the reaction between an azide and a strained cyclooctyne, forming a stable triazole 
ring (Fig 2C). The most well known strained cyclooctynes are; diﬂ uorinated cyclooctyne 
(DIFO) (44), biarylazacyclooctynone (BARAC) (45), dibenzocyclooctyne (DIBO) (32), 
azadibenzocyclooctyne (DIBAC/DBCO) (46) and bicyclo[6.1.0]nonyne (BCN) (47) (Fig 
1, chapter 2). All these strained alkynes have their advantages and disadvantages, 
which are extensively reviewed (34,48). SPAAC is a popular method to label glycans on 
living cells (32,47,49) and in living organisms (50-52). The reaction rates can be even 
further improved by using different SPAAC-like reactions such as the strain-promoted 
inverse-electron-demand Diels–Alder cycloaddition (SPIEDAC) between a trans-
cyclooctyne and a tetrazine, or the similar reaction between a cyclooctene and a tetrazine 
(53,54). However, these reactions have not been used for glycan labeling thus far.
The role of glycosylation in the regulation of the calcium homeostasis 
The activity of most proteins is regulated by glycosylation, as around 50% of the total 
cellular proteome and 90% of the secreted proteome are glycosylated (5). One of 
the cell membrane proteins that is regulated via its N-glycan, is the epithelial calcium 
(Ca2+) channel transient receptor potential vanilloid type 5 (TRPV5). TRPV5, and its 
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orthologue TRPV6, are part of the large TRP ion channel family (55). These channels 
are highly selective for Ca2+ and share biophysical properties that are distinct from the 
other TRP channels (56,57). Moreover, they are known key players in the maintenance 
of the body’s Ca2+ balance and expressed in the Ca2+ transporting organs; the kidney, 
the bone and the intestine. Regulation of the Ca2+ balance is a concerted action 
balancing Ca2+ absorption with Ca2+ excretion and storage. While the bone is mainly 
used for Ca2+ storage, the kidney and intestine are involved in Ca2+ (re)absorption (55). 
Subtle dysregulation in the balance causes alterations in plasma Ca2+ levels (hyper/
hypocalcemia) that are associated with major diseases such as cardiac disease, 
osteoporosis, schizophrenia, bipolar disorder and Alzheimer’s disease (58). TRPV5 
is expressed at the resorptive surface of osteoclasts, facilitating the removal of bone 
matrix (59). In the kidney, TRPV5 is the gatekeeper of active Ca2+ transport (60,61). 
Ca2+ reabsorption in the kidney
The kidney controls the excretion of Ca2+ and thereby allows the body to adapt to 
changes in Ca2+ demands and to ﬂ uctuations in dietary Ca2+ intake via a strictly 
regulated mechanism. The Ca2+ needs in the human body varies as a result of growth, 
pregnancy or aging (62). Ca2+ plays crucial roles in many processes such as the release 
of hormones or neurotransmitters, bone mineralization and muscle contraction (63). 
 Only 1-2% of the ﬁ ltered Ca2+ is excreted by the kidney, therefore the largest 
fraction is reabsorbed along the different segments of the nephron (64,65) (Fig 3A). 
Ca2+ reabsorption is accomplished via two main mechanisms; passive paracellular and 
active transcellular transport. The majority of Ca2+ is absorbed paracellularly along the 
proximal tubule (PT) and the thick ascending limb (TAL), driven by the electrochemical 
gradient (55). Active transcellular transport (~10%) takes place in the distal convolutions 
(distal convoluted tubule (DCT) and connecting tubule (CNT)) and is responsible for the 
ﬁ ne-tuning of the ﬁ nal urinary Ca2+ excretion (55,66) (Fig 3A). The active transcellular 
transport starts with apical (luminal) inﬂ ux of Ca2+ from the pro-urine via TRPV5. To 
maintain a low cytosolic Ca2+ concentration, Ca2+ is bound by buffering proteins called 
calbindin-D28K (kidney) or calbindin-D9K (intestine). Finally, calbindin-bound Ca
2+ is shuttled 
to the basolateral side and extruded into the bloodstream via a Na+/Ca2+ exchanger 
(NCX1) and the plasma membrane Ca2+-ATPase 1b or 4 (PMCA1b, PMCA4) (Fig 3B).
 The importance of the renal transcellular Ca2+ reabsorption in the late DCT and CNT 
is illustrated by several knockout mouse models. The TRPV5 knockout (TRPV5-/-) mice 
model shows the importance of TRPV5 as the gatekeeper of the Ca2+ balance in the kidney 
(68), as these mice exhibit several phenotypical deviations correlated to a diminished active 
Ca2+ reabsorption. TRPV5-/- mice display hypercalciuria, compensatory hyperabsorption 
of dietary Ca2+ and disturbances in bone structure such as reduced trabecular and cortical 
bone thickness (68). Recently, a mice strain generated using N-ethyl-N-nitrosourea, a 
chemical mutagen causing point mutations, displayed autosomal dominant hypercalciuria 
(69). Linkage studies identiﬁ ed a heterozygous S682P mutation in TRPV5 that affects 
channel trafﬁ cking, conﬁ rming the importance of TRPV5 in Ca2+ homeostasis (69).
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Figure 3. Ca2+ reabsorption along the nephron. 
A) Paracellular transport takes place in the PT and TAL of the kidney. ~10% of the total Ca2+ reabsorption 
takes place in the DCT2/CNT where TRPV5 is expressed, illustrated in blue. This part of the kidney 
is responsible for the ﬁ ne-tuning of Ca2+ excretion. Adapted from Glaudemans et al. (67). B) TRPV5 
mediates the transcellular Ca2+ uptake from the pro-urine. In the cell, calbindin-D28K transports Ca
2+ 
to the basolateral side, where it is extruded by NCX1 and PMCA1b. Adapted from Dimke et al. (55).
The cytosolic Ca2+ levels (~ 100 nM) are low, whereas the extracellular Ca2+ levels are 
about 10.000 times higher, indicating the importance of calbindin-D28K for Ca
2+ buffering 
in the cell (56). Calbindin-D28K
-/- mice displayed normal plasma Ca2+ concentrations and 
urinary Ca2+ excretion. However, when placed on high Ca2+ diet, these mice had a two- 
to threefold increase in urinary Ca2+ (70). The modest effect on the mice phenotype 
is probably a result of the co-expression of calbindin-D9K together with calbindin-D28K 
in the kidney of mice, in contrast to humans that express calbindin-D9K mainly in the 
intestine (71). Calbindin-D9K might compensate for the calbindin-D28K loss in mice. 
Double calbindin-D28K/9K
-/- mice display reduced transcellular Ca2+ transport, based on 
changes in the phenotype (decreased bone length and serum Ca2+ levels) and the 
expression of active Ca2+ transport genes (72). Moreover, the lack in transcellular Ca2+ 
reabsorption is compensated via paracellular Ca2+ reabsorption, as the level of tight 
junction related transcripts and proteins has been increased (73). Mice ablated of NCX1 
in the distal part of the nephron are hypercalciuric, have a higher urine volume and 
lower urinary pH compared to the wild type (WT) mice. To compensate for chronic Ca2+ 
loss, the intestinal TRPV6-mediated Ca2+ absorption is increased (74). Homozygote 
PMCA1-/- mice are embryonic lethal, while heterozygous mutants show no apparent 
phenotype. PMCA4-/- mice appear normal, however the males are infertile (75).
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Structure of TRPV5 
The human TRPV5 gene, located on chromosome 7 and encoding 15 exons, is expressed 
as a membrane bound protein of 729 amino acids with a molecular mass of 83 kDa (76). 
TRPV5 consists of 6 transmembrane (TM) segments with intracellular amino (N) and 
carboxyl (C) termini (56) (Fig 4A) and is thought to function as a constitutively active 
Ca2+ channel, as Ca2+ transport is also detected in absence of a ligand or stimulus (77).
  The functional TRPV5 channel is assembled as a tetramer, with a highly Ca2+-
selective pore (78,79). The pore region is composed at the interface of the four subunits 
between TM 5 and 6. This was recently conﬁ rmed by Liao et al. who elucidated the 
tertiary structure of TRPV1, a related cation channel (80) (Fig 4B). The amino acid 
composition of the selectivity ﬁ lters of TRPV5 and TRPV6 are distinct from other TRP 
channels, explaining the more pronounced selectivity for Ca2+ over monovalent cations 
(80). The D542 residue in the selectivity ﬁ lter of TRPV5 and TRPV6 is essential for 
the Ca2+ selectivity of the channel (77) (Fig 4B). Mutating this residue into an alanine 
abolishes Ca2+ permeability without altering the permeability for monovalent cations. 
Interestingly, the positively charged H712 is highly important for constitutive internalization 
of TRPV5. Mutation of this histidine in a neutral or negatively charged amino acid 
stimulates TRPV5 activity by increasing the plasma membrane expression (81).
Figure 4. Monomeric and tetrameric topology of the TRPV5 channel. 
A) TRPV5 spans the plasma membrane 6 times, and has an intracellular C- and N-terminal tail. The 
ANK repeating domains at the N-terminal region are highlighted in pink. Glycosylation of the channel 
takes place at N358 with a complex type N-glycan. The phosphorylation sites are indicated with green 
stars (S144, S299, S654, T709). The VATTV recognition site for S100A10/Annexin 2 is highlighted in 
green, while the MLERK recognition site (highlighted in yellow) is bound by NHERF2 and 80K-H. 
Finally, the recognition site for NHERF2 is located at the end of the C-terminal region (YHF, highlighted 
in orange). B) Top view of the tetrameric TRPV5 channel. The pore consists of TM 5, 6 and the pore 
forming region, with D542 (green) as a crucial residue to mediate the Ca2+ selectivity of the pore. 
The N-terminal region of TRPV5 contains an ankyrin-repeat domain (ARD) consisting 
of 6 ankyrin (ANK) motives. These motives are involved in channel tetramerization 
(78,82,83), as they are frequently associated with protein-protein interactions. The 
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C-terminal region of TRPV5 can bind to different proteins including S100A10/annexin 
2, Ras-related protein 11a (Rab11a), protein kinase C substrate 80K-H (80K-H) and 
Na+/H+ exchanger regulatory factor 2 (NHERF2) (84-87). S100A10/annexin 2 binds to 
the VATTV amino acid sequence in the C-terminal region of TRPV5. Mutation of this 
binding site reduces TRPV5 membrane trafﬁ cking in Xenopus laevis oocytes (84). 
S100A10/annexin 2 is involved in various intracellular protein trafﬁ cking processes, 
therefore it is likely that the complex is responsible for TRPV5 routing towards the 
plasma membrane. Rab11a binds to the MLERK motif and is involved in the recycling 
of endosomes. Direct binding of Rab11a translocates TRPV5 from the endosomes to 
the plasma membrane (85). The calcium-sensing protein, 80K-H, binds to the same 
motif as Rab11a, and is postulated to increase channel activity (86). Finally, NHERF2 
binds to the YHF motif at the end of the C-terminus, thereby stabilizing TPRV5 at the 
plasma membrane, probably by linking the channel to cytoskeletal proteins (87) (Fig 4A). 
The TRPV5 channel is subjected to different posttranslational modiﬁ cations. 
Phosphorylation of TRPV5 at S144, S299, S654 and/or T709 regulates the channel activity 
(88-90). In addition, the channel is glycosylated at N358, with most likely a tetra-antennary 
complex N-glycan (91) whose exact composition remains unknown. Regulation of TRPV5 
function by this posttranslational modiﬁ cation will be extensively discussed in this thesis.
Regulation of TRPV5 by hormones, biochemical and biophysical factors
A variety of factors control TRPV5 function at three different levels i) gene/
protein expression; ii) channel activity and iii) channel plasma membrane 
expression (Fig 5). The expression of TRPV5 channels is regulated by calciotropic 
hormones including parathyroid hormone (PTH), 1,25-dihyroxy vitamin D3 
(1,25-(OH)2D3), ﬁ broblast growth factor 23 (FGF23) and estrogens (92-94). 
Figure 5. The TRPV5 channel can be 
regulated at three different levels. 
TRPV5 function can be controlled at 
three different levels:  gene/protein 
expression, channel plasma membrane 
expression and channel activity. Finally 
the protein is endocytosed and degraded.
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In addition to TRPV5 protein expression, the Ca2+ reabsorption is dependent on TRPV5 
single-channel activity. Conductance in combination with the open probability (Po) 
determine TRPV5 single-channel activity. The probability of a channel being open is 
termed Po, whereas conductance is the amount of electrical charge that is conducted 
during the open state (56). Factors inﬂ uencing single-channel activity are intracellular Ca2+, 
calmodulin (CaM), PTH, shear force and pH (95-100). Stabilization of TRPV5 at the plasma 
membrane is often regulated via glycosylation. Several factors stabilize TRPV5 on the 
plasma membrane, such as tissue transglutaminase (tTG), tissue kallikrein (TK), NHERF2, 
with-no-lysine kinase 4 (WNK4), pH, uromodulin (UMOD) and klotho (89,101-106).
Divalent ions regulate TRPV5 activity
A high intracellular Ca2+ level functions as a negative feedback mechanism and will 
inhibit TRPV5 channel activity (95). This inhibition is controlled by the concentration of 
Ca2+ in a micro-domain near the inner mouth of the channel. Recovery of TRPV5 activity 
follows after restoration of the basal Ca2+ levels (95), and depends on dissociation of 
Ca2+ from an internal Ca2+-binding site in TRPV5. Since the half maximal inhibition (IC50) 
value is in the range of the intracellular Ca2+ concentration, this effect is likely to be 
physiologically relevant. Intracellular Ca2+ sensing takes place at the C-terminal region 
of TRPV5. Removal of the last 30 amino acids desensitizes TRPV5 to intracellular Ca2+ 
concentrations (96). A second Ca2+-sensing domain is present between amino acids 
650-653 (96). Part of this Ca2+-mediated negative feedback mechanism functions via 
the binding of CaM, a binding protein that is activated upon Ca2+ binding (107). The Po 
of TRPV5 is reduced upon CaM binding (97). A high intracellular Ca2+ concentration 
enhances this CaM binding and inhibits Ca2+ uptake via TRPV5. Removal of the 
C-terminal fragment of TRPV5 (696-729) abolishes TRPV5 sensitivity by CaM (97). 
 The combined action of phosphatidylinositol 4,5-bisphosphate (PIP2) and Mg
2+ 
is an important factor involved in TRPV5 channel activity (108). Intracellular Mg2+ 
reduces TRPV5 channel activity by binding to D542, thereby blocking the pore ﬁ lter, 
resulting in a voltage-dependent TRPV5 inhibition (109). In addition, Mg2+ binding to 
the same position impedes TRPV5 channel activity via a slow inactivation mechanism 
(109). It has been hypothesized that slow inhibition is caused by a conformational 
change in the channel structure. The membrane phospholipid PIP2 reduces the slow 
inhibition by Mg2+ by preventing the Mg2+-induced conformational change of TRPV5. 
Thereby TRPV5 is stabilized in the open conformation at the plasma membrane (109).
Dual function of PTH
The primary role of the PTH-vitamin D axis is to maintain the plasma Ca2+ levels within 
a narrow range. Minor variations in extracellular Ca2+ levels are sensed by the Ca2+-
sensing receptor (CaSR) located in the parathyroid gland (110,111) and the loop of 
Henle (112). A decline in the extracellular Ca2+ concentration triggers the release 
of PTH. Subsequently, PTH acts on several organs throughout the body to maintain 
the Ca2+ balance. Elevation of plasma PTH levels increases the mobilization of Ca2+ 
from hollow trabecular bones and at the same time stimulates the 1α-hydroxylase 
(1α-OHase) activity in the kidney (92). 1α-OHase is responsible for the conversion 
of 25-hydroxyvitamin D3 into the active hormone 1,25-(OH)2D3. The active vitamin 
D hormone stimulates transcription of many proteins involved in renal active Ca2+ 
reabsorption, such as TRPV5 and calbindin-D28k (93). 1,25-(OH)2D3 functions as a 
negative feedback mechanism and lowers plasma PTH levels (94). In contrast, low PTH 
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levels resulting from allosteric activation of the CaSR via calcimimetic drugs can alter the 
expression levels of TRPV5 and calbindin-D28k independent of the 1,25-(OH)2D3 levels 
(113). This could imply that the expression of proteins involved in renal Ca2+ reabsorption 
is also directly associated with PTH levels, without the inﬂ uence of 1,25-(OH)2D3 (113). 
 Intertwined in the PTH-vitamin D axis is the hormone FGF23 via the so-called FGF23-
bone-kidney axis (92). FGF23 directly increases the PTH production, stimulating hormonal 
regulation by 1,25-(OH)2D3 and thereby stimulating Ca
2+ reabsorption (114). In addition, 
renal Ca2+ reabsorption and membrane abundance of TRPV5 are reduced in FGF23-/- mice 
(115). Binding of the assumed glycosidase klotho to the FGF receptor (FGFR) increases 
the afﬁ nity for FGF23. Next, FGF23 binding results in activation of a signaling cascade 
involving the extracellular regulating kinase 1/2 (ERK1/2), serine/threonine kinase 1 (SGK1) 
and WNK4, thereby increasing renal TRPV5 transport to the plasma membrane (115). 
 Next to the long-term effect, PTH can also act directly on TRPV5 channel 
function. Binding of PTH to its receptor initiates an increase in TRPV5 plasma membrane 
retention via activation of the protein kinase C (PKC) signaling cascade (116). This will 
result in phosphorylation of the residues S229/S654 in the TRPV5 channel, which will 
increase the plasma membrane expression. Moreover, PTH mediates phosphorylation 
of TRPV5 T709 via protein kinase A (PKA). Phosphorylation at this position diminishes 
CaM binding and thereby increases Po, stimulating TRPV5-mediated Ca
2+ transport (97). 
pH regulates TRPV5 activity
Shifts in the extracellular acid-base balance can regulate the Ca2+ balance by inﬂ uencing 
TRPV5 transcription (117). Metabolic acidosis decreases the expression of the TRPV5 
channel and leads to hypercalciuria. Moreover, metabolic acidosis in TRPV5-/- mice does 
not further inﬂ uence the hypercalciuria, implying that TRPV5 is involved in hypercalciuria 
upon metabolic acidosis (117). Chronic metabolic alkalosis increases the expression of 
Ca2+ transport proteins such as TRPV5 and calbindin-D28K in WT mice, which decreases 
the urinary Ca2+ excretion. However, this effect is not TRPV5 dependent, since this 
Ca2+ sparing effect is also present in TRPV5-/- mice. In addition, cell surface delivery of 
TRPV5 is dynamically controlled by the extracellular pH via TRPV5-containing vesicles. 
Upon extracellular acidiﬁ cation, vesicles are retrieved from the plasma membrane, 
which results in decreased TRPV5 activity, while alkylation has the opposite effect (104). 
 Single channel activity is also regulated by the pH. Two residues, E522 (located 
extracellular) and K607 (located intracellular), are involved in pH sensing (118,119). 
Protonation of either of these residues results in a change of the pore helix, reducing 
channel activity. E522 is important for extracellular pH sensing (119). Mutation of 
K607 into a non-charged residue ablates the intracellular pH sensitivity of the TRPV5 
channel (100). Intracellular acidiﬁ cation results in conformational changes of the pore 
helix, thereby closing the channel (100). The exact mechanism causing the rotation 
of the pore helix remains elusive. However, mathematical models based on the 
experimental data suggest that pH-dependent changes in channel activity is only of 
minor importance for the in vivo Ca2+ regulation (120,121). These models imply that 
the changes in TRPV5 abundance upon acidiﬁ cation contribute more to the renal Ca2+ 
wasting observed in chronic metabolic acidosis than changes in TRPV5 activity (121). 
TRPV5 activity is regulated by posttranslational modiﬁ cations
The TRPV5 channel is subjected to different posttranslational modiﬁ cations. Plasmin, 
a urokinase, stimulates TRPV5 phosphorylation at S144 (90). Thereby, the Po of the 
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channel is decreased, inhibiting TRPV5-mediated Ca2+ reabsorption. Phosphorylation 
of S299 and S654 is stimulated by serine protease TK and PTH, delaying TRPV5 
retrieval from the plasma membrane (89). PTH also stimulates the phosphorylation of 
TRPV5 T709, via the adenylyl cyclase-cAMP-protein kinase A pathway as described 
previously. Phosphorylation at this position increases the Po of the channel (88).
 As previously pointed out, TRPV5 is regulated posttranslationally via its N-glycan. 
The anti-aging protein klotho is a hormone that plays a key role in this type of TRPV5 
regulation. In the kidney, klotho co-localizes with TRPV5 and calbindin-D28k (91). Klotho is a 
single-pass transmembrane protein with the majority of amino acids located extracellularly. 
The extracellular part consists of two domains, KL1 and KL2, which shares homology to 
the family 1 glycosidases (122). Interestingly, two highly conserved residues essential 
for enzymatic activity and present in all glycosidases, are not conserved in klotho (122). 
The extracellular domain is cleaved by a disintegrin and metalloprotease (ADAM) 10 and 
17, thereby enabling klotho to enter the pro-urine, a process that is stimulated by insulin 
(123). The secreted form of klotho increases the cell surface abundance of TRPV5. 
Since the N-glycan depleted TRPV5N358Q mutant does not respond to klotho stimulation, 
klotho is expected to function via the TRPV5 N-glycan (124). Initially, it was suggested 
that klotho has β-glucuronidase activity and acts through hydrolysis of glucuronic acids 
from the TRPV5 N-glycan (124). Later, Tohyama et al. detected that klotho-mediated 
β-glucuronidase activity is approximately 26 times lower than that of the original 
β-glucuronidase (125). This ﬁ nding in combination with the fact that glucoronic acids are 
rarely present in N-glycans, makes it unlikely that klotho contains β-glucuronidase activity 
(126). Recently, Cha et al. proposed that klotho could cleave sialic acids from the TRPV5 
N-glycan. Thereby galectins, speciﬁ cally galectin-1, can bind and stabilize the tetrameric 
channel at the plasma membrane (106). Klotho does not regulate TRPV5 membrane 
expression in Chinese hamster ovarian (CHO) cells, which lack α2,6-sialyltransferase, a 
protein responsible for the synthesis of α2,6-linked glycosidic bonds between galactose 
and sialic acids. Cleavage of the sialic acids, results in exposure of a LacNAc region, 
consisting of a galactose and an N-acetylglucosamine. It is proposed that galectin-1 binds 
to this LacNAc region, preventing endocytosis, stabilizing the Ca2+ channel at the plasma 
membrane (106). The mutant CHO cell line depleted of the β1,6-N-acetylglucosamine 
branch and transfected with α2,6-sialyltransferase, is also not responsive to klotho (106). 
 tTG and shear stress also regulate TRPV5 dependent on the N-glycan of the 
channel. TRPV5 is inhibited by extracellular tTG treatment, as shown in Human embryonic 
kidney 293 (HEK293) cells over-expressing the channel (98). tTG is a Ca2+-dependent 
protein that is responsible for the speciﬁ c cross-linking of lysine and glutamine residues 
(127). It reduces the pore diameter of the channel in an N-glycan dependent manner. The 
exact mechanism and its dependence on the TRPV5 N-glycan has not been unraveled (98). 
 Shear force activates TRPV5 and TRPV6 channels, thereby increasing 
the intracellular Ca2+ concentration (99). The N-glycan-deﬁ cient TRPV5 mutant, 
however, shows reduced sensitivity to stimulation by ﬂ uid ﬂ ow (99). The molecular 
mechanism underlying the glycosylation-dependent TRPV5 regulation via shear 
force has not been elucidated. Of note, various studies emphasize the importance of 
shear force, generated by ﬂ uid ﬂ ow, and its inﬂ uence on renal tubule proteins (128).
Purpose and line of this thesis
As outlined in the introduction, protein glycosylation is of signiﬁ cant importance for 
many regulatory processes in the cell. This is reﬂ ected by the large amount of proteins 
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subjected to different complex forms of glycosylation. TRPV5 is an example of a protein 
that is regulated via its N-glycan. Since it is essential that the channel is tightly controlled, 
the N-glycan-dependent regulation is likely to be strictly organized. As a result of the 
high complexity and the poor methods for proper glycan labeling, N-glycan-dependent 
TRPV5 regulation is not well understood. The general aim of this thesis was, therefore, to 
investigate the role of the N-glycan of TRPV5 in the physiological process of renal Ca2+-
reabsorption. Chapter 2 describes a novel method for more speciﬁ c in vitro glycan labeling 
via cycloadditions. Small changes in the chemical structure of the cyclooctyne greatly aid 
in the labeling speciﬁ city via SPAAC in HEK293 cells. Increasing the hydrophilicity of the 
cyclooctyne allows more speciﬁ c TRPV5 detection via the sialic acids in its N-glycan. 
Chapter 3 elucidates on the klotho-dependent TRPV5 stimulation. Klotho increases 
TRPV5 plasma membrane expression in a caveolae-independent manner, only in 
the presence of TRPV5 its N-glycan. Sialidase, on the other hand, stimulates TRPV5 
membrane expression also in the absence of the TRPV5 N-glycan. TRPV5 plasma 
membrane stabilization after sialidase treatment is a result of reduced caveolae-mediated 
endocytosis. The importance of ß-galactosidase for TRPV5 membrane stabilization and 
thereby Ca2+ transport is outlined in chapter 4. β-galactosidase is present, as an active 
protein, in the pro-urine from where it apically can stimulates the expression of TRPV5 at the 
plasma membrane. A TRPV5 homology model, based on a previously published TRPV1 
structure is presented in chapter 5. Using the homology model, a gating mechanism for 
TRPV5 has been characterized. TRPV5 is gated via a tryptophan (W)-gate, in combination 
with a glycine (G)-hinge. Mutations at the W-gate and the G-hinge have been designed 
and characterized, showing the importance of this system for TRPV5 regulation. Finally, 
the studies presented in this thesis are summarized and discussed in chapter 6.
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Abstract
The ability of cells to incorporate azidosugars metabolically is a useful tool for extracellular 
glycan labelling. The exposed azide moiety can covalently react with alkynes, such as 
bicyclo[6.1.0]nonyne (BCN), by strain-promoted alkyne-azide cycloaddition (SPAAC). 
However, the use of SPAAC can be hampered by low speciﬁ city of the cycloalkyne. In this 
article we describe the synthesis of more polar BCN derivatives and their properties for 
selective cellular glycan labelling. The new polar derivatives [amino-BCN, glutarylamino-
BCN and bis(hydroxymethyl)-BCN] display reaction rates similar to those of BCN and 
are less cell-permeable. The labelling speciﬁ city in HEK293 cells is greater than that of 
BCN, as determined by confocal microscopy and ﬂ ow cytometry. Interestingly, amino-
BCN appears to be highly speciﬁ c for the Golgi apparatus. In addition, the polar BCN 
derivatives label the N-glycan of the membrane calcium channel TRPV5 in HEK293 cells 
with signiﬁ cantly enhanced signal-to-noise ratios.
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Introduction
Glycosylation is the most abundant form of post-translational protein modiﬁ cation in 
nature, with a wide range of functional implications. Whereas intracellular glycosylation 
contributes to signalling, dimer formation, membrane trafﬁ cking and polarised sorting 
of glycoproteins (1,2), extracellular glycans of plasma membrane proteins are involved 
in additional signalling processes, apoptosis and cell-cell contacts. The composition of 
extracellular glycans is strictly regulated by the activity of extracellular glycosidases,(3,4) 
which have important implications for the properties of membrane glycoproteins. 
Membrane stabilisation of the epithelial calcium channel, known as transient receptor 
potential vanilloid type 5 (TRPV5), for example, is closely associated with the composition 
of its N-glycan (5). Klotho, a hormone expressed in the pro-urine, can regulate TRPV5 
channel activity through modiﬁ cation of the extracellular TRPV5 N-glycan (6,7).
 Increasing interest in the biological role of cell-surface glycans has enhanced the 
development of new tools for selective labelling of extracellular glycoproteins. In particular, 
bioorthogonal reactions have numerous applications for in vitro glycan labelling.(8-10). 
This was ﬁ rst demonstrated in 2000 in a Staudinger reaction between an azide and 
a phosphine, two abiotic functional groups that are mutually reactive, but inert toward 
native biomolecular functionality (11). Despite its promises, the utility of the Staudinger 
ligation is compromised by the oxygen-sensitivity of the requisite phosphine reagents 
and the slow reaction rates (12). In the past decade, the 1,3-dipolar cycloaddition of an 
azide with a terminal acetylene in the presence of copper(I) (13,14), typically referred 
to as a “click” reaction, has been shown to react in vitro with increased reaction rates. 
However, extensive optimisation of reaction conditions might be necessary, to reduce 
concomitant oxidative damage to biomolecular structures and copper(I) toxicity, and this 
limits its application in living systems (15). In 2004, metal-free cycloaddition between 
cyclooctynes and azides, the so-called strain-promoted alkyne-azide cycloaddition 
(SPAAC), was ﬁ rst applied as a tool for bioconjugation (16). Because initial reaction rates 
were relatively low, a vast number of cyclooctyne derivatives with increased reaction rates 
were developed in subsequent years; these include dimethoxyazacyclooctyne (DIMAC)
(18), diﬂ uorocyclooctyne (DIFO) (19,20) and bisarylazacyclooctynone (BARAC) (21). 
 Currently, the most frequently used, cyclooctynes that are commercially available 
are dibenzocyclooctynol (DIBO) (22,23), dibenzoazacyclooctyne (DIBAC / DBCO) 
(23,24) and bicyclo[6.1.0]nonyne (BCN)(25) (Fig 1). These three cyclooctynes display 
moderate to high reactivity in 1,3-dipolar cycloadditions, not only with azides, but also 
with nitrones (26,27), nitrile oxides (28,29) and diazo compounds (29). Most recently, it 
was found that BCN –unlike the dibenzofused cyclooctynes DIBO and DBCO– undergoes 
(4+2) cycloaddition with diphenyltetrazine at reaction rates at least 1000 times faster 
than with the azide (30). For example, genetic encoding of BCN into green ﬂ uorescent 
protein (GFP), followed by reaction with tetrazine proved to be highly efﬁ cient (31,32).
36
Chapter 2
Figure 1. Structures of the most commonly used cyclooctynes.
Lipophilicity is a prime consideration in the selection of a particular cyclooctyne for 
bioconjugation or in vitro labelling. Under physiological conditions, hydrophobic 
interactions or thiol-yne additions (17,33) can give rise to unspeciﬁ c signals and 
compromise studies of live cell endocytosis and protein mobility. To avoid this, Bertozzi 
et al. developed a highly polar cyclooctyne (DIMAC) from a carbohydrate precursor, but 
the lengthy synthesis and attenuated reactivity have hampered its broad application (18). 
The benzoannulated cyclooctynes (DIBO, DBCO, BARAC and others) show improved 
reactivity, but at the expense of increased size and lipophilicity. To overcome this, a 
more hydrophilic, sulfonylated variant of DIBO was synthesised and shown to exhibit 
reduced unspeciﬁ c staining in human skin ﬁ broblast (34). Leeper et al. synthesised a 
more hydrophilic DIBO variant through the introduction of four methoxy substituents 
(TMDIBO); it displayed increased reaction speciﬁ city in Lewis lung carcinoma cells (35). 
A) Structure of BCN-biotin (1) and the newly developed hydrophilic BCN probes 2-4, conjugated to biotin. 
B) ﬂ uorogenic azidocoumarin (5). 
Figure 2. Structures of the synthesized derivatives.
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We reasoned that BCN, the only non-benzoannulated cyclooctynes with practical 
reactivity and straightforward synthetic accessibility, would form a logical starting 
point for the development of a more polar, potentially water-soluble cyclooctyne.
Here we report a new set of BCN-derived structures (Fig 2A) with enhanced 
hydrophilicity, retained reactivity and high labelling speciﬁ city. Three BCN variants 
were developed: amino-BCN (A-BCN, 2), glutarylamino-BCN (GA-BCN, 3) and 
bis(hydroxymethyl)-BCN (BHM-BCN, 4). In each of these variants a biotin moiety was 
attached as a functional group to enable cellular and biochemical imaging. The polarities 
of the BCN probes strongly inﬂ uence membrane permeability and reaction speciﬁ city in 
HEK293 cells, thereby leading to signiﬁ cantly improved signal-to-noise ratios (SNRs). 
In particular, the A-BCN derivative 2 was found to display selectivity in Golgi staining, 
thereby offering considerable promise for the study of glycan-controlled protein trafﬁ cking.
Experimental procedures
Reaction kinetics
1 equiv of 5 (0.5 mM) was added to 2 equiv of (1R,8S,9s)-bicyclo [6.1.0]non-4-yn-9-
ylmethanol, 1, 2, 3 or 4 (1 mM) in MeCN:H2O 1:2. After 1, 2, 4, 8, 15, 30 and 45 min 10 
µl was taken and diluted 400 times in MeCN:H2O 1:2. Fluorescence was measured (ex: 
395 nm, em: 460 nm) on a LS55 Perkin Elmer ﬂ uorescence spectrometer. 
Fluorescence confocal microscopy. 
HEK293 cells were plated on 12 mm glass coverslips coated with 50 µg/ml ﬁ bronectin 
(Roche Diagnostics, Mannheim, Germany). Next, they were treated for 48 h with 60 µM 
Ac4ManNAz, or left untreated. The cells were washed once with with ice-cold PBS (pH 
8.0, adjusted with NaOH) containing 1 mM MgCl2 and 0.5 mM CaCl2 (PBSB) and treated 
with 60 µM 1, 2, 3 or 4 in PBSB for 1 h at RT. After incubation, the cells were washed 
three times with PBSB and ﬁ xed with 1% (w/v) paraformaldehyde (Sigma-Aldrich, St. 
Louis, MO, USA) in PBS for 5 min. Afterwards, the cells were washed twice with PBS 
and permeabilised for 10 min using 0.3% (v/v) Triton X-100, 0.1% (w/v) Bovine Serum 
Albumin (BSA) (Sigma life Science, St. Louis, MO, USA) in PBS. Finally, the cells were 
incubated with 50 mM NH4Cl (Merck, Boom B.V. Meppel, Darmstadt, Germany) in PBS for 
15 min and washed with PBS. After incubation for 30 min at RT with goat serum dilution 
buffer (GSDB; 16% goat serum, 0.3% (v/v) triton X-100 and 0.3 M NaCl in PBS), the 
cells were incubated overnight with a Golgi 58K antibody (Sigma, Saint Louis, Missouri, 
USA)(1:800) at 4 °C in GSDB. The cells were then washed with PBSB and incubated 
with a combination of streptavidin-Alexa Fluor 488 (Invitrogen, Eugene, OR, USA)
(1:200) and Alexa Fluor 647 conjugated to goat anti-mouse IgG (Invitrogen, Eugene, 
OR, USA) (1:2000) in PBSB for 1 h. The cells were washed twice with PBS and stained 
with 4’,6-diamidino-2-phenylindole (DAPI, Roche Diagnostics, Mannheim, Germany) in 
PBSB for 10 min. After three wash steps with PBSB, the coverslips were attached to a 
glass microscope slide with polyvinyl alcohol (Mowiol; Hoechst, Frankfurt, Germany). 
Cells were imaged using an Olympus FV1000 Confocal laser scanning microscope with 
the 488 nm argon laser, the 405 nm and the 635 nm diode lasers. Images were acquired 
using Olympus FluoView software.
FACS analysis. 
HEK293 cells were incubated for 48 h with or without 60 µM Ac4ManNAz. Next, cells were 
detached using 0.02% EDTA (Merck, Darmstadt, Germany) in PBS. After centrifugation 
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(1250 rpm, 4 min), the cells were washed twice with PBS and plated on a 96-well cell 
culture plate. The cells were resuspended and incubated with 60 µM of 1, 2, 3 or 4 in PBS 
for 1 h at 4, 20 or 37 °C. After centrifugation and three wash steps with PBS, the cells 
were incubated for 30 min at 4°C in streptavidin-Alexa Fluor 488 (Invitrogen, Eugene, OR, 
USA) (1:200) in PBS. Finally, the cells were washed twice with PBS and once with PBS 
enriched with 0.5% (w/v) BSA and suspended in a total volume of 400 µl PBS. Just prior 
to analysis, 2.5 µg/ml propidium iodide (MACS, Miltenyi Biotec Inc. Auburn, CA, USA) 
was added to the cells. The cells were analyzed by ﬂ ow cytometry using FACSCalibur 
(Becton Dickinson BD Biosciences, California, USA) with BD CellQuestTM Pro software. 
Images were acquired using FCS Express 4 Plus research edition (De Novo software).
DNA constructs
The pCINeo/IRES-GFP plasmid encoding TRPV5 was generated as described 
previously (36). All constructs were veriﬁ ed by DNA sequence analysis. HEK293 cells 
were transiently transfected with the relevant DNA constructs using Lipofectamine 
TM2000 (Invitrogen, Carlsbad, CA, USA), following the manufacturer’s instructions.
Immunoblotting 
TRPV5 protein expression was determined with 8 % (w/v) SDS-PAGE and Western-
blotting, using anti-HA (6E2) (Cell Signalling Technology, Danvers, MA, USA)(1:5000), 
and peroxidase-labeled goat anti-mouse IgG (1:10.000, Sigma-Aldrich, St. Louis, MO, 
USA) antibodies. 
Plasma membrane biotinylation
HEK293 cells were transiently transfected with TRPV5 in pCINeo/IRES-GFP or the empty 
pCINeo/IRES-GFP vector (mock) and cultured for 2 days in the presence or absence of 
60 µM Ac4ManNAz. Next, cells were washed twice with ice-cold PBSB and biotinylated 
via treatment with 60 µM of 1, 2 or 3 in PBSB for 1 h at RT. The cells were then washed 
three times with ice-cold PBSB and disrupted in 1 ml lysis buffer [1 % (v/v) NP-40, 150 
mM NaCl, 5 mM EDTA, 50 mM Tris (pH 7.5 adjusted with HCl), 1 mM PMSF, 10 µg/ml 
leupeptin, 10 µg/ml pepstatin, 5 µg/ml proteinase A]. TRPV5 protein expression containing 
the azido-glycan and in total cell lysate was investigated as described previously (5).
Reversed-Phase HPLC 
RP-HPLC, on a C18 150 mm long column (prodigy ODS-3 C18, Phenomenex, Torrance, 
CA, USA), used 50 mM phosphate buffer adjusted to pH 7.4 as mobile phase A and 
MeCN as mobile phase B, at 1 ml/min. A run of 50 min with 95% mobile phase A up to 
80% of phase B over 30 min, was used to detect the retention time of the compounds. The 
compounds were detected using the 214 nm detector. The RP-HPLC was performed on a 
Shimadzu LC-20A Prominence system (Shimadzu, ‘s-Hertogenbosch, The Netherlands).
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Synthesis
(1R,8S,9s)-bicyclo [6.1.0]non-4-yne-9-carbaldehyde (6)
To (1R,8S,9s)-bicyclo [6.1.0]non-4-yn-9-ylmethanol (0.499 g; 3.32 mmol; 1.0 
equiv.) dissolved in DCM (330 ml) was added Dess-Martin periodinane (2.10 
g; 4.95 mmol; 1.5 equiv.). The reaction mixture was stirred for 2 h at RT. The 
complete reaction mixture was ﬁ ltered over celite and immediately used for 
further synthesis.
N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2- oxohexahydro-1H-
thiono[3,4-d]imidazol-4-yl)pentanamide (Biotin-amine) (7)
To 2,2’-(ethane-1,2-diylbis(oxy))
diethanamine (4.55 ml; 30.7 mmol; 
3.0 equiv.) dissolved in DMF 
(700 ml) was added dropwise a 
solution of biotin-OSu (3.5 g, 10.3 
mmol; 1.0 equiv.) in DMF (700 ml). 
The reaction mixture was stirred 
overnight at RT. The solvent was 
removed in vacuo and the crude product was puriﬁ ed by silica column 
chromatography with 7N ammonia in MeOH: MeOH: DCM / 2:13:85 as the eluent to 
give the title compound as a white solid. Yield 2.66 g (69%), Rf 0.40 (7N ammonia in
MeOH: DCM / 1:4).
1H NMR (DMSO-d6, 300 MHz): 7.84 (m, 1H), 6.42 (s, 1H), 6.35 (s, 1H), 4.33–4.29 (m, 
1H), 4.15–4.11 (m, 1H), 3.51 (s, 4H), 3.38 (q, J = 6.0 Hz, 4H), 3.18 (q, J = 6.0 Hz, 
3H), 3.11–3.07 (m, 1H), 2.79, 2.83 (2 × d, J = 6.0 Hz, 1H), 2.67 (t, J = 5.7 Hz, 2H), 
2.06 (t, J = 7.2 Hz, 2H), 1.68–1.37 (m, 4H), 1.37–1.24 (m, 2H).  13C NMR (DMSO-d6, 
75 MHz): 172.1, 162.7, 72.5, 69.5 (2C), 69.1, 61.0, 59.2, 55.4, 41.1, 40.3, 40.1, 35.1, 
28.2, 28.0, 25.2. IR (cm-1): 3278, 2924, 2855, 1692, 1645, 1260, 1113, 698, 594. [ESI-
MS]: calculated for C16H30N4O4S, 374.20, found: (M+H
+) 375.21 and (M+Na+) 397.19.
N-(2-(2-(2-(((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyl)amino)ethoxy)
ethoxy)ethyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)
pentanamide (A-BCN) (2)
Biotin-amine (7) (1.25 g; 3.32 
mmol; 1.0 equiv.) and sodium 
cyanoborohydride (0.775 g; 3.66 
mmol; 1.1 equiv.) were dissolved in 
DCM (15 ml). 6 (0.493 g; 3.33 mmol; 
1.0 equiv.) dissolved in DCM (330 ml) 
was added dropwise. 0.1 M aqueous 
sodium hydroxide solution (300 ml) 
was added to the reaction mixture. The aqueous layer was extracted with DCM (3 × 
100 ml). The combined organic washings were dried (Na2SO4), and the solvent was 
removed in vacuo. The residue was puriﬁ ed by silica column chromatography with 7N 
ammonia in MeOH: DCM / 1:99  2:98  5:95 as the eluent to give the title compound 
as a yellow solid. Yield 695 mg (41%), Rf 0.60 (7N ammonia in MeOH: DCM / 1:4) (37).
1H NMR (CDCl3, 300 MHz): 6.85 (m, 1H), 6.57 (s, 1H), 5.61 (s, 1H), 4.46 (m, 1H), 4.28 (m, 
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1H), 3.58 (s, 4H), 3.57–3.52 (m, 4H), 3.43–3.38 (m, 3H), 3.10 (sex, J = 4.5 Hz, 1H), 2.84, 
2.90 (2 × d, J = 6.0 Hz, 1H), 2.78, (t, J = 5.1 Hz, 2H), 2.64, (d, J = 7.2 Hz, 2H), 2.27–2.13 
(m, 7H), 2.05–1.35 (m, 10H), 1.21–1.02 (m, 1 H), 0.86–0.79 (m, 2H). 13C NMR (CDCl3, 75 
MHz): 173.5, 164.2, 99.1 (2C), 70.7, 70.3 (2C), 70.2, 62.0, 60.4, 55.8, 49.4, 45.7, 40.7, 
39.3, 36.2, 29.3 (2C), 28.3, 25.8, 21.7 (2C), 21.5, 19.6 (2C), 19.4. IR (cm-1): 3283, 2920, 
2846, 1701, 1640, 1550, 1243, 1117, 728. [ESI-MS]: calculated for C26H42N4O4S, 506.29, 
found: (M+H+) 507.30; (M+Na+) 529.28.
6-((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyl)-5,16-dioxo-20-((3aR,4R,6aS)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-9,12-dioxa-6,15-diazaicosan-1-oic 
acid (GA-BCN) (3)
To a solution of 2 (121 mg; 0.240 
mmol; 1.0 equiv.) in DCM (30 ml) 
were added 4-(dimethylamino)
pyridine (20.4 mg; 0.167 mmol; 0.7 
equiv.) and glutaric anhydride (51.8 
mg; 0.462 mmol; 1.9 equiv.). The 
resulting mixture was stirred for 
16 h at RT. The organic layer was 
washed with 30 ml 0.1 M aqueous 
hydrochloric acid. The aqueous 
layer was extracted with DCM (30 mL) and the combined organic layers were dried over 
Na2SO4. The solvent was removed in vacuo and the crude product was puriﬁ ed by silica 
column chromatography with MeOH: DCM / 1:15 with 1% acetic acid as the eluent to 
give 3 as an opaque colorless oil. Yield 116 mg (78%), Rf 0.13 (7N ammonia in MeOH: 
DCM / 1:4). 
1H NMR (CDCl3, 300 MHz): 8.07 (s, 1H), 7.14 (m, 1H), 6.84 (m, 1H), 5.70 (s, 1H), 4.54 
(m, 1H), 4.38 (m, 1H), 3.61 (s, 4H), 3.68–3.36 (m, 8H), 3.20 (q, J = 7.2 Hz, 1H), 2.92, 2.98 
(2 × d, J = 6.0 Hz, 1H), 2.77 (t, J = 6.9 Hz, 5H), 2.54, (t, J = 7.2 Hz, 2H), 2.48–2.16 (m, 
6H), 2.04 (m, 4H), 1.81–1.63 (m, 4H), 1.54–1.43 (m, 4H), 1.27–1.15 (m, 1H), 0.99–0.86 
(m, 2H). 13C NMR (CDCl3, 75 MHz): 175.1, 174.1, 173.4 (2C), 99.0, 98.9, 71.1, 70.9, 
70.3, 68.7, 62.1, 60.6, 55.6, 46.6, 45.3, 44.5, 40.6, 39.5, 35.9, 32.4, 29.3 (2C), 28.2, 25.7, 
21.5 (2C), 20.8, 19.7 (2C), 19.5, 17.6. IR (cm-1): 3291, 2920, 1697, 1636, 1450, 1264, 
1126, 733. [ESI-MS]: calculated for C31H48N4O7S, 620.32, found: (M+H
+) 621.32; (M+Na+) 
643.31.
(Z)-diethyl bicyclo[6.1.0]non-4-ene-9,9-dicarboxylate (8)
To a solution of 1,5-cyclooctadiene (3.29 mL; 26.8 mmol; 5.0 
equiv.) and rhodium(II) acetate (23.3 mg; 0.053 mmol; 0.2 
mol%) in DCM (5 ml) was added dropwise a solution of diethyl 
2-diazomalonate (1.00 g; 5.39 mmol; 1.0 equiv.) in DCM (5 ml) 
under nitrogen conditions. The mixture was stirred for 24 h at 
RT. The solvent was removed in vacuo and the crude product 
was puriﬁ ed by silica column chromatography (pentane as the ﬁ rst eluent to remove 
1,5-cyclooctadiene  ethyl acetate: pentane / 1:10 as the second eluent) to give the 
compound as colorless oil. Yield 893 mg (62%), Rf 0.31 (ethyl acetate: heptane / 1:10) (25).
1H NMR (CDCl3, 300 MHz): 5.60–5.53 (m, 2H), 4.16 (q, J = 6.9 Hz, 2H), 4.10 (q, J = 6.9 
Hz, 2H), 2.35–2.29 (m, 2H), 2.11–2.05 (m, 4H), 1.80–1.68 (m, 4H), 1.26 (t, J = 7.2 Hz, 3H), 
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1.21 (t, J = 7.2 Hz, 3H). 13C NMR (CDCl3, 75 MHz): 171.3, 167.7, 129.6 (2C), 61.6, 61.1, 
39.3, 31.3 (2C), 27.0 (2C), 24.7 (2C), 14.3 (2C). IR (cm-1): 2980, 1718, 1316, 1260, 1217, 
1169, 1104, 1027, 715. [ESI-MS]: calculated for C15H22O4 266.15, found: (M+Na+) 289.14.
Bicyclo[6.1.0]non-4-ene-9,9-diyldimethanol (9)
To a suspension of lithium aluminium hydride (294 mg; 7.75 mmol; 2.1 
equiv.) in diethyl ether (25 ml) was added dropwise, a solution of 8 (966 
mg; 3.63 mmol; 1.0 equiv.) in diethyl ether (10 ml). The suspension 
was stirred for 15 min at RT. The reaction mixture was cooled to 0°C 
and water (10 ml) was added carefully until the grey solid turned white. 
The solid was ﬁ ltered and washed thoroughly with diethyl ether (50 ml). The aqueous and 
organic layers were separated and the aqueous layer was extracted with diethyl ether (3 
× 50 ml). The combined organic layers were dried over Na2SO4. The solvent was removed 
in vacuo and the crude product was puriﬁ ed by silica column chromatography with ethyl 
acetate: pentane / 2:1 as the eluent to give (Z)-bicyclo[6.1.0]non-4-ene-9,9-diyldimethanol 
as a white solid. Yield 546 mg (83%), Rf 0.25 (ethyl acetate: heptane / 2:1) (25).
Bicyclo[6.1.0]non-4-yne-9,9-diyldimethanol (10) 
To a solution of 9 (546 mg; 3.00 mmol; 1.0 equiv.) in DCM (30 ml) was 
added dropwise at 0°C, a solution of bromine (0.290 ml; 5.63 mmol; 
1.8 equiv.) in DCM (10 ml). The reaction mixture was quenched with a 
10% sodium thiosulfate solution (15 ml), extracted with DCM (2 × 20 
ml) and combined organic layers were dried over Na2SO4. The solvent 
was removed in vacuo and the crude product (4,5-dibromobicyclo[6.1.0]nonane-9,9-diyl)
dimethanol) was puriﬁ ed by silica column chromatography with ethyl acetate: pentane 
/ 10:1 as the eluent to give the title compound as a white solid. Yield 705 mg (69%), Rf 
0.35 (ethyl acetate: heptane / 10:1) (25). Next, to a solution of (4,5-dibromobicyclo[6.1.0]
nonane-9,9-diyl)dimethanol) (201 mg; 0.588 mmol; 1.0 equiv.) in THF (25 ml) was added 
dropwise at 0°C a solution of 1 M potassium tert-butoxide (2.57 ml; 2.57 mmol; 4.4 equiv.) 
in THF and the reaction mixture was reﬂ uxed for 2 h. This experiment was carried out 
under nitrogen conditions, with dry solvents and oven dry glassware. After cooling down 
to RT, the reaction mixture was quenched with saturated aqueous ammonium chloride 
solution (20 ml) and extracted with DCM (3 × 20 ml). The combined organic layers were 
dried over Na2SO4. The solvent was removed in vacuo to give the title compound as an 
opaque colorless solid. Yield 101 mg (66%), Rf 0.26 (ethyl acetate: heptane / 10:1) (25).
1H NMR (CDCl3, 300 MHz): 3.88 (s, 2H), 3.62 (s, 2H), 2.34–2.16 (m, 6H), 1.68–1.56 (m, 
2H), 0.88–0.79 (m, 2H). 13C NMR (CDCl3, 75 MHz): 98.9 (2C), 73.7, 63.5, 30.7, 29.7 (2C), 
26.3 (2C), 21.5 (2C). [ESI-MS]: calculated for C11H16O2, 180.24, found: (M+Na+) 203.10517.
Spiro[bicyclo[6.1.0]non[4]yne-9,5’-[1,3]dioxan]-2’-one (11)
This experiment was accomplished under nitrogen conditions, with dry 
solvents and oven dry glassware. To a solution of 10 (115 mg; 0.588 mmol; 
1.0 equiv.) and pyridine (0.127 ml; 1.60 mmol; 2.7 equiv.) in THF (20 ml) at 
-78°C, was added a solution of triphosgene (74.8 mg; 0.253 mmol; 0.4 
equiv.) in DCM (20 ml). The reaction mixture was warmed to RT and 
continued to stir for 1 h. The solvent was removed in vacuo and the crude 
product was puriﬁ ed by silica column chromatography (ethyl acetate: 
pentane / 1:4  1:1 as the eluent) to give the title compound as a white 
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solid. Yield 41.2 mg (34 %), Rf 0.24 (ethyl acetate: heptane / 1:1) (38).
1H NMR (CDCl3, 300 MHz): 4.36 (s, 2H), 4.17 (s, 2H), 2.36–2.21 (m, 6H), 1.62–
1.47 (m, 2H), 1.14–1.05 (m, 2H). 13C NMR (CDCl3, 75 MHz): 149.3, 98.4 (2C), 68.9 
(2C), 28.9 (2C), 25.9 (2C), 21.9, 21.0 (2C). IR (cm-1): 2920, 2846, 1744, 1407, 1264, 
1169, 1130. [ESI-MS]: calculated for C12H14O3, 206.09, found: (M+Na
+) 229.08493. 
(9-(hydroxymethyl)bicyclo[6.1.0]non-4-yn-9-yl)methyl (2-(2-(2-aminoethoxy)
ethoxy)ethyl)carbamate (12)
To a solution of 11 (20 mg; 0.097 mmol; 1.0 
equiv.) in MeCN (2 ml) was added 2,2’-(ethane-
1,2-diylbis(oxy))diethanamine (0.044 ml; 0.294 
mmol; 3.0 equiv.), this mixture was stirred for 
24 h at RT. The reaction mixture was warmed to 
50 °C and stirred continuously for 12 h. Water 
(10 ml) and DCM (10 ml) were added to the reaction mixture and the aqueous layer was 
extracted with DCM (2 × 10 ml). The combined organic layers were dried over Na2SO4. 
The solvent was removed in vacuo and the crude product was puriﬁ ed by silica column 
chromatography (7N ammonia in MeOH: DCM / 2:98  5:95 as the eluent). This synthesis 
yielded 12 as a white solid. Yield 14.9 mg (43%). The product was obtained as a mixture 
of diastereomers.
1H NMR (CDCl3, 300 MHz): 5.54–5.49 (m, 1H, both diastereomers), 4.26 (s, 1H), 4.00 
(s, 1H), 3.63–3.54 (m, 7H), 3.49 (t, J = 5.0 Hz, 2H), 3.39–3.35 (m, 3H), 2.85 (t, J = 5.2 
Hz, 1H, diastereomer 1), 2.84 (t, J = 5.2 Hz, 1H, diastereomer 2), 2.26–2.14 (m, 8H), 
1.63–1.57 (m, 2H), 0.85–0.81 (m, 2H). 13C NMR (CDCl3, 75 MHz): 157.4, 98.8 (2C), 73.4, 
70.4 (2C), 70.1, 69.4, 59.2, 41.9, 41.1, 29.5, 29.3 (2C), 26.3 (2C), 21.5 (2C).
(9-(hydroxymethyl)bicyclo[6.1.0]non-4-yn-9-yl)methyl (2-(2-(2-(5-((3aR, 4R,6aS)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethoxy)ethoxy)ethyl)
carbamate (BHM-BCN) (4)
To a solution of 12 (14.9 mg; 
0.042 mmol; 1.0 equiv.) and 
triethylamine (0.0176 ml; 0.126 
mmol; 3.0 equiv.) in DMF (2 
ml) was added dropwise biotin-
OSu (15.8 mg; 0.046 mmol; 1.1 
equiv.) in DMF (2 ml). The reaction mixture was stirred for 1 h at RT. DCM (5 ml) was added 
to the reaction mixture and the organic layer was washed successively with saturated 
aqueous ammonium chloride (5 ml) and saturated aqueous sodium bicarbonate (5 ml). 
The aqueous layers were extracted with DCM. The combined organic layers were dried 
over Na2SO4 and the solvent was removed in vacuo to give the title compound as a white 
solid. Yield 14.0 mg (57%), Rf 0.48 (7 N ammonia in MeOH: DCM / 1:4).
1H NMR (CDCl3, 300 MHz): 6.69 (m, 1H), 6.48 (m, 1H), 5.68 (m, 1H), 5.58 (m, 1H), 4.47 
(t, J = 6.0 Hz, 1H), 4.30–4.26 (m, 1H), 4.01 (s, 1H), 3.66 (s, 1H), 3.59 (s, 4H), 3.54 (t, J = 
5.1 Hz, 4H), 3.44–3.34 (m, 4H), 3.11 (q, J = 4.5 Hz, 1H), 2.93 (s, 1H), 2.85 (s,1H), 2.85, 
2.90 (2 × d, J = 6.0 Hz, 1H), 2.73 (s, 1H), 2.68 (s, 1H), 2.27–2.15 (m, 7H), 1.75–1.57 
(m, 6H), 1.45–1.36 (m, 2H), 1.22 (s, 1H), 0.85–0.82 (m, 2H). 13C NMR (CDCl3, 75 MHz): 
173.7, 164.2, 157.6, 98.8 (2C), 72.5, 70.2 (2C), 69.9, 63.7, 62.0, 60.4, 59.9, 55.8, 41.1, 
40.7, 39.4, 36.6, 36.1, 29.3, 28.4 (2C), 28.3, 26.3 (2C), 25.8, 21.5 (2C). IR (cm-1): 3304, 
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2924, 1697, 1537, 1459, 1260, 1117, 1027. ESI-MS: calculated for C28H44N4O7S 580.29: 
(M+H+) 581.30, found; (M+Na+) 603.28.
Synthesis of compounds 2 and 3 commenced with oxidation of commercially available 
BCN alcohol to the corresponding aldehyde 6. Aldehyde 6 was found to be highly 
unstable, and hence unsuitable for storage or puriﬁ cation, and was therefore further 
processed crude after oxidation. Reductive amination with NaCNBH3 in the presence 
of biotin-amine 7, led to the desired amino-linked conjugate 2. Subsequent acylation 
of 2 with glutaric anhydride yielded the second desired BCN derivative 3 (Scheme 1). 
Scheme 1. Synthesis of A-BCN (2) and GA-BCN (3).
A) Dess–Martin periodinane, CH2Cl2, RT, 2 h. B) Biotin-amine 7, NaCNBH3, CH2Cl2, RT, 2 h (41%). C) 
4-dimethylaminopyridine (DMAP), CH2Cl2, RT, 16 h (78 %).
The synthesis of compound 4, featuring a BHM-BCN scaffold, could not be achieved 
from the same BCN starting material but required a different approach from simple 
starting materials. To this end, a synthetic route resembling that to the earlier 
reported BCN alcohol was devised (25). Cycloocta-1,5-diene (in excess) was treated 
with diethyl diazomalonate (39), in the presence of rhodium acetate. The resulting 
cyclopropanated derivative 8 was subjected to a three-step procedure involving lithium 
aluminumhydride reduction, bromination and then double elimination and afforded 
the bishydroxymethyl bicyclo[6.1.0]non-4-yne (10) in reasonable yield. Conversion 
of 10 into the projected biotin derivative 4 required a slight modiﬁ cation of the earlier 
procedure. As expected, treatment of 10 with triphosgene, did not afford a mono-
activated NHS-carbonate derivative, but led to cyclic carbonate 11 instead. Interestingly, 
we discovered that the cyclic carbonate 11 possessed sufﬁ cient electrophilicity for 
spontaneous acylation of an alkylamine, potentially due to the strained character of 
the spiro system. Thus, treating 11 with (excess) diamine led to monoselective ring 
opening, and after puriﬁ cation and acylation the desired carbamate-linked BCN-biotin 
conjugate 4 was obtained in good yield as a mixture of diastereomers (Scheme 2).
The reactivity of the new bicyclo[6.1.0]nonyne analogues 2-4 was determined for a 
prototypical SPAAC reaction with the ﬂ uorogenic substrate 3-azido-7-hydroxycoumarin 
(5, Fig2B), by monitoring and quantifying the resulting ﬂ uorescent signal over time. A 
Kinetics
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kinetic olot is made and the reaction rate is determined. In a mixture of acetonitrile and 
water (1:2), the different BCN-biotin analogues displayed nearly similar reaction rates 
with 5 (Table 1), which was expected, given the fact that the reactive bicyclononyne 
moiety is constant across the set of probes. We were surprised, however, that the rate 
constant of approximately 2 M-1s-1 is almost 10-fold higher than the rate established earlier 
(0.29 M-1s-1) for cycloaddition of BCN with benzyl azide (25). Apparently, the aromatic 
coumarin substituent on the azide has a profound inﬂ uence on its reactivity, an effect 
that cannot be readily explained at this stage, all the more so because Hosoya et al. 
recently reported that the reaction of phenyl azide with a dibenzofused cyclooctyne is 
6.8 times slower than for a benzyl azide (an aliphatic azide) (40). At this point, however, 
no further attention was given to this observation, since, apart from the permeability 
studies, subsequent experiments were performed exclusively with aliphatic azides.
Scheme 2. Synthesis of BHM-BCN (4). 
A) Rh2(OAc)4, diethyl 2-diazomalonate, CH2Cl2, RT, 24 h (62%). B) Br2, CH2Cl2, 0 ºC, 30 min. C) KOtBu, 
THF, 0 ºC, 30 min, RT, 2 h (46 %). D) LiAIH4, Et2O, RT, 15 min (83%). E) pyridine, THF,-78 ºC, 30 min, 
triphosgene, CH2Cl2, RT, 1 h (34%). F) CH3CN, RT, 24 h. G) 50 ºC, 12 h (43%). H) biotin-OSu, Et3N, DMF, 
RT, 1 h (57 %).
Polarity
To assess the relative hydrophilicities of compounds 1-4, each individual analogue 
was subjected to reversed-phase HPLC (RP-HPLC) analysis, with a 50 mM phosphate 
buffer (pH 7.4) and MeCN as eluents and a 30 min solvent gradient from 95:5 to 20:80 
of phosphate buffer versus MeCN. The higher polarities of the newly synthesised 2-4 
were nicely reﬂ ected in the signiﬁ cantly reduced retention times, which varied between 
11.59, 11.63 and 13.27, respectively (Fig 3); in comparison, the known BCN (1) 
appeared after 16.27 min with this gradient. These particularly high hydrophilicities of 
compounds 2 and 3 can be explained on the basis of pKa values published previously, 
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which predict that compounds 2 and 3 should be positively and negatively charged, 
respectively, at neutral pH 7.4 (41). 
Membrane permeability
Cyclooctynes may penetrate the cell membrane and give rise to enhanced background 
signal, because removal by washing steps is not possible as long as the cells are intact. 
We reasoned that the more polar BCN analogues (2-4) should display a reduced tendency 
for transport across the plasma cell membrane relative to BCN (1). Therefore, the uptake 
of BCN into HEK293 cells was evaluated by confocal microscopy, to ascertain the effects 
of active transport mechanisms and differences in membrane lipid composition of living 
cells. HEK293 cells were cultured for 24 h on glass cover slips before treatment with 60 μM 
of one of the biotinylated BCN probes (1-4) for 1 h at room temperature. Cells were then 
ﬁ xed and permeabilised with paraformaldehyde (PFA), and incubated with streptavidin-
Alexa Fluor 488 (green) for the direct detection of the BCN distribution through the cells. 
At the same time, DAPI staining was used to visualise the cell nucleus (blue), whereas 
the Golgi 58k antibody allowed the detection of the Golgi apparatus (red). 
As anticipated, cells treated with the least polar BCN (1) showed high ﬂ uorescence 
distributed throughout the cell (Fig 4A), whereas the more hydrophilic BCN analogues 2-4 
Figure 3. RP-HPLC proﬁ les from the BCN derivatives. 
RP-HPLC on a C18 column was performed using 50 mM phosphate buffer adjusted to pH 7.4 
as mobile phase A, and MeCN as mobile phase B. The gradient proﬁ le started with 95% mobile 
phase A up to 80% mobile phase B in 30 min. A) As expected the retention time of 1 was highest 
(16.27 min). B) Compound 2 is likely to be charged at pH 7.4 and therefore had a retention 
time of 11.59 min. C) GA-BCN (3) is probably negatively charged at pH 7.4 and therefore more 
polar (11.63 min). D) 4 is slightly more hydrophilic than 1 with a retention time of 13.27 min.
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showed a reduced ﬂ uorescence intensity (Fig 4B-D), thus indicating that internalization is 
reduced compared to the mother compound BCN. Treatment with GA-BCN (3) resulted in 
the lowest ﬂ uorescent intensity, comparable to the intensity found without BCN treatment 
(Fig 4B). Furthermore, no speciﬁ c co-localisation with the nucleus or the Golgi apparatus 
was found for the BCN analogues, and no cross-over between the different channels 
was detected; this supports the conclusion that the developed probes give reduced 
background staining.
Figure 4. Representative confocal images of HEK293 cells treated with cyclooctyne-biotin followed 
by secondary labelling with streptavidin-Alexa Fluor 488 (green). 
Blue represents nucleus staining with DAPI and red represents the Golgi apparatus. A) Treatment with 
BCN (1) results in a strong intracellular signal. B) 2. C) 3 or D) 4 results in weak intracellular signal. Bar: 
10µm.
Metabolic incorporation
We analysed the speciﬁ c binding and labelling capacities of the different BCN analogues 
for cellular staining of metabolically labelled azidoglycans. HEK293 cells were grown on 
glass cover slips and treated with 60 μM peracetylated N-azidoacetyl-D-mannosamine 
(Ac4ManNAz) for 3 days. Subsequently, cells were incubated with one of the BCN-biotin 
probes (1-4) (60 µM) for 1 h, washed, permeabilised and stained with streptavidin-Alexa 
Fluor 488. As expected, we found that labelling with 1 resulted in marginal membrane 
detection in combination with a strong intracellular signal (Fig 5A). In previous studies, the 
cells were not permeabilised, so only BCN bound to the cell membrane is visualized,(25) 
a method that is often used in combination with glycan labelling. Labelling with A-BCN 
(2), unlike with 1, resulted in clear and selective membrane visualisation. In addition, the 
Golgi apparatus was labelled consistently (Fig 5B), a phenomenon reported before for 
DIBO and DIFO (20,42). This effect might be a result of the extreme high concentration 
47
SPAAC with polar BCN derivatives
of ManNaz in the trans-Golgi where the glycan is composed. GA-BCN (3) also showed 
selective membrane labelling but with a relatively low ﬂ uorescent intensity, thus indicating 
that the membrane staining was highly speciﬁ c, but less efﬁ cient (Fig 5C). Treatment 
with BHM-BCN (4) gave rather weak ﬂ uorescent signals for both extracellular and 
intracellular staining (Fig 5D). No cross-over between the different channels was detected. 
Figure 5. Representative confocal images of HEK293 cells after Ac4ManNAz treatment followed by 
reaction with cyclooctyne-biotin and secondary labelling with streptavidin-Alexa Fluor 488 (green). 
Blue represents nucleus staining with DAPI, whereas the Golgi apparatus is labelled red. A) BCN (1) labelling 
is not restricted to plasma membrane labelling. B) Treatment with A-BCN (2) results in low background 
labelling. Membrane and Golgi network are detected. C) Biotinylation with probe 3 shows relatively low 
background labelling. Clear membrane staining is visible, but the Golgi apparatus is not clearly stained. 
D) A higher background signal is detected after labelling with probe 4, however the membrane is stained. 
Bar: 10µm.
To quantify the plasma membrane labelling efﬁ ciencies of the different BCN analogues, 
the ﬂ uorescent intensities were measured by ﬂ ow cytometry. To this end, HEK293 cells 
were either treated with 60 μM Ac4ManNAz for 3 days or left untreated as a control. The 
reaction efﬁ ciencies of all four BCN probes were tested at three different temperatures 
(4 °C, RT, 37°C), and the cyclooctynes were visualised by binding of streptavidin-Alexa 
Fluor 488 and analysed by Fluorescence Activated Cell Sorting (FACS). Because 
streptavidin is not internalized at 4 °C and whole, non-permeabilised cells are measured, 
only extracellular BCN can be labelled and detected. Rather strong unspeciﬁ c signals on 
48
Chapter 2
the cell membranes were found for BCN (1) and BHM-BCN (4) in HEK293 cells (Fig 6). 
To our satisfaction, the most hydrophilic compounds 2 and 3 were found to give better 
signal-to-noise ratio (SNR) then 1 at all temperatures (Table 2, Fig 6). Labelling with 
either A-BCN (2) or GA-BCN (3) gave signiﬁ cantly higher SNR’s. For 2 the SNR was 
increased with a factor of two with respect to 1, and this is consistent with the confocal 
microscopy data. Speciﬁ c membrane labelling was most efﬁ cient at 37°C, independent 
of the cyclooctyne (Fig 6C). 
 
Figure 6. Metabolic labelling efﬁ ciencies assessed by ﬂ ow cytometry. 
Representative graphs of the ﬂ uorescent intensities from the BCN analogues. The peaks on the left 
represent the unspeciﬁ c signal (without Ac4ManNAz treatment). The peaks on the right side represent the 
signal after Ac4ManNAz treatment. A) Representative graph of the ﬂ uorescent intensities from the BCN 
analogues at 4°C, B) at RT, C) at 37°C.
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Finally, we tested whether the newly developed cyclooctynes could label speciﬁ c 
membrane glycoproteins, with use of the complex N-glycosylated TRPV5 membrane 
channel as our model protein. This epithelial calcium transporter functions as the 
rate-limiting step in renal calcium reabsorption. Because modiﬁ cation of the TRPV5 
N-glycan is known to inﬂ uence the membrane retention of the channel signiﬁ cantly 
(5,6,43), a direct glycoprotein read-out would be valuable for obtaining further insight 
into the role of glycosylation for TRPV5 function. Because BHM-BCN (4) had a low 
SNR after FACS analysis, this probe was not evaluated. HEK293 cells overexpressing 
TRPV5, or the empty vector (“mock”), were either treated with 60 μM Ac4ManNAz or 
left untreated. This was followed by labelling with one of the BCN-biotin analogues at 
room temperature for 1 h. Analysis by SDS-PAGE, followed by western blot, indicated 
that treatment with BCN (1) resulted in a strong TRPV5-biotinylated signal. However, 
an unspeciﬁ c biotinylation signal was detected as well (SNR of 3.96 ± 0.93, n=9; 3 
independent experiments, bottom panel, Fig 7A), probably due to unspeciﬁ c thiol-yne 
additions. Treatment with A-BCN (2) signiﬁ cantly increased the speciﬁ c biotinylation, 
with reduced background labelling and a SNR of 7.91 ± 1.55 (p<0.05 with respect to 
BCN, n=9; 3 independent experiments, bottom panel, Fig 7B). The more hydrophilic 
GA-BCN (3) also showed a reduction in background labelling, with a SNR of 7.03 ± 
1.59 (p= 0.13, ns with respect to BCN, n=11; 4 independent experiments, bottom panel, 
Fig 7C). The total loading of TRPV5 was determined as a control (top panels, Fig 7).
Figure 7. Western blots showing the TRPV5 channel through glycan labelling. 
Top panel in each case represents the total TRPV5 expression, bottom panel represents the biotinylated 
fraction of TRPV5 with and without Ac4ManNAz treatment. Representative blots of three independent 
experiments. A) Treatment with BCN (1) results in a relatively high unspeciﬁ c background labelling 
compared to the total signal. B) Biotinylation with A-BCN (2) showed a weak background signal compared 
to the Ac4ManNAz signal. C) Labelling with probe 3 resulted in a slightly weaker background signal than 
in the case of BCN.
Conclusions 
The ability to introduce azide-functionalized glycans into biomolecules, followed by SPAAC 
gives rise to many opportunities in the glycobiology ﬁ eld (20,44,45). The high reaction 
rates of the non-benzoannulated, relative non-lipophilic bicyclo[6.1.0]nonyne make this 
cyclooctyne derivative particularly suitable for labelling in living systems (25). We have 
designed, synthesized and evaluated a second-generation of BCN analogues with 
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reduced intracellular labelling capacity. In passing we noted the exceptional reactivity of 
BCN and its analogues for 5, an effect that we are currently investigating in our laboratory.
 All BCN derivatives were evaluated for their relative lipophilicities; the newly 
synthesised derivatives were found to be more hydrophilic than the mother compound 
1. Metabolic labelling studies in HEK293 cells showed that the polar BCN probes had 
a reduced tendency to pass through the plasma membrane. After treatment of HEK293 
cells with Ac4ManNAz, followed by probe 2 or 3, plasma membrane staining became 
apparent. Interestingly, probe 2 also showed selective staining of the Golgi apparatus 
after Ac4ManNAz treatment. Golgi labelling by means of copper-free click chemistry can 
be used to study dynamic glycan trafﬁ cking (20,42). The SNRs of the reactions of the most 
hydrophilic compounds, 2 and 3, at the cell surfaces were increased compared to those 
with the unmodiﬁ ed BCN. The key advantages in using more hydrophilic BCN analogues 
are their reduced tendency to undergo membrane transport in HEK293 cells and their 
increased labelling speciﬁ cities. Treatment with probe 2 resulted in the most speciﬁ c 
labelling of the TRPV5 N-glycan. The SNR is signiﬁ cantly better than that achieved 
with the commonly used BCN. We therefore expect that the polar BCN probes 2-4, with 
retained reaction rate and reduced unspeciﬁ c labelling, will ﬁ nd useful application in the 
visualisation of glycans of cell membrane proteins in living cells and live-cell imaging.
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Abstract
The transient receptor potential vanilloid type 5 (TRPV5) Ca2+ channel facilitates 
transcellular Ca2+ transport in the distal convoluted tubule (DCT) of the kidney. The channel 
is glycosylated with a complex type N-glycan and it has been postulated that hydrolysis 
of the terminal sialic acid(s) stimulate TRPV5 activity. The present study delineates the 
role of the N-glycan in TRPV5 activity using biochemical assays in Human embryonic 
kidney 293 cells expressing TRPV5, isoelectric focusing and total internal reﬂ ection 
ﬂ uorescent microscopy. The anti-aging hormone klotho and other glycosidases stimulate 
TRPV5-dependent Ca2+ uptake. Klotho was found to increase the plasma membrane 
stability of TRPV5, via the TRPV5 N-glycan. Sialidase mimicked this stimulatory action. 
However, this effect was independent of the N-glycosylation state of TRPV5, since the 
N-glycosylation mutant (TRPV5N358Q) was activated to the same extent. We showed that 
the increased TRPV5 activity after sialidase treatment is caused by inhibition of lipid-
raft-mediated internalization. In addition, sialidase modiﬁ ed the N-glycan of transferrin, 
a model glycoprotein, differently from klotho. Previous studies showed that after klotho 
treatment, galectin-1 binds the TRPV5 N-glycan and thereby increases TRPV5 activity. 
However, galectin-3, but not galectin-1, was expressed in the DCT. Besides, an increase 
in TRPV5-mediated Ca2+ uptake was detected after galectin-3 treatment. In conclusion, 
two distinct TRPV5 stimulatory mechanisms were demonstrated; a klotho-mediated 
effect that is dependent on the N-glycan of TRPV5 and a sialidase-mediated stimulation 
that is lipid raft-dependent and independent of the N-glycan of TRPV5. 
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Introduction
Calcium (Ca2+) plays a crucial role in multiple physiological processes such as muscle 
contraction, neuronal excitability, enzymatic activity, bone formation, cell membrane 
formation and exocytosis. It is of physiological importance to tightly regulate intra- and 
extracellular Ca2+ levels. To this end, the Ca2+ balance is maintained by the bone, kidney, 
duodenum and parathyroid glands (1). Secretion of parathyroid hormone (PTH) by the 
parathyroid glands results in increased Ca2+ re(ab)sorption from both bone and kidney. 
The rate-limiting step in renal active Ca2+ reabsorption is the uptake by the transient 
receptor potential vanilloid type 5 (TRPV5) channel, which is apically expressed in the 
distal convoluted tubule (DCT) of the kidney (2-5). The channel is responsible for 3-7% 
of the total Ca2+ reabsorption (6). TRPV5 is a tetrameric membrane protein containing 
6 transmembrane segments, with a cytosolic amino- and carboxyl-terminus and an 
extracellular N-glycan at Asn 358. The N-glycan is an important post-translational 
regulatory site, that can affect the plasma membrane retention of the channel (7). 
 Previous studies have shown that intracellular N-glycans contribute to signalling 
processes, dimer formation, membrane trafﬁ cking and polarized sorting of glycoproteins 
to the apical surface of epithelial cells (8,9). Extracellular N-glycans of plasma membrane 
glycoproteins are involved in signalling processes, apoptosis and cell-cell contacts. The 
composition of these glycans and the properties of the glycoproteins can be inﬂ uenced 
by the activity of extracellular glycosidases (10-12). For example, previous studies 
demonstrated that sialidase, a glycosidase, affects caveolar-mediated endocytosis by 
interacting with glycolipids in the plasma membrane (13). Trafﬁ cking of TRPV5 is crucial for 
controlling its abundance at the plasma membrane and therefore, the Ca2+ reabsorption. 
 A protein that modiﬁ es the extracellular N-glycan of TRPV5 is the type-1 
glycoprotein, klotho (7,14,15). Klotho is a glycosidase that participates in the degradation 
of glycans and thereby affects different glycoproteins (7,15-17). Other glycosidases, 
such as  -glucuronidase and sialidase, mimic the plasma membrane stabilization effect 
of klotho on TRPV5 by modifying its N-glycan. It was hypothesized that klotho had 
β-glucuronidase activity, because this enzyme had homology with β-glucuronidase and is 
able to hydrolyze glucuronic acids (16). Treatment of Human embryonic kidney 293 cells 
(HEK293) expressing TRPV5 with β-glucuronidase also increased the Ca2+ uptake through 
TRPV5 (7). However, Tohyama et al. found that the β-glucuronidase activity of klotho is 
approximately 26 times lower than that of β-glucuronidase (16). In addition, two highly 
conserved glutamate residues, essential for the enzymatic activity of β-glucuronidase, 
are not conserved in klotho. Furthermore, glucuronic acids are uncommon moieties in 
N-glycans of membrane proteins such as TRPV5. Cha et al. proposed that klotho operates 
instead as an exo-sialidase, speciﬁ cally breaking the α-2,6 linked bonds of the negatively 
charged sialic acids (14). They postulated that in Chinese hamster ovary (CHO) cells, 
cleavage of sialic acids by klotho exposes the underlying disaccharide galactose-β-(1-4)-
N-acetylglucosamine, followed by binding of galectins, a group of carbohydrate-binding 
proteins with a high afﬁ nity for the exposed galactose-N-acetylglucosamine disaccharides. 
 One of the galectin family members is galectin-1, a polyvalent protein 
expressed in various tissues and with a wide range of biological activities. It is 
suggested that galectin-1 forms a stable complex with TRPV5, resulting in a 
stimulatory effect on Ca2+ reabsorption by TRPV5 retention at the cell surface (14). 
Galectin-1 is present in both extra- and intracellular compartments, where it binds to 
carbohydrate and non-carbohydrate molecules, respectively (18). Galectin-1 is found 
in human tubular epithelial cells and in extensive amounts in the porcine kidney (19). 
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 The aim of the present study was to investigate the underlying molecular 
mechanism of the klotho-mediated TRPV5 regulation and the involvement of galectins. 
To this end, we delineated the action of different glycosidases, viz. klotho and sialidase. 
Total Internal Reﬂ ection Fluorescent Microscopy (TIRF-M) combined with a photo-
switchable ﬂ uorescent protein enabled us to study the dynamics of TRPV5 proteins on 
the plasma membrane in HEK293 cells. Finally, isoelectric focusing (IEF), allowed the 
detection of klotho-mediated sialic acid hydrolysis on a model glycoprotein, transferrin. 
Experimental procedures
DNA constructs
The pCINeo/IRES-GFP plasmid encoding TRPV5 was generated as described previously 
(20). TRPV5N358Q was obtained by in vitro mutagenesis of TRPV5-pCINeo/IRES-GFP 
cDNA according to the manufacturer’s instructions (Stratagene, La Jolla, CA, USA). 
The pcDendra-2 (Evrogen, Moscow, Russia) was ampliﬁ ed by PCR and ligated into the 
pCINeo/IRES-HA TRPV5 construct using the NheI and EcoNI (New England Biolabs, 
Ipswich, MA, USA) restriction sites. All constructs were veriﬁ ed by DNA sequence analysis.
Immunoblotting and protein concentration determination 
TRPV5 protein expression was determined by 8 % (w/v) SDS-PAGE and 
Western-blotting using anti-TRPV5 (1:4.000, (21)) with peroxidase-labeled goat 
anti-mouse IgG (1:10.000, Sigma-Aldrich, St. Louis, MO, USA) antibodies. 
Protein concentration was measured using the BCA protein assay kit (Thermo 
Scientiﬁ c, Rockford, IL, USA), according to the manufacturer’s manual.
Electrophysiology
Whole-cell currents were measured with an EPC-10 (HEKA electronic) ampliﬁ er using 
Patchmaster V2.20 software. The borosilicate glass electrode resistance was between 
2.5 and 4 MΩ. The ramp protocol for measuring the current-voltage (I/V) relationship of 
Na+ consisted of linear voltage ramps from -100 to +100 mV within 450 ms repeated every 
5 s. The step protocol for measuring the Ca2+ current consisted of a 10 s long voltage-step 
applied from +70 to -100 mV. Current traces were sampled at 0.5 ms for the ramp and 2 ms 
for step protocol. Reported current densities were calculated from the current at -80 mV 
during the ramp protocol. The standard extracellular solution contained 150 mM NaCl, 6 
mM CsCl, 10 mM HEPES (pH 7.4 adjusted with NaOH), 50 µM EDTA and 10 mM glucose. 
For Ca2+ current measurements NaCl was replaced with equimolar NMDG-Cl and 10 mM 
CaCl2 was added. Osmotic differences were adjusted by adding a respective amount of 
mannitol. The internal (pipette) solution contained 20 mM CsCl, 100 mM Cs-aspartate, 
1 mM MgCl2, 10 mM BAPTA, 4 mM Na2ATP and 10 mM HEPES (pH 7.2 adjusted with 
CsOH). Data was analyzed using Igor-pro software (WaveMetrics, Oswego, OR, USA). 
45Ca2+ uptake assay 
HEK293 cells were transiently transfected with TRPV5 in pCINeo/IRES-GFP, TRPV5N358Q 
in pCINeo/IRES-GFP or the empty pCINeo/IRES-GFP vector (mock). One day after 
transfection, cells were reseeded on poly-L-lysine-coated (0.1 mg/ml) culture dishes and 
incubated with recombinant klotho (2 µg/ml, R&D systems, Minneapolis, MN, USA), sialidase 
from Vibrio Cholerae (27 mU/ml, Sigma-Aldrich), β-glucuronidase from bovine liver (310 U/
ml, Sigma-Aldrich), endoF (1 kU/ml, New England), a combination of glycosidases, or human 
galectin-3 (0.67 µg/ml, Prospec, Ness Ziona, Israel) for 16 h at 37 °C. Radioactive 45Ca2+-
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uptake in TRPV5-transfected HEK293 cells was determined as described previously (22).
Plasma membrane biotinylation and TRPV5 cell surface turnover 
HEK293 cells were transiently transfected with TRPV5 in pCINeo/IRES-GFP, TRPV5N358Q 
in pCINeo/IRES-GFP or the empty pCINeo/IRES-GFP vector (mock). One day after 
transfection, cells were reseeded on poly-L-lysine-coated (0.1 mg/ml) culture dishes and 
incubated with recombinant klotho (2 µg/ml, R&D systems), sialidase from Vibrio Cholerae 
(27 mU/ml, Sigma-Aldrich), β-glucuronidase from bovine liver (310 U/ml, Sigma-Aldrich), 
or endoF (1 kU/ml, New England Biolabs) for 16 h at 37 °C. Subsequently, cells were 
biotinylated as described previously (7). For time point 0 h cells were collected from the 
plates and disrupted in 1 ml lysis buffer [1 % (v/v) NP-40, 150 mM NaCl, 5 mM EDTA, 50 mM 
Tris (pH 7.5 adjusted with HCl), 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml pepstatin, 5 µg/ml 
proteinase A] immediately after biotinylation. For the other investigated time points, cells 
were cultured in the absence of glycosidases for an additional 1 or 3 h at 37 °C, subsequently 
washed with ice-cold PBS and homogenized in 1 ml lysis buffer. TRPV5 protein expression 
at the cell surface and in total cell lysate was investigated as described previously (7).
Total Internal Reﬂ ection Microscopy (TIRF-M) 
HEK293 cells were transiently transfected with pcDNA3-Dendra2-HA-TRPV5 and 
pcDNA3-Dendra2-HA-TRPV5N358Q 24 h before the experiment. TIRF-M cells were 
harvested in 15 ml tubes and resuspended in conditioned medium containing recombinant 
klotho (2 µg/ml, R&D systems) or sialidase from Vibrio Cholerae (27 mU/ml, Sigma-
Aldrich). The tubes were rotated for 1.5 h at 37 °C to increase the effective reactive 
surface of the cells. Cells were reseeded on small petri dishes (WilCo, Amsterdam, The 
Netherlands) coated with 50 μg/ml ﬁ bronectin and cultured for 2-7 h before subjected 
to TIRF-M. Dishes were washed and placed in a custom-made chamber with Krebs 
buffer (135 mM NaCl, 5 mM KCl, 1.5 mM MgCl2, 1.5 mM CaCl2, 20 mM HEPES (pH 
7.4 with NaOH), 10 mM D-glucose,) and imaged at room temperature. The Olympus 
Fluoview FV1000-IX81 confocal microscope, with fully integrated TIRF module, and 
equipped with a PLAPON60xO/TIRFM-SP – PlanApochromatic objective 60x oil, NA 
1.45 and WD = 0,10 mm lens was used to measure ﬂ uorescence. Photoconversion of 
Dendra2 was carried out using a 405 nm laser for 2 s. TRPV5 membrane trafﬁ cking 
was followed for about 36 min and every 3 min images were acquired of unswitched 
(488 nm laser, 20 frames/5 s) and switched (559 nm laser, 20 frames/5 s) dendra-
TRPV5 proteins. All imaging acquisition was performed with Cell^M (Tokyo, Japan).
Biotinylation of TRPV5 
HEK293 cells transiently transfected with TRPV5 in pCINeo/IRES-GFP, TRPV5N358Q 
in pCINeo/IRES-GFP, or the empty pCINeo/IRES-GFP vector (mock) were reseeded 
on poly-L-lysine-coated (0.1 mg/ml) culture dishes one day after transfection 
and incubated with sialidase from Vibrio Cholerae (27 mU/ml, Sigma-Aldrich) or 
recombinant klotho (2 µg/ml, R&D systems) for 16 h at 37 °C. Subsequently, cells 
were biotinylated, lysed, and the biotinylated proteins were precipitated from the cell 
lysate with neutravidin beads (Pierce, Etten-leur, The Netherlands) as described 
previously (7). For the biotinylation after ﬁ lipin treatment, the same protocol was used, 
but the cells were treated with ﬁ lipin (5 μg/ml, Sigma-Aldrich) for 45 min prior to lysis.
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Transferrin Isoelectric focusing (tIEF)
The IEF assay was carried out as previously described (23), with the following 
differences. Brieﬂ y, plasma samples were incubated for 30 min, with a solution of 6.7 
mM ferric citrate and 0.17 M sodium hydrogen carbonate, in a ratio of 1:1 (plasma to 
solution), to saturate the transferrin with iron. The iron-saturated plasma was treated 
with 2 U/ml sialidase (Roche Applied Science, Mannheim, Germany), 150 µg/ml 
recombinant klotho (R&D systems) or left untreated for each of the investigated time 
points (1, 2, 4, 7 h or overnight). Subsequently, the samples were applied to a hydrated 
immobiline gel (pH 5-7) on a PhastSystem (GE-Healthcare Life Sciences, Piscataway, 
USA). Transferrin isoforms were detected after immunoﬁ xation with rabbit anti-human 
transferrin antibody (Dako, Glostrup, Denmark) and Coomassie brilliant blue staining.
COPAS Sorting and PCR
Transgenic mice expressing eGFP under the control of the TRPV5 promoter have been 
described previously (24). Fluorescently labeled DCT/CNT tubules were isolated from 
transgenic animals, using a Complex Object Parametric Analyzer and Sorter (COPAS) 
sorter (Union Biometrica, Somerville, MA) as previously described (25,26). The animal 
ethics board of the Radboud University Nijmegen approved all of the experimental 
procedures. Tubular, HEK293 and CHO cell RNA was extracted using TRIzol Total RNA 
Isolation Reagent (Life Technologies BRL, The Netherlands) and processed into cDNA. 
The cDNA was mixed with Power SYBR green PCR Mastermix (Applied Biosystems, 
Foster City, CA) and exon-overlapping primers against TRPV5 and galectin-1 and -3. 
Statistical analysis 
In all experiments, the data are expressed as mean ± S.E.M. Statistical signiﬁ cance 
(p < 0.05) was determined by analysis of variance and a Bonferroni post-hoc test.
Results
Stimulation of TRPV5 plasma membrane retention by glycosidases
To study the molecular mechanism of the klotho-dependent TRPV5 stimulation, we 
investigated the effect of various glycosidases on the activity of the channel. HEK293 
cells transiently over-expressing TRPV5 were treated with recombinant mouse klotho (2 
µg/ml), sialidase (27 mU/ml), β-glucuronidase (310 U/ml) or endoglycosidase-F (endoF) 
(1 kU/ml) for 16 h and subjected to patch clamp analysis. HEK293 cells transfected with 
TRPV5 all showed typical representative inwardly-rectifying I/V curves. Fig 1A represents 
cells transiently transfected with TRPV5, untreated or treated with klotho or endoF. The 
tested glycosidases signiﬁ cantly increased the TRPV5-mediated Na+ current density (Fig 
1B), while the current density of mock-transfected cells was not affected (data not shown). 
The stimulation of TRPV5 channel activity was conﬁ rmed by measuring 45Ca2+ uptake 
in cells after glycosidase treatment (Fig 1C). EndoF showed the highest stimulation of 
TRPV5 (205±6%), but also β-glucuronidase, sialidase and klotho increased signiﬁ cantly 
the TRPV5-dependent Ca2+ uptake (166±4%, 147±8%, 155±4%, respectively, P<0.05).
Subsequently, we investigated the plasma membrane retention via time-chase 
analysis. HEK293 cells expressing TRPV5 were treated for 16 h with different glycosidases 
and subjected to cell-surface biotinylation. To follow the fate of the biotinylated proteins, 
the cells were incubated for 0, 1 or 3 h without glycosidases. In untreated cells, the 
amount of biotinylated TRPV5 decreased signiﬁ cantly after 1 and 3 h compared to the 
initial time point (0 h) (Fig 1D, upper panels). For klotho, sialidase and endoF treated 
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cells, only a small decrease of biotinylated TRPV5 channels was detected after 1 and 3 
h (Fig 1D, upper panels). The total expression of TRPV5 was not signiﬁ cantly altered by 
the glycosidase treatment (Fig 1D, lower panels). 
To  further e lucidate the mechanism responsible for the increase in TRPV5 
activity after glycosidase treatment, the N-glycosylation-deﬁ cient mutant TRPV5N358Q, 
was subjected to time-chase analysis. Compared to wild-type TRPV5 the plasma 
membrane abundance of the mutant TRPV5N358Q channel was markedly stable, even 
after 3 h of incubation (Fig 1E).
Figure 1. Different glycosidases increase the TRPV5-mediated Ca2+uptake via plasma membrane 
stabilization of the channel. 
A) The I/V relationships of untreated, klotho- or endoF-treated HEK293 cells expressing TRPV5 
are presented. Solid line represents untreated cells, dashed line represents klotho-treated cells 
(light grey) and the dotted line represents endoF-treated cells (dark grey). B) The TRPV5-mediated 
Na+ current in HEK293 cells was measured. Treatment with β-glucuronidase, klotho, sialidase or 
endoF all resulted in a signiﬁ cantly increased current (n=17-42). C) 45Ca2+ uptake assays of HEK293 
cells transfected with TRPV5 or the empty vector (mock). These cells were untreated or treated with 
glycosidase (β-glucuronidase, klotho, sialidase or endoF). D) Time-chase assay of cells transfected 
with TRPV5. The membrane proteins were biotinylated at 0 h. After 3 h incubation without glycosidase, 
the membrane fraction of TRPV5 was decreased. E) Time-chase assay of cells transfected 
with TRPV5N358Q. All data are presented as mean ± SEM; n=3; *P< 0.05, statistically signiﬁ cant.
 
Glycosidase treatment retains TRPV5 at the plasma membrane 
Traditional time-chase experiments are not able to distinguish between delayed recycling 
of proteins from the plasma membrane or reduced degradation. To overcome this limitation, 
we established a novel approach by combining live-cell TIRF-M with a photo-convertible 
(green to red) ﬂ uorescent protein, Dendra-2, that was fused to the N-terminus of the 
TRPV5 channel (27). Via this technique an evanescent ﬁ eld at the glass-cell membrane 
interface permitted speciﬁ c detection and excitation of the channels close to the plasma 
membrane (~ 70-100 nm). Proteins in close vicinity to the plasma membrane were photo-
switched in TIRF mode using evanescent UV light (λ=405 nm). TIRF-M images are shown 
of the control and treated conditions for Dendra-2-TRPV5 and Dendra-2-TRPV5N358Q, 
captured at the initial time point after photo-switching and after 30 min (Fig 2A,B). The 
ratio of ﬂ uorescent intensity at an initial time point was calculated by (Fi-Fo)/Fo, where 
Fo= ﬂ uorescent intensity at an initial time point and Fi= ﬂ uorescent intensity at a new time 
point. To follow the presence of the protein at the plasma membrane in time, the ratio 
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between the switched red fraction (F559) and unswitched green fraction (F488) was calculated 
((F559 /F488)/(F559 /F488)max). After treatment with sialidase (70±3%) or klotho (75±4%) the 
ratio at 30 min was signiﬁ cantly increased compared to control (47±8%) indicating that 
TRPV5 is more stable at the plasma membrane (Fig 2C). To investigate whether there 
is a glycosidase-dependent effect on the N-glycosylation-deﬁ cient mutant, Dendra-2-
TRPV5N358Q was subjected to klotho and sialidase treatment. After glycosidase treatment, 
no signiﬁ cant decrease in the ﬂ uorescent ratio of Dendra-2-TRPV5N358Q was found (Fig 2D).
Figure 2. Klotho and sialidase stabilize TRPV5 on the plasma membrane. 
A, B) TIRF-M images of HEK293 cells expressing Dendra-2-TRPV5 or Dendra-2-TRPV5N358Q in both red 
and green channels, after 0 and 30 min. C) Ratio of switched red/unswitched green fraction of HEK293 
cells expressing Dendra-2-TRPV5. These cells were subjected to live-cell TIRF-M. At 0 min Dendra-2 
was subjected to UV light (λ=405 nm), resulting in a switch from green to red. D) Ratio of switched red/
unswitched green fraction of HEK293 cells expressing Dendra-2-TRPV5N358Q. These cells showed no 
increase in plasma membrane retention after glycosidase treatment. Control;  klotho treated;  sialidase 
treated. All data are expressed as mean ± SEM; n=3. 
Klotho and sialidase regulate TRPV5 plasma membrane retention differently 
TIRF-M showed that the cells expressing TRPV5N358Q appeared brighter after sialidase 
treatment, but not after klotho treatment. The difference between sialidase-treated 
and klotho-treated HEK293 cells expressing TRPV5N358Q was further investigated. 
Treatment with klotho of the cells expressing TRPV5N358Q did not alter the plasma 
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membrane availability of this mutant as detected by cell surface biotinylation (104±6%, 
P>0.2) (Fig 3A,B). For the cells transfected with wild-type TRPV5, the TRPV5 plasma 
membrane fraction signiﬁ cantly increased after klotho treatment (140±9%, P<0.05). 
In contrast, sialidase treatment enhanced the plasma membrane fraction of both 
TRPV5 and TRPV5N358Q (151±8% and 153±7%, respectively, P<0.05) (Fig 3C,D). 
 The distinct actions of klotho and sialidase were further studied by 45Ca2+ uptake assays. In 
line with our biochemical observations, klotho augmented the 45Ca2+ inﬂ ux in HEK293 cells 
transfected with TRPV5 (120±2%), but not in cells expressing TRPV5N358Q (103±5%) (Fig 
3E). In contrast, sialidase increased TRPV5-mediated 45Ca2+ uptake in TRPV5-expressing 
cells (150±11%) as well as in cells expressing TRPV5N358Q (149±10%) (Fig 3E). Co-treatment 
with sialidase and klotho resulted in an additive increase in TRPV5-mediated Ca2+ inﬂ ux 
(170±8%). In contrast, no additional 45Ca2+ inﬂ ux was observed after treatment of cells 
over-expressing TRPV5N358Q (149±10% versus 144±9%). The TRPV5 blocker ruthenium 
red was applied to determine the magnitude of the TRPV5-mediated 45Ca2+ inﬂ ux (28).
Figure 3. TRPV5 stabilization via klotho is N-glycan dependent.
A) Biotinylation of HEK293 cells expressing TRPV5 or TRPV5N358Q after klotho treatment, a representative 
blot is depicted; B) Relative TRPV5 cell surface expression with or without klotho treatment (white and 
black bar, respectively); C) Biotinylation of HEK293 cells expressing TRPV5 or TRPV5N358Q after sialidase 
treatment, a representative blot is depicted; D) Relative TRPV5 cell surface expression with or without 
sialidase treatment (n=3) (white and black bar, respectively); E) 45Ca2+ uptake assay of cells transfected 
with TRPV5 or TRPV5N358Q after treatment with klotho, sialidase, a combination of these glycosidases, 
ruthenium red or left untreated. All data are presented as mean ± SEM; n=3; *P< 0.05, statistically signiﬁ cant. 
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Disruption of lipid rafts increases TRPV5 plasma membrane abundance
Sialidase is known to affect protein trafﬁ cking by interacting with glycolipids in lipid 
rafts (13). To determine whether TRPV5 is present in lipid rafts, lipid rafts in HEK293 
cells expressing either TRPV5 or TRPV5N358Q were disrupted using the cholesterol-
chelating drug ﬁ lipin. After ﬁ lipin treatment, cell surface biotinylation showed a 
signiﬁ cant increase in TRPV5 and TRPV5N358Q abundance at the plasma membrane 
(120±8% versus 121±4%, respectively, P<0.05) (Fig 4A,B,C). Likewise, 45Ca2+ uptake 
assays revealed a proportional increase in the functional activity of TRPV5 and 
TRPV5N358Q after ﬁ lipin treatment (119±3% versus 122±4%, respectively, P<0.05) 
(Fig 4D). A combination of ﬁ lipin and klotho signiﬁ cantly stimulated TRPV5-mediated 
45Ca2+ uptake (100±6% versus 143±10%, P<0.05). No additional 45Ca2+ uptake was 
observed after combining sialidase with ﬁ lipin (100±6% versus 113±6%) (Fig 4E). 
Figure 4. TPRV5 plasma membrane retention is regulated via lipid rafts.
A) Biotinylation of HEK293 cells expressing TRPV5 after ﬁ lipin treatment, a representative blot is depicted. 
B) Biotinylation of cells expressing TRPV5N358Q after ﬁ lipin treatment, a representative blot is depicted. C) 
Relative cell surface expression, with or without ﬁ lipin treatment (white and black bar, respectively), of 
TRPV5 (n=6) or TRPV5N358Q (n=3) over-expressing cells. D) 45Ca2+ uptake assay in the presence of ﬁ lipin 
(n=3). Filipin signiﬁ cantly increases 45Ca2+ uptake independent on the N-glycan of TRPV5 (white bar). E) 
45Ca2+ uptake assay in the presence of ﬁ lipin and klotho or sialidase (n=3). Klotho signiﬁ cantly increased 
TRPV5-dependent 45Ca2+-uptake in the presence of ﬂ ilipin, while sialidase treatment gave no additional 
effect. All data are presented as mean ± SEM; *P< 0.05, statistically signiﬁ cant.
Sialidase and klotho modify the N-glycan of transferrin in a different manner
The difference between klotho and sialidase was further conﬁ rmed by isoelectric focusing 
(IEF), using human blood transferrin as a model glycoprotein. Via this technique, 
proteins are separated based on their isoelectric focus point. Since sialic acids are 
negatively charged, a change in the isoelectric focusing pattern can be detected 
after sialidase treatment. Plasma transferrin was used as model glycoprotein, since 
its isoelectric focusing point after removal of the sialic acids has been characterized. 
The main isoform of human plasma transferrin contains two complex biantennary 
N-glycans, each terminated by two α-2,6-linked sialic acids (23). The protein was 
treated with klotho (150 µg/ml) or sialidase (2 U/ml) for different time intervals. 
Sialidase treatment resulted in a clear shift in the IEF pattern of transferrin, indicating 
the loss of sialic acids (Fig 5A). Before treatment, a main isoform with four sialic 
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acids was detected and after 2 h of sialidase treatment all sialic acids were cleaved. 
Treatment with klotho did not signiﬁ cantly alter the IEF pattern of transferrin (Fig 5B).
Figure 5. The isoelectric focusing pattern of transferrin is not modiﬁ ed by klotho.
A) Isoelectric focusing of transferrin (tIEF) after sialidase treatment. Hydrolysis of sialic acids by sialidase 
treatment results in a shift of the IEF pattern. B) Isoelectric focusing of transferrin after klotho treatment. 
Klotho has no inﬂ uence on the amount of sialic acids. 
Galectin-3 partially mediates klotho-dependent TRPV5 activity 
The premise that klotho might not be a speciﬁ c sialidase, would add new mechanistic 
data to the hypothesis proposed by Cha et al., who suggested that galectin-1 stabilizes 
TRPV5 on the plasma membrane after N-glycan modiﬁ cation by klotho-mediated sialidase 
activity. In CHO cells they showed that the stimulatory klotho effect on TRPV5 was absent 
after the knock down of galectin-1 (14). However, immunohistochemistry of mouse 
kidney sections failed to show co-localization between TRPV5 and galectin-1 (Fig 6A). In 
addition, galectin-1 was expressed in CHO cells, but not in HEK293 cells, that were used 
for this study (Fig 6B). Since the potential ligands for galectin-1 and galectin-3 are similar 
(29), the expression of galectin-3 in mice sections, HEK293 cells and in Complex Object 
Parametric Analyzer and Sorter (COPAS)-sorted distal convoluted and connecting tubules 
(DCT/CNT) was checked. Galectin-3 showed a clear co-localization with TRPV5 in mice 
kidney sections. Some tubuli were positive for galectin-3, but not for TRPV5, indicating that 
galectin-3 activity is not restricted to TRPV5-expressing tubuli (Fig 6C). Galectin-3 also 
expressed in HEK293 cells, as was shown by RT-PCR (Fig 6D). The expression of galectins 
in the DCT/CNT was further studied after collecting the nephron segments from mouse 
kidney, by the COPAS large particle ﬂ ow cytometry (25). In isolated DCT/CNT segments, 
only galectin-3 mRNA was detected by RT-PCR (Fig 6E). In addition, in mouse urine, only 
galectin-3 was found, which implies that it has access to the glycan of TRPV5 (Fig 6F).
The involvement of galectin-3 in TRPV5 regulation was further investigated. 
HEK293 cells, transiently over-expressing TRPV5 were treated with 0.67 µg/mL 
recombinant human galectin-3. 45Ca2+ uptake assays revealed an increase in TRPV5 
channel activity after galectin-3 treatment (100±2% versus 131±6%, P<0.05) (Fig 7A), 
while the activity of the TRPV5N358Q mutant was not affected by galectin-3 treatment 
(100±2% versus 104±4%) (Fig 7A). Combining galectin-3 and klotho-treatment, or 
galectin-3 and sialidase-treatment, did not result in additional stimulation of channel 
activity (Fig 7B). 
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Figure 6. Galectin-3 is a candidate mediator of the klotho effect on TRPV5.
A) Immunohistochemistry on DCT/CNT for TRPV5 and galectin-1 shows no co-localization. B) Immunoblot 
of CHO cell lysate demonstrated that galectin-1 was present. After RT-PCR on the cDNA of HEK293 cells, 
no galectin-1 was detected. C) Immunohistochemistry on DCT/CNT for TRPV5 and galectin-3 demonstrate 
a co-localization. D) Immunoblot of CHO cell lysate demonstrated that galectin-3 was expressed. After 
RT-PCR on the cDNA of HEK293 cells, galectin-3 was detected. E) The cDNA of the DCT/CNT cells was 
analyzed by RT-PCR and only galectin-3 was detected. F) Total kidney lysate of mouse contains both 
galectin-1 and galectin-3, while mouse urine only contains galectin-3.
Figure 7. TRPV5 channel activity is regulated by extracellular galectin-3. 
A) 45Ca2+-uptake assay in cells over-expressing TRPV5 (n=5) or TRPV5N358Q (n=3) in the presence and 
absence of human galectin-3. Galectin-3 signiﬁ cantly increased wild type TRPV5 (white bar) but not 
TRPV5N358Q channel activity (white bar). All data are presented as mean ± SEM; *P<0.05, statistically 
signiﬁ cant. B) 45Ca2+ uptake assay of cells over-expressing TRPV5 treated with klotho, sialidase, galectin-3 
or a combination of these enzymes. No additional stimulation was detected after treatment with klotho and 
galectin-3. All data are presented as mean ± SEM; n=5; *P< 0.05, statistically signiﬁ cant. 
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Discussion
Our study demonstrates that glycosidases augment the plasma membrane retention 
of TRPV5, where klotho and sialidase increase the TRPV5 plasma membrane fraction 
via distinct mechanisms. The effect of sialidase, in contrast to klotho, is independent 
of the glycosylation status of TRPV5. Moreover, galectin-3 is a potential mediator for 
klotho-dependent TRPV5 stabilization. Our conclusions are based on the following 
observations: i) biochemical assays show that klotho, sialidase, β-glucuronidase and 
endoF increase the TRPV5 channel activity and membrane retention; ii) the plasma 
membrane stability of TRPV5N358Q is altered by sialidase, but not by klotho; iii) IEF 
demonstrate no modiﬁ cation of the N-glycan sialic acids after klotho treatment in 
transferrin; iv) only galectin-3, but not galectin-1, co-localizes with TRPV5 in DCT/CNT of 
the kidney; v) galectin-3 increases the TRPV5-mediated Ca2+ inﬂ ux N-glycan dependent. 
 It was demonstrated that glycosidase treatment increases the TRPV5 channel 
activity. This effect was detected by treatment with different types of glycosidase (endoF, 
sialidase and β-glucuronidase). TRPV5 channel activity was measured via time-chase 
experiments in combination with functional analyses (7,14). A general mechanism or 
pathway for all the applied glycosidases remains unknown, since their enzymatic effects 
are distinct: endoF cleaves the entire N-glycan (30), sialidase hydrolyses end-standing 
sialic acids, while β-glucuronidase cleaves glucuronic acids (31). One hypothesis is 
that any modiﬁ cation of the N-glycan improves the plasma membrane stabilization of 
TRPV5. Alternatively, since all glycans on the plasma membrane were hydrolyzed, the 
detected stabilizing effect could be independent of the N-glycan of TRPV5. This would 
mean that the plasma membrane stabilization is due to an indirect effect on TRPV5. 
However, the stimulatory effect of klotho is dependent on the N-glycan of TRPV5. 
 Plasma membrane retention can occur via two distinct routes; a delayed retrieval 
from the plasma membrane and subsequent degradation of the channel, or via an 
accelerated/increased insertion at the plasma membrane. It is difﬁ cult to distinguish 
between both routes based on time-chase experiments. To pinpoint the fate of glycosidase-
treated TRPV5, we developed a novel assay, combining the live-cell imaging technique, 
TIRF-M, with photoactivatable ﬂ uorophores. Important advantages of TIRF-M over 
confocal microscopy are the higher Z resolution, high signal to noise ratio, increased 
contrast in ﬂ uorescence and reduced bleaching. The ease in combining kinetic studies 
with local information in living samples results in fast data acquisition (32). We showed 
that TRPV5 has a reduced mobile fraction after sialidase- or klotho-treatment, indicating 
that these glycosidases enable TRPV5 to reside longer on the plasma membrane. Our 
control, TRPV5N358Q lacks N-glycosylation and is devoid of any glycosylation-dependent 
regulation. This mutant demonstrated no decrease in the mobile fraction after glycosidase 
treatment. Overall this mutant had a smaller mobile fraction compared to TRPV5. 
 While conducting the TIRF-M based live-cell imaging it was observed that after 
sialidase treatment, the cells expressing TRPV5N358Q appeared brighter. This effect was 
not detected after klotho treatment. This prompted us to investigate the effect of sialidase 
on TRPV5N358Q. An increased plasma membrane abundance of TRPV5N358Q was detected 
via biotinylation, after sialidase treatment. It was noticed that biotinylated TRPV5 often runs 
as a smear band on SDS-PAGE. The reason for this effect remains unclear, however, it 
suggests that membrane TRPV5 is more heterogeneous compared to intracellular TRPV5. 
 The effect of sialidase treatment on the TRPV5N358Q mutant was conﬁ rmed using 
45Ca2+ uptake experiments. TRPV5-mediated 45Ca2+ uptake was increased after treatment 
with both sialidase and klotho in an additive manner, indicating that klotho and sialidase act 
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via different pathways. Interestingly, Cha et al. postulated that sialidase did not increase 
the plasma membrane abundance of TRPV5N358Q (14). However, in their study CHO cells 
were used as a model system, while in the present study HEK293 cells were employed
 We proved that ﬁ lipin, an inhibitor of microdomain clustering, increases the 
cell surface expression of TRPV5/TRPV5N358Q and 45Ca2+ uptake through TRPV5 and 
TRPV5N358Q. This ﬁ nding indicated that TRPV5 and TRPV5N358Q channels are present and 
internalized in clustered microdomains. Recently, it has been suggested that sialidase 
prevents microdomain clustering and lipid raft formation by hydrolyzing sialic acids 
from glycosphingolipids (13). Microdomain clustering is known to stimulate caveolae-
mediated endocytosis and since sialidase treatment inhibits this microdomain clustering, 
the endocytosis is reduced (13). Because TRPV5 is present in these microdomains, the 
channel is most likely stabilized on the plasma membrane by sialidase via reduced lipid raft 
formation and thereby a decreased caveolae-mediated endocytosis. In agreement with 
this hypothesis, sialidase treatment did not result in additional stimulation of 45Ca2+ uptake 
after disrupting the lipid rafts by ﬁ lipin. This ﬁ nding, together with the sialidase-mediated 
stimulation of Ca2+ uptake via TRPV5N358Q, and increased wild type TRPV5 activation 
after klotho treatment in the presence of ﬁ lipin, suggested that klotho and sialidase act 
via two different pathways to modulate channel activity. Sialidase, in contrast to klotho, 
stimulates TRPV5 via a mechanism that is independent of the N-glycan of TRPV5. 
 To further conﬁ rm this hypothesis IEF was used, with the well-characterized 
transferrin as a model protein. Sialidase altered the IEF pattern of transferrin, a substrate 
exposing terminal sialic acids, including α2,6 linked sialic acids (33,34). Klotho-treatment 
did not result in any modiﬁ cation, suggesting a lack of sialidase activity of klotho. 
Alternatively, it is possible that sialidase activity of klotho is tightly structure-related, 
cleaving only one sialic acid that is presented in a speciﬁ c sugar signature, which may 
be absent in transferrin. The difference between sialidase and klotho prompted us to 
investigate the following step in the proposed mechanism. Cha et al. suggested that 
galectin-1 is a key player in the regulation of TRPV5. Interestingly, immunohistochemistry 
on renal mouse cortex sections showed no co-localization of galectin-1 with TRPV5. 
Galectin-1 is not expressed in HEK293 cells and therefore the in vitro measured effect 
of klotho is likely to be galectin-1 independent. Since the potential ligands for galectin-1 
and galectin-3 are highly similar, we investigated the role of galectin-3 in this process. 
Galectin-3 is a carbohydrate-binding protein that is highly abundant in type A intercalated 
cells of the cortical collecting duct and the distal tubules (35,36). An important difference 
between galectin-1 and galectin-3 is that the dimer galectin-1 requires a terminal 
galactose for binding, while the oligomer galectin-3 binds to repeating [-3Gal-β-(1-4)-
GlcNAc-β-1-]n or poly-N-acetyllactosamine sequences that not necessarily contain a 
terminal β-galactoside residue (37). Galectin-3 co-localized with TRPV5, although the 
presence of galectin-3 is not restricted to TRPV5-expressing tubuli. In addition, COPAS 
sorted DCT/CNT cells were enriched with galectin-3 mRNA, while galectin-1 mRNA 
was not detected, indicating that galectin-3 may be involved in TRPV5 regulation. In 
contrast to the TRPV5N358Q mutant, wild type TRPV5 channel activity was increased 
upon treatment with galectin-3. This suggests that galectin-3-mediated channel activity 
is dependent on the N-glycan of TRPV5. Interestingly, co-treatment with galectin-3 and 
klotho did not additively stimulate TRPV5 activity implying that klotho and galectin-3 
stimulate TRPV5 activity in a similar manner. An interesting observation, as detected with 
TIRF-M, biotinylation, 45Ca2+ uptake experiments and electrophysiology was the stable 
expression of TRPV5N358Q mutant on the plasma membrane without any treatment. It 
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was proposed that galectin stabilizes TRPV5 on the plasma membrane. However, due 
to the absence of an N-glycan on the TRPV5N358Q mutant, it is striking that this mutant 
retains on the plasma membrane. Since the TRPV5N358Q mutant was transiently over-
expressed, one could hypothesize that some glycosylation-deﬁ cient channels are forced 
to the plasma membrane. Since the entire N-glycan is absent, the protein cannot be 
appropriately regulated by the cell and will remain stable on the plasma membrane. 
 Interestingly, Kohno et al. demonstrated a signiﬁ cant difference between the 
internalization rates of the wild type endothelial differentiation gene-1 product (Edg-1, 
a G-coupled receptor) and the nonglycosylated N30D-Edg-1 mutant (38). The wild type 
G-coupled receptor was internalized at higher rates compared to the nonglycosylated 
N30D-Edg-1 receptor. However, more research for TRPV5 is needed to understand this 
internalization process. Another explanation could be that the channel is destabilized 
due to steric hindrance in the presence of the N-glycan, resulting in a reduced amount 
of TRPV5 on the cell surface. Consequently, any reduction of the N-glycan of TRPV5 
will result in an increase of plasma membrane stability and, therefore, channel activity. 
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Abstract
Transcellular Ca2+ transport in the late distal convoluted tubule and connecting tubule 
(DCT2/CNT) of the kidney is a ﬁ nely controlled process mediated by the transient 
receptor potential vanilloid type 5 (TRPV5) channel. A complex-type N-glycan is bound 
at the extracellular residue Asn358 of TRPV5 through post-translational glycosylation. 
This N-glycan has been postulated to regulate TRPV5 channel activity. Using in vitro 
Ca2+ transport assays, immunoblot analysis, immunohistochemistry, patch clamp 
electrophysiology and total internal reﬂ ection ﬂ uorescence microscopy, it is demonstrated 
that the glycosidase β-galactosidase (β-gal), an enzyme that hydrolyzes galactose, 
stimulates TRPV5 channel activity. This stimulation depends on the presence of the 
TRPV5 N-glycan, since the activity of the non-glycosylated TRPV5N358Q mutant was not 
altered in the presence of β-gal, and resulted from plasma membrane stabilization. In 
addition, β-gal was found to stimulate transcellular Ca2+ transport in isolated mouse 
primary DCT2/CNT cells. β-gal expression was detected at the apical membrane of the 
proximal tubules and in mice urine. In summary, β-gal is expressed in the pro-urine from 
where it is thought to stimulate TRPV5 activity.
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The extracellular calcium (Ca2+) concentration is tightly regulated due to the critical 
involvement of Ca2+ in numerous signalling cascades, muscle contraction and bone 
mineralization (1). The transient receptor potential vanilloid type 5 (TRPV5) channel 
mediates the apical entry of Ca2+ in the kidney epithelial cell, which constitutes a ﬁ nely 
regulated rate-limiting step in renal Ca2+ reabsorption (2,3). TRPV5 is expressed in the 
epithelial cells of the late distal convoluted tubule (DCT2) and connecting tubule (CNT) 
segments of the nephron, where it mediates ~5-10% of the total Ca2+ reabsorption in the 
kidney (4,5). The channel is regulated by a variety of factors including 1,25-dihydroxyvitamin 
D3, parathyroid hormone, dietary Ca
2+, acid/base status and glycosylation (6-8).
 Each subunit of the tetrameric TRPV5 channel contains an intracellular C- 
and N-terminus, and six transmembrane segments. TRPV5 possesses a single 
N-glycan on the Asn358 (N358) amino acid located in the extracellular loop situated 
between the ﬁ rst and second transmembrane domain. This glycan plays an important 
role in regulating the plasma membrane expression of TRPV5 channels (9-11).
 Glycosylation is one of the most common post-translational modiﬁ cation in 
eukaryotic cells, as it is estimated that ~50% of the proteome is glycosylated (12). 
Extracellular N-glycans of plasma membrane glycoproteins are involved in signalling 
processes, such as apoptosis and cell-cell contacts (13). Mammalian extracellular 
glycosidases modify the structure of cell surface glycans by hydrolyzing speciﬁ c 
sugars (14). For example, sialidase (also known as neuraminidase) hydrolyzes 
terminal sialic acids from N-glycans and gangliolipids (15), while β-galactosidase 
(β-gal) hydrolyzes galactose units (13). Modiﬁ cation of the glycan of proteins can alter 
substrate binding, enzymatic activity or protein stability at the plasma membrane (13,16).
 Previous studies have shown that glycosidases inﬂ uence TRPV5 channel activity via 
the N-glycan. For instance, the putative pro-urinary glycosidase klotho stabilizes TRPV5 at 
the plasma membrane, an effect that is absent in the non-glycosylated N358Q mutant (9-11).
 A different glycosidase, β-gal, is present in its active form in the urine of 
human subjects (17). Deﬁ ciencies of β-gal cause human metabolic disorders 
such as GM1 gangliosidosis (OMIM nr.230500) and Morquio B disease (OMIM 
nr.253010), both characterized by heterogeneous clinical phenotypes (18,19). A 
common phenotype among these patients is bone malformations. Interestingly, 
TRPV5 knockout (-/-) mice also exhibit signiﬁ cant disturbances in bone structure (20).
 Here, we hypothesized that β-gal regulates the activity of TRPV5 via the 
TRPV5 N-glycan. To investigate this hypothesis, a combination of techniques 
including immunoblotting, radioactive 45Ca2+ uptake assays, electrophysiology 
and Total Internal Reﬂ ection Fluorescent Microscopy (TIRF-M) were applied. 
The physiological relevance of such mechanism was investigated using 
45Ca2+ transport assays in primary mice DCT2/CNT cells. In addition, the 
expression of β-gal in kidney and its presence in mouse urine were investigated.
Experimental procedures
DNA constructs 
The pCINeo/IRES-GFP plasmid encoding TRPV5 was generated as described previously 
(21). The TRPV5N358Q mutant was obtained by in vitro site-directed mutagenesis 
of wild type (wt)-TRPV5-pCINeo/IRES-GFP (Stratagene, La Jolla, CA, USA). The 
pcDNA3-Dendra2-HA-TRPV5 and pcDNA3-Dendra2-HA-TRPV5N358Q vectors were 
generated as previously described (9). Mouse β-galactosidase (Biosource Bioscience 
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LifeSciences, Cambridge, UK) was subcloned into the pCINeo/IRES-GFP vector using 
the XhoI and AscI restriction sites. All constructs were veriﬁ ed using DNA sequencing. 
Cell culture and transfections  
HEK293 cells were grown in Dulbecco’s modiﬁ ed eagle’s medium (DMEM, Bio Whittakker-
Europe, Verviers, Belgium) containing 10% (v/v) fetal calf serum (PAA, Liz Australia), 
2mM L-glutamine and 10 µg/ml non-essential amino acids at 37 ºC in a humidity-
controlled incubator with 5% (v/v) CO2. HEK293 cells were transiently transfected using 
lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), or Polyethyleneimine (PEI) (Brunswig/
PolySciences). Transfections were performed according to manufacturer’s protocol.
Immunoblotting and determination of protein concentration 
TRPV5 protein expression was determined by 8 % (w/v) SDS-PAGE and immunoblotted 
using anti-HA-tag (1:5,000, Cell Signalling Technology, Beverly, MA, USA) with peroxidase-
labelled sheep anti-mouse IgG (1:10,000, Chemie Brunschwig, Basel, Switzerland) 
antibodies. Protein concentration was measured with a BCA protein assay kit (Thermo 
Scientiﬁ c, Rockford, IL, USA), according to manufacturer’s instructions. Two days after 
transfection, cells were lysed in 0.5 mL lysis buffer containing: Triton X-100 (1% v/v), 150 
mM NaCl, 5 mM EDTA, 50 mM Tris/HCl pH 7.5, 1 mM phenylmethanesulfonylﬂ uoride 
(PMSF), 10 µg/mL leupeptin, 10 µg/mL pepstatin A, 5 µg/mL protinin and subjected to 
immunoblotting. β-gal protein expression was determined by 10 % (w/v) SDS-PAGE 
and immunoblotting using goat anti-β-galactosidase antibody (1:250, Santa Cruz 
Biotechnology, Texas, USA; C-20, polyclonal) with peroxidase-labelled mouse anti-
sheep IgG (1:10,000, Jackson ImmunoResearch Laboratories, Suffolk, UK) antibodies. 
16µL wt mice urine was treated with 4 µL Leammli for 30 minutes at 37°C. Next, the 
β-gal protein expression in these samples was determined via immunoblotting.
45Ca2+ uptake assay 
HEK293 cells were transfected with TRPV5, TRPV5N358Q or the empty pCINeo/
IRES-GFP vector (mock). One day after transfection, cells were reseeded on poly-L-
lysine-coated (0.1 mg/mL) culture dishes and incubated with β-gal from E. coli (1 U/
mL, Worthington Biochemical Corporation, Lakewood, NJ, USA), β(1-4)-gal from 
Bacteroides fragilis (20 mU/mL, New England Biolabs, Ipswich, MA, USA), β(1,3)-gal 
from Xanthomonas manihotis (20 mU/mL, New England Biolabs), or D-(+)galactose (2 
µg/mL or 3 µg/mL, Sigma, St. Louis, MO, USA) for 16 h at 37 °C. Radioactive 45Ca2+ 
uptake in TRPV5-transfected HEK293 cells was determined as previously described (22). 
Electrophysiology  
Experiments were performed using an EPC-9 ampliﬁ er and the Patchmaster software 
(HEKA electronics, Lambrecht, Germany). The sampling interval was set to 200 ms for 
whole-cell recordings and 20 ms for single-channel recordings. Whole-cell recordings 
were acquired with a low-pass ﬁ lter set at 3.6 kHz, while single-channel recordings 
had a low-pass ﬁ lter set at 5 kHz. The electrical noise was reduced further using the 
Humbug 50/60 Hz noise eliminator (Quest Scientiﬁ c, Vancouver, Canada). Whole-cell 
patch clamp pipettes were pulled from thin-walled borosilicate glass (Harvard Apparatus, 
March-Hugstetten, Germany) and had resistances between 1 and 3 MΩ when ﬁ lled with 
the pipette solution. Series resistance compensation was set to 75-95% in all whole-cell 
experiments. Single-channel patch clamp pipettes were made of thick-walled borosilicate 
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glass (Harvard Apparatus and World Precision Instruments) and had resistances between 
8 and 11 MΩ when ﬁ lled with the pipette solution. Single-channel recordings were analyzed 
using the Qub software package (23). Three different extracellular solutions were used to 
obtain whole-cell recordings of TRPV5 activity. A nominally divalent-free (nDVF) solution 
comprised of (in mM): 150 NaCl, 6 CsCl, 10 glucose, 10 HEPES and CsOH to adjust the pH 
adjusted to 7.4. A divalent-free (DVF) solution based on nDVF solution with 50 µM EGTA. 
A Krebs solution containing (in mM): 150 NaCl, 6 CsCl, 1 CaCl2, 1 MgCl2, 10 glucose, 
10 HEPES and pH adjusted to 7.4 using CsOH. The pipette solution was comprised 
of (in mM): 20 CsCl, 100 CsAspartate, 1 MgCl2, 10 BAPTA, 4 Na2ATP, 10 HEPES and 
pH adjusted to 7.2 using CsOH. The extracellular solution for cell-attached recordings 
contained (in mM): 150 NaCl, 6 CsCl, 10 Glucose, 10 HEPES and pH adjusted to 7.4 
using CsOH. The pipette solution comprised (in mM): 150 NaCl, 10 EGTA, 10 HEPES 
and pH adjusted to 7.3 using CsOH (24). Cells were initially bathed in nDVF extracellular 
solution. The whole-cell EGTA-sensitive current was obtained by measuring the current 
sensitive to the perfusion of 50 µM EGTA. At the end of the recording protocol, the Ca2+-
sensitive current was obtained by perfusion of Krebs solution containing 1 mM of CaCl2.
Total Internal Reﬂ ection Fluorescent Microscopy (TIRF-M)  
HEK293 cells were transfected with Dendra2-HA-TRPV5 or Dendra2-HA-TRPV5N358Q two 
days prior to the experiment. Following treatment with β(1-4)-gal (16 h, 20 mU/mL), cells 
were harvested and resuspended in medium containing β(1-4)-gal (20 mU/mL). The tubes 
were rotated for 2 h at 37 °C. Cells were reseeded on petri dishes (WilCo, Amsterdam, The 
Netherlands) coated with 50 μg/mL ﬁ bronectin and cultured for 4-7 h in the presence or 
absence of β(1-4)-gal (20 mU/mL). Monolayers were washed with Krebs buffer containing 
(in mM): 135 NaCl, 5 KCl, 1.5 MgCl2, 1.5 CaCl2, 20 HEPES, 10 D-glucose, pH adjusted 
to 7.4 with NaOH, and imaged at room temperature. Fluorescence was measured by 
an Olympus Fluoview confocal microscope (FV1000-IX81) with fully integrated TIRF 
module, -PLAPON60xO/TIRFM-SP - PlanApochromatic objective (60x oil, NA=1.45 and 
WD=0,10 mm) lens. A 2 s 405 nm laser pulse photo-converted Dendra2. Unswitched (488 
nm) and switched (559 nm) Dendra2-TRPV5 proteins were imaged in a 4 Hz series of 5 s 
every minute for a total duration of 20 min. To calculate the time-dependent expression of 
the protein at the plasma membrane, the ratio between the switched red signal (F559) and 
unswitched green signal (F488) was calculated using the following equation: ((F559/F488)/(F559/
F488)max). All imaging acquisition was performed with the Cell^M software (Tokyo, Japan).
COPAS Sorting 
Transgenic mice expressing eGFP under the control of the TRPV5 promoter were 
generated as described previously (25,26). Fluorescent DCT2/CNT tubules were 
isolated from transgenic animals, using the Complex Object Parametric Analyzer and 
Sorter (COPAS) (Union Biometrica, Somerville, MA), as previously described (25). In 
short: mice aged 4-6 weeks were anesthetized (ketamine 0.1 mg/g body weight and 
xylazine 0.01 mg/g) and perfused with ice-cold KREBS buffer. The kidney cortex was 
dissected, minced and subjected to digestion. Finally, the mice are sacriﬁ ced by cervical 
dislocation. The animal ethics board of the Radboud University Nijmegen approved 
all the experimental procedures involving mice (permit number: RU-DEC 2013-095).
45Ca2+ transport in primary DCT2/CNT cells 
COPAS sorted DCT2/CNT tubules were cultured for 7-8 days as previously described 
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(25). The epithelial resistance was measured one day prior to the 45Ca2+ transport assay. 
Cell monolayers were incubated for 16 h with β(1-4)-gal (32 mU/mL) or left untreated. 30 
min prior to the 45Ca2+ transport assay, indomethacin (5 µM ﬁ nal concentration, Sigma) 
was added to the culture medium, on both apical and basolateral sides. The assay was 
performed at 37 °C with pre-heated buffers. Cells were washed with physiological salt 
solution (PSS) containing (in mM): 140 NaCl, 2 KCl, 1 K2HPO4, 1 MgCl2, 1 CaCl2, 5 
D-glucose, 5 L-alanine, 0.005 indomethacin, 10 HEPES/Tris pH 7.4. Subsequently, 
apical buffer was replaced with PSS (100 µl) containing 3 µCi/mL 45Ca2+. PSS containing 
forskolin (10 µM, Sigma) or β(1-4)-gal (32 mU/mL) in combination with 3 µCi/mL 45Ca2+ 
were added apically as needed. Basolateral buffer (600 µl) was replaced with PSS. A 10 
µl sample was taken from the apical and basolateral compartments at time point 0. Next, 
basolateral samples were taken at subsequent time points: 15, 30, 60 and 120 min and 
analyzed for radioactivity using a liquid scintillation counter as previously described (22). 
 
Immunohistochemistry  
Kidneys of wt C57BL/6N mice were harvested and ﬁ xed in 1% (w/v) poly-L-lysine 
paraformaldehyde. Kidneys were immerged in 15% (w/v) sucrose (MP Biomedicals, 
California, USA), after which they were snap frozen in liquid nitrogen. Co-staining for 
β-gal with TRPV5, breast cancer resistant protein (BCRP) or uromodulin were performed 
on 5-μm kidney sections, which were incubated for 16 h at 4 °C with chicken anti-β-
gal (1:100, Abcam, Cambridge, UK), guinea pig anti-TRPV5 (27) (1:50), rat anti-BCRP 
(1:250, Kamiya Biomedical Company, Seattle, WA, USA) or sheep anti-uromodulin 
(1:750, Biotrend, Cologne, Germany; polyclonal) primary antibodies. Finally, kidney 
sections were incubated for 45 min at room temperature with a FITC-conjugated 
secondary anti-chicken antibody (1:200, Jackson ImmunoResearch, West Grove, 
PA, USA) combined with an Alexa Fluor 594-conjugated antibody (goat anti-guinea 
pig, goat anti-rat or donkey anti-sheep (1:300, life technologies, CA, USA) for TRPV5, 
BCRP or uromodulin respectively). Images were acquired with an AxioCam camera 
and processed using the AxioVision software (Zeiss, Sliedrecht, the Netherlands). 
Statistical analysis  
All data are shown as mean ± S.E.M. Statistical signiﬁ cance (p < 0.05) was 
determined by analysis of variance and a Dunn post-hoc test. For electrophysiological 
data, unpaired student t-test was used to assess statistical signiﬁ cance. 
  
Results
β-Galactosidase stimulates TRPV5 activity in the presence of the TRPV5 N-glycan.  
To   investigate  the effect of   β-gal on either TRPV5, HEK293 cells were transfected with TRPV5, 
TRPV5N358Q or empty vector. After 48 h, the activity of TRPV5 was assessed using a 45Ca2+ 
uptake assay. Ruthenium red, a TRPV5 inhibitor (10 µM, (28)), signiﬁ cantly inhibited 45Ca2+ 
uptake. β-gal (16 h, 1 U/mL) signiﬁ cantly stimulated 45Ca2+ uptake in cells expressing TRPV5, 
but had no effect on cells expressing TRPV5N358Q (Figure 1A). PCR analysis performed 
on cDNA from HEK293 cells using speciﬁ c β-gal primers showed that HEK293 cells 
endogenously express β-gal (Figure 1B). Exogenous galactose can inhibit endogenous 
β-gal activity and may therefore reduce TPRV5 activity. The addition of D(+)-galactose 
(2-3 µg/mL, 16 h) signiﬁ cantly inhibited 45Ca2+ uptake of TRPV5, but not that of TRPV5N358Q 
(Figure 1C). β-gal hydrolyses both end-standing β(1-3) and β(1-4) linkages (13). To clarify 
the mechanism of β-gal-stimulated TRPV5 activity, the effect of enzymes speciﬁ c for β(1-3) 
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(β(1-3)-gal, 20 mU/mL) or β(1-4) linkages (β(1-4)-gal, 20 mU/mL) were investigated. While 
the β(1-3)-gal enzyme did not stimulate 45Ca2+ uptake, β(1-4)-gal signiﬁ cantly enhanced 
TRPV5-mediated Ca2+ uptake in a similar manner as β-gal (Figure 1D). Importantly, 
β(1-4)-gal treatment did not alter the expression levels of TRPV5 protein (Figure 1D). 
TRPV5N358Q was insensitive to both β(1-3)-gal and β(1-4)-gal treatment (Figure 1E). 
Figure 1. β-gal speciﬁ cally stimulates TRPV5 activity. 
A) β-gal (1 U/mL, 16 h) stimulates TRPV5-mediated 45Ca2+ uptake in an N-glycan-dependent manner. 
Ruthenium Red (RR, 10 µM) inhibits 45Ca2+ uptake (n=17-19, from ﬁ ve independent experiments). B) 
Endogenous β-gal is detected in the presence of HEK293 cDNA (+), but not in its absence (-). C) Exogenous 
D(+)-galactose (2-3 µg/mL) treatment prevents β-gal-mediated stimulation of TRPV5 (n=19-20, from four 
independent experiments). D) β(1-4)-gal, but not β(1-3)-gal, stimulates TRPV5 activity (n=19-20, from ﬁ ve 
independent experiments). E) Neither β(1-4)-gal nor β(1-3)-gal (20 mU/mL) alter the activity of TRPV5N358Q 
(n=19-20, from ﬁ ve independent experiments). Data shown are mean ± SEM and statistical signiﬁ cance is 
denoted by * (p<0.05). F) Time-course  of  ß(1-4)-gal-mediated  TRPV5  stimulation  (n=11-12, from four 
independent experiments).  
β(1-4)-gal stimulates the activity of TRPV5 
To validate the speciﬁ city of the β(1-4)-gal-mediated TRPV5 stimulation, the function of 
TRPV5 and TRPV5N358Q was studied by whole-cell patch clamp measurements. Using Na+ 
80
Chapter 4
as the main charge carrier, Ca2+-sensitive inwardly rectifying currents were observed in cells 
expressing TRPV5 or TRPV5N358Q (Figure 2A). The shape of the EGTA-sensitive current-
voltage curve was similar for TRPV5 and TRPV5N358Q (Figure 2B-C). Pre-treatment with 
β(1-4)-gal signiﬁ cantly increased the current density of TRPV5-expressing cells at -100
mV, but did not affect the currents of the TRPV5N358Q mutant (Figure 2B-C). Further analysis
observable macroscopic parameters at -100 mV. Subsequently, cells expressing TRPV5 
or TRPV5N358Q were subjected to cell-attached patch clamp, as previously described (29). 
Using this approach, single-channel activity was detected for both TRPV5 and TRPV5N358Q 
(Figure 3A). Detailed analysis revealed that the single-channel conductance (Figure 3B) 
and open probability (Figure 3C) were not different between TRPV5 and TRPV5N358Q.
Figure 2. Patch clamp measurement of TRPV5 and TRPV5N358Q with or without β(1-4)-gal treatment. 
A) Inwardly-rectifying currents were observed in response to a voltage step protocol (top inset). Currents 
were sequentially measured in a solution lacking divalent cations (nDVF), nDVF solution containing 50 µM 
EGTA and ﬁ nally in Krebs buffer. Maximal current values were obtained by averaging a 25 ms time window 
at the end of each voltage pulse. B) The current-voltage curve of TRPV5 in the presence of 50 µM EGTA 
is signiﬁ cantly increased with β(1-4)-gal pre-treatment (n=19-23). C) The current density of TRPV5N358Q is 
insensitive to β(1-4)-gal at all tested voltages (n=8-13).  TRPV5/ TRPV5N358Q;  TRPV5/TRPV5N358Q + β(1-
4)-gal. Data shown are mean ± SEM and statistical signiﬁ cance is denoted by * (p<0.05).
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Figure 3. TRPV5 and TRPV5N358Q demonstrate similar intrinsic properties at the single-channel level. 
A) Single channel activity was detected in cell-attached mode in cells expressing TRPV5 or TRPV5N358Q. 
Channel activity was observed in response to a series of 10 x 10 s hyperpolarization from 0 to -80 mV in 
nDVF solution. Typical traces with corresponding amplitude histograms were shown for TRPV5 (top, 3 
channel) and TRPV5N358Q (bottom, 2 channels). B) Average current-voltage curves were obtained by ﬁ tting 
amplitude histograms obtained at -100, -80, -60 and -40 mV for TRPV5 (n=6, open symbol) and TRPV5N358Q 
(n=5, ﬁ lled symbol). The conductance, taken as the slope of the IV curve, was 81.7 ± 2.1 and 78.3 ± 1.8 
pS for TRPV5 and TRPV5N358Q, respectively. C) The open probability at -80 mV was calculated by weighting 
the average areas of the different open states in individual histograms (n=5-6).  TRPV5;  TRPV5N358Q. 
Data shown are mean ± SEM.
β(1-4)-gal promotes retention of TRPV5 at the plasma membrane 
Live-cell TIRF-M was performed on cells expressing a Dendra-2-TRPV5 fusion protein 
(9,30,31), as described previously (9), permitting the time-dependent visualization of 
channels situated in close vicinity to the plasma membrane (~70-100 nm). The Dendra2 
proteins were photo-converted using a brief UV-light pulse (405 nm, 2 s). A typical ﬁ eld 
of view for Dendra2-TRPV5 and Dendra2-TRPV5N358Q is shown (Figure 4A). To assess 
the time-dependence of plasma membrane TRPV5 and TRPV5N358Q expression, the 
ratio between the switched red fraction (F559) and unswitched green fraction (F488) was 
monitored over approximately 20 min. Subsequently, a region in the TIRF ﬁ eld was 
selected and the ratio between the switched red fraction (F559) and unswitched green 
fraction (F488) was calculated ((F559/F488)/(F559/F488)max). Before subjected to TIRF-M, cells 
were either treated with β(1-4)-gal for 16 h or left untreated, similarly to the cells in 45Ca2+ 
assays. This analysis revealed a signiﬁ cant increase of TRPV5 in plasma membrane 
retention time following β(1-4)-gal treatment (Figure 4B). Dendra2-TRPV5N358Q was 
subjected to an identical protocol. Under these conditions, the basal plasma membrane 
retention time increased, while β(1-4)-gal had no additional effect (Figure 4C). 
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Figure 4. β-gal stabilizes TRPV5 at the plasma membrane. 
Cells were subjected to live-cell TIRF-M. At 0 min, Dendra-2 was switched from green to red using an UV 
light pulse (λ=405 nm, 2 s) and ﬂ uorescence was followed over time. A) Typical TIRF-M ﬁ eld of view in 
HEK293 cells of the control and β(1-4)-gal treated conditions for Dendra2-TRPV5 and Dendra2-TRPV5N358Q, 
captured at the initial time point after photo-switching and after 18 min. B) Ratio of switched red/unswitched 
green fraction in HEK293 cells expressing Dendra2-TRPV5 over time (n=18). C) Ratio of switched red/
unswitched green fraction in HEK293 cells expressing Dendra2-TRPV5N358Q (n=11).   Control;  β(1-4)-gal 
treated. Data shown are mean ± SEM and statistical signiﬁ cance is denoted by * (p<0.05).
β-gal is expressed in the proximal tubule and enhances 45Ca2+ transport in mouse 
DCT2/CNT 
Immunoblot analysis indicated that β-gal was present in mice urine (Figure 5A). 
In addition, tubular β-gal protein expression was present in kidney sections, with an 
apparently stronger signal on the apical side. Co-localization was not observed between 
TRPV5 (DCT2/CNT marker) or uromodulin (thick ascending limb (TAL) marker) and 
β-gal. BCRP, a proximal tubule marker (32), did co-localized with β-gal (Figure 5B).
 Kidneys obtained from mice expressing enhanced GFP (eGFP) under the 
TRPV5 gene promoter were utilised (25,33) to assess the effect of β-gal on Ca2+ 
transport in a physiological setting. GFP-positive segments (DCT2/CNT) were sorted 
by COPAS (see Experimental procedures) and seeded on permeable transwell ﬁ lters. 
After 7 days in culture, these DCT2/CNT primary cells developed a monolayer with 
a transepithelial resistance of 547 ± 37 Ωcm2 (n=33). The monolayers were treated 
apically with β(1-4)-gal for 16 h (32 mU/mL) while forskolin, a known TRPV5 activator, 
was used as a positive control (34,35). Forskolin stimulates the cAMP/PKA pathway 
resulting in TRPV5 phosphorylation and thereby increasing channel activity (36). 
 Transepithelial Ca2+ transport was followed over time by supplying apical 45Ca2+ 
and sampling basolateral medium at different time points (t= 0, 15, 60 and 120 min) 
(Figure 5C). Treatment with either β(1-4)-gal or the positive control forskolin (10 µM) 
signiﬁ cantly increased Ca2+ transport across primary mouse DCT2/CNT monolayers 
(Figure 5D). 
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Figure 5. Expression of β-gal in mouse kidney and the 45Ca2+ transport in mouse DCT2/CNT. 
A) β-gal is expressed in mice urine (three different mouse urine samples). HEK293 cells transfected with 
mouse β-gal were used as positive control (β-gal). B) The localization of β-gal in mice kidney sections. 
β-gal is apically expressed in the proximal tubules along the nephron. Co-localization was found between 
β-gal and BCRP, a proximal tubule marker. C) 45Ca2+ transport in COPAS sorted primary mouse DCT2/CNT 
cells in time.  Control;  β(1-4)-gal (32 mU/mL);  forskolin (10 µM). D) The slope of 45Ca2+ transport was 
signiﬁ cantly increased upon forskolin and β(1-4)-gal treatment (n=13, from ﬁ ve independent experiments). 
Data shown are mean ± SEM and statistical signiﬁ cance is denoted by * (p<0.05).
Discussion
This study revealed a new regulatory mechanism of transepithelial Ca2+ transport by which 
the extracellular glycosidase β(1-4)-gal stimulates TRPV5 channel activity via the TRPV5 
N-glycan. This conclusion is based on the following observations: i) β(1-4)-gal enhanced 
TRPV5 activity; ii) this stimulatory effect was absent in the non-glycosylated TRPV5N358Q 
mutant; iii) β(1-4)-gal stabilized TRPV5 on the cell plasma membrane; iv) β-gal was present 
in mouse urine; v) apical β-gal stimulated Ca2+ transport in primary DCT2/CNT cells.
 This study demonstrated that TRPV5N358Q and β(1-4)-gal-treated TRPV5 channels 
had increased plasma membrane stability without a signiﬁ cant change in their intrinsic 
biophysical properties. Even though β(1-4)-gal could affect numerous glycoproteins, 
the effect on the Ca2+ uptake is speciﬁ c for TRPV5 as the TRPV5N358Q expressing cells 
are not responsive to β(1-4)-gal treatment. Other members of the TRPV family have 
also been shown to present glycosylation-dependent regulation (37,38). For instance, 
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ablation of the unique N-glycan in TRPV4 enhanced plasma membrane residency of 
the channel without affecting its function (37). In contrast, preventing glycosylation 
of TRPV1 at the residue N604 altered its ionic permeability and capsaicin sensitivity. 
An N-glycan-mediated alteration of plasma membrane stability of TRPV1 cannot 
be excluded, due to the presence of multiple glycosylation sites in TRPV1 (38). Our 
ﬁ ndings suggest that the N358 residue does not take part in the gating or structural 
constituents of the pore of TRPV5. In accordance, mutational ablation of the TRPV5 
N-glycan could reduce clathrin-mediated internalization, as previously suggested for 
sphingosine 1-phosphate receptor Edg-1 and the dendritic cell-speciﬁ c intracellular 
adhesion molecule-3-grabbing nonintegrin (DC-SIGN) (9,39,40). Further experiments 
studying the details of TRPV5 trafﬁ cking will be necessary to validate this hypothesis.
 Extracellular galectins are glycan-binding proteins with high afﬁ nity for 
N-acetyllactosamine (LacNAc), a saccharide repeat of Gal-(β-1,4)-GlcNAc units (41). 
Galectin-1, -3, -8 and -9 are expressed in mammalian kidneys (42). A galectin-mediated 
regulation of TRPV5 could be a new regulatory mechanism of Ca2+ transport. Previous 
reports have suggested that binding of galectin-1 and galectin-3 stabilizes TRPV5 
at the plasma membrane (9,10). Furthermore, TRPV5 co-localized with galectin-3, 
but not with galectin-1. Finally, TRPV5-mediated Ca2+ uptake in HEK293 cells was 
stimulated by extracellular galectin-3 and galectin-1 (9,10). In contrast, galectin-3 
can also stimulate the internalization of proteins after binding (9,43-45). Galectin-
mediated interactions may restrict the mobility of plasma membrane proteins to 
clathrin-enriched regions (40). Ablation of the glycan would results in larger membrane 
exploration and reduced interaction with clathrin, thereby compromising clathrin-
dependent internalization. It is, therefore, tempting to hypothesize that galectins bind 
to the TRPV5 N-glycan and thereby reduce the plasma membrane mobility of the 
channel, and thus favouring clathrin-mediated endocytosis. Treatment with β-gal 
can alter the binding of galectins, thereby inhibiting clathrin-mediated endocytosis.
 Ca2+ transport is increased in isolated mice DCT cells expressing endogenous 
TRPV5 by apical β(1-4)-gal treatment. However, it remains uncertain if the β-gal derived 
in the proximal tubules can have the same effect. Future research should show the direct 
effect of proximal β-gal on TRPV5 activity. Interestingly, a correlation between TRPV5 
and β-gal is found in diabetic mellitus diseased patients. This disease is associated 
with renal Ca2+ wasting, although the molecular mechanisms underlying these ﬁ ndings 
are not known. A compensatory upregulation of TRPV5 mRNA and protein levels have 
been observed in diabetic rats (46). Interestingly, diabetes mellitus type 1 patients show 
elevated β-gal levels in blood as well as in urine, suggesting that β-gal upregulation may 
represent an additional mechanism of compensation to prevent renal Ca2+ wasting (47,48).
 Finally, patients with a deﬁ ciency in β-gal expression commonly present 
skeletal anomalies (18,19). GM1 gangliosidosis is associated with ﬂ attening of 
vertebral bodies, while Morquio B disease is associated with skeletal dysplasia. This 
phenotype is comparable to the TRPV5-/- mice, which show signiﬁ cant alterations 
in bone structure (20). Future in vivo studies may substantiate the link between 
the observed phenotype in β-gal-diseased patients and TRPV5 dysregulation.
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Abstract
The transient receptor potential vanilloid type 5 (TRPV5) Ca2+ channel facilitates 
transcellular Ca2+ reabsorption in the kidney. It is of importance that this epithelial Ca2+ 
channel is tightly regulated, as it is responsible for the ﬁ ne-tuning of Ca2+ excretion. 
Based on the recently elucidated TRPV1 structure, a TRPV5 homology model has been 
designed by an automatic script using the YASARA and WHAT IF Twinset. Structural 
analysis of this homology model proposes a gating mechanism based on an aromatic 
gate in combination with a helix hinge. The present study delineates two residues that 
are essential in the gating mechanism of the TRPV5 channel. First, a tryptophan (W583) 
that is located at the end of the inner pore helix, transmembrane six, with its side chain 
facing the permeation pathway. Mutation of this residue heavily increased the TRPV5-
mediated Ca2+ inﬂ ux. The expression of mutated TRPV5 channels led to high basal Ca2+ 
levels and consequently to an increased cell death. Substitution to an aromatic residue 
had intermediate effects with a nearly 10-fold increase in Ca2+ uptake levels, while 
replacement with a non-aromatic residue yielded a stronger phenotype of an averaged 
30-fold increase in Ca2+ uptake levels. Moreover, the open probability of the non-aromatic 
mutant channels was increased. A ﬂ exible glycine residue (G579), located one α-helical 
turn above the tryptophan residue, was shown to be important for channel opening. 
Replacement of this residue with alanine ablated TRPV5-mediated Ca2+ transport and 
decreased the open probability ~5-fold. It is concluded that the TRPV5 gating machinery 
is composed of the highly conserved tryptophan-gate in combination with a glycine-hinge. 
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Introduction
The transient receptor potential vanilloid type 5 (TRPV5) channels form the apical gate for 
transepithelial Ca2+ reabsorption in the kidney (1). TRPV5, formerly known as ECaC1/CaT2, 
is expressed in the late distal convoluted tubule and connecting tubule of the nephron in the 
kidney, the early intestine and the placenta (1-4). Functional channels are composed of four 
subunits, each containing six transmembrane (TM) segments and intracellular amino (N)- 
and carboxyl (C)-termini (5,6). The Ca2+-selective pore is formed at the interface of the four 
subunits, by TM segment ﬁ ve, six and the pore loop between these two segments. TRPV5 
is a constitutively active Ca2+-selective cation channel, with a substantial permeability 
at physiological membrane potentials and a Ca2+-dependent feedback regulation (7). 
 The TRP family consists of ion channels with a similar structure but a great variety 
in their mechanisms of activation. TRPV5 is most homologous to TRPV6, a Ca2+-selective 
channel expressed in the intestine. Compared to TRPV1-4, TRPV5 and TRPV6 display 
a speciﬁ c selectivity ﬁ lter sequence, allowing a more pronounced selectivity for Ca2+ 
over monovalent cations (8). The TRPV5 Ca2+-selectivity ﬁ lter is composed of a ring of 
four aspartic acid residues (D542), which are localized in the pore loop (9). This single 
residue is crucial for the channel characteristics such as a high Ca2+ permeability, block 
by Mg2+, and Ca2+-dependent current decay (7). Mutation of this residue into an alanine 
abolishes Ca2+ permeability without altering the permeability for monovalent cations (7). 
 A high intracellular Ca2+ level functions as a negative feedback mechanism and will 
inhibit TRPV5 channel activity (10). This inhibition is controlled by the concentration of Ca2+ 
in a micro domain near the inner mouth of the channel. Calmodulin (CaM), a ubiquitous Ca2+-
binding protein, has been postulated to mediate part of the Ca2+-dependent inactivation 
by binding to the C-terminus of TRPV5 (11-13). A high intracellular Ca2+ concentration 
enhances the CaM binding. CaM binding decreases TRPV5-mediated Ca2+-uptake by 
reducing the open probability. Removal of the C-terminal fragment of TRPV5 (S696X) 
abolishes the sensitivity for CaM (12). Moreover, PTH-mediated T709 phosphorylation 
diminishes the CaM binding and thereby increases TRPV5-mediated Ca2+ transport (12). 
 The current knowledge about the gating mechanism of TRPV5 and other Ca2+ 
selective channels is limited. In contrast, several mechanisms have been proposed for 
the gating of voltage-gated K+ channels (14): i) rotation of the inner pore helix around the 
pore axis, ii) kinking of the inner pore helix, and iii) helix kinking in combination with an 
aromatic gate. Most eukaryotic K+ channels are regulated by kinking of the inner pore 
helix at a proline-valine-proline (PVP) sequence (15), a motif that is absent in TRPV5. 
Prokaryotic K+ channel gating is often mediated by helix kinking in combination with 
an aromatic gate (15). Channel regulation via an aromatic gate is often accompanied 
by a ﬂ exible hinge point at the bottom of the α-helix, composed of a glycine (14). 
 Recently, the ﬁ rst high resolution 3D structure of a TRP channel (TRPV1) has 
been solved at 3.4 Å. Electron cryo-microscopy elucidated the structure of TRPV1 in a 
closed conformation (16). Rat TRPV1 may serve as a suitable template for homology 
modeling of the rabbit TRPV5 structure (17). The present study shows a homology model 
of TRPV5 that is used to delineate the gating mechanism of TRPV5. The tryptophan 
residue at position 583 (W583) is investigated in view of its localization at the intracellular 
end of the pore and the unusual orientation of its side chain pointing towards the solvent. 
Mutation of this residue is severely affecting the channel function of TRPV5. In addition, 
a glycine residue (G579) has been detected one α-helical turn above W583. Mutation 
of this residue in the rigid and slightly bigger alanine abolishes Ca2+ transport through 
the channel. These results provide the ﬁ rst evidence that the gating mechanism of 
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TRPV5 involves the combination of an aromatic tryptophan gate and glycine hinge point.
Experimental procedures
Generating the TRPV5 homology model 
The YASARA (18) & WHAT IF (19) Twinset was used to build a homology 
model of TRPV5, based on the TRPV1 structure as a modelling template 
(29% sequence identity, PDB ﬁ le 3j5p) (16). An automatic script with standard 
parameters was used. The model contained residue 1-644 of rabbit TRPV5. 
DNA constructs and transfections 
The pCINeo/IRES-GFP plasmid encompassing either HA-tagged rabbit TRPV5 or 
untagged rat CaM were generated as described previously (11,20). The TRPV5G579A and all 
TRPV5W583 mutants were obtained by site-directed mutagenesis of TRPV5-pCINeo/IRES-
GFP. The TRPV5D542A mutation was introduced by site-directed mutagenesis of TRPV5-
pCINeo/IRES-GFP. Subsequently, this construct was digested with BspEI and AgeI and a 
PCR product of TRPV5698X was introduced. All constructs were veriﬁ ed by DNA sequencing. 
Cell culture and transfections 
HEK293 cells were grown in Dulbecco’s modiﬁ ed eagle’s medium (DMEM, Bio 
Whittakker-Europe, Verviers, Belgium) containing 10% (v/v) fetal calf serum 
(PAA, Liz Australia), 2 mM L-glutamine and 10 µg/ml non-essential amino acids 
at 37 ºC in a humidity-controlled incubator with 5% (v/v) CO2. The cells were 
transiently transfected with the respective DNA construct using lipofectamine 
2000 (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions.
Immunoblotting and determination of protein concentration 
HEK293 cells expressing TRPV5 and indicated mutants were disrupted in lysis buffer 
containing Triton X-100 1% (v/v), 150 mM NaCl, 5 mM EDTA, 50 mM Tris/HCl pH 7.5, 
1 mM phenylmethanesulfonylﬂ uoride (PMSF), 10 µg/ml leupeptin, 10 µg/ml pepstatin 
A, 5 µg/ml aprotinin. Protein concentration was measured using the BCA protein assay 
kit (Thermo Scientiﬁ c, Rockford, IL, USA), according to manufacturer’s instructions. 
Cell lysates were subjected to 8 % (w/v) SDS-PAGE and immunoblotted using anti-HA-
tag (1:5,000, Cell Signalling Technology, Beverly, MA, USA) with peroxidase-labelled 
goat anti-mouse IgG (1:10,000, Chemie Brunschwig, Basel, Switzerland) antibodies. 
45Ca2+ uptake assay 
HEK293 cells were transfected with TRPV5, indicated mutants, or the empty pCINeo/
IRES-GFP vector (mock). One day after transfection, cells were reseeded on poly-L-
lysine-coated (0.1 mg/ml) culture dishes. Radioactive 45Ca2+ uptake in TRPV5-transfected 
HEK293 cells was determined as previously described (21). If required, cells were 
incubated with 10 μM ruthenium red (RR) 30 min prior to the 45Ca2+ uptake measurements. 
Trypan blue assay
HEK293 cells were transfected as indicated. Two days after transfection the cells were 
collected and precipitated by centrifugation (2 min, 200 g). The supernatant was discarded and 
cells were resuspended in phosphate buffered saline (PBS), pH 7.4, adding 4 % (w/v) trypan 
blue (Sigma) to a ﬁ nal concentration of 0.08%. Cells were counted using a hemocytometer.
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Intracellular Ca2+ measurements using fura-2-AM 
HEK293 cells were seeded on ﬁ bronectin-coated coverslips (diameter, 25 mm) 
and transfected as indicated. After one day, cells were loaded for 20 min with 3 
µM fura-2-acetoxymethyl ester (fura-2-AM; Molecular Probes) and 0.01% (v/v) 
Pluronic F-129 (Molecular Probes) in Krebs solution (5.5 mM KCl, 147 mM NaCl, 
1.2 mM MgCl2, 1.5 mM CaCl2, 10 mM glucose, and 10 mM HEPES/NaOH, pH 7.4) 
at 37°C. Subsequently, the cells were washed once with Krebs solution and allowed 
to equilibrate at 37°C for another 10 min. Details of microscopy procedures and 
quantitative image analysis have been described previously (22). In short, fura-2-
loaded cells were placed on an inverted microscope using an incubation chamber 
containing Krebs solution and intracellular Ca2+ levels were determined with fura-2 
excited at 340 and 380 nm. All measurements were performed at room temperature. 
Electrophysiology 
Experiments were performed using an EPC-9 ampliﬁ er and the Patchmaster software 
(HEKA electronics, Lambrecht, Germany). The sampling interval was set to 200 ms for 
whole-cell recordings and 100 ms for single-channel recordings. Whole-cell recordings 
were acquired with a low-pass ﬁ lter set at 3.6 kHz, while single-channel recordings 
had a low-pass ﬁ lter set at 5 kHz. The electrical noise was further reduced using the 
Humbug 50/60 Hz noise eliminator (Quest Scientiﬁ c, Vancouver, Canada). Whole-cell 
patch clamp pipettes were pulled from thin-walled borosilicate glass (Harvard Apparatus, 
March-Hugstetten, Germany) and had resistances between 1 and 3 MΩ when ﬁ lled with 
the pipette solution. Series resistance compensation was set to 75-95% in all whole-cell 
experiments. Single-channel patch clamp pipettes were made of thick-walled borosilicate 
glass (Harvard Apparatus and World Precision Instruments) and had resistances 
between 8 and 11 M when ﬁ lled with the pipette solution. Two different extracellular 
solutions were used to obtain whole-cell recordings. A nominally divalent-free (nDVF) 
solution comprising (in mM): 150 NaCl, 6 CsCl, 10 glucose, 10 HEPES and pH adjusted 
to 7.4 using NaOH. A divalent-free (DVF) solution based on nDVF solution with 50 µM 
of added EGTA. The pipette solution comprised (in mM): 20 CsCl, 100 CsAspartate, 1 
MgCl2, 10 BAPTA, 4 Na2ATP, 10 HEPES and pH adjusted to 7.2 using CsOH. Cells were 
initially bathed in nDVF extracellular solution. The whole-cell EGTA-sensitive current 
was obtained by measuring the current sensitive to the perfusion of 50 µM EGTA. A 
voltage step protocol, consisting of voltage steps from -100 to +40 mV was applied 
from a holding potential of +20 mV. Current densities were calculated by normalizing 
the current amplitude at −80 mV to the cell membrane capacitance. The extracellular 
solution for cell-attached recordings contained (in mM): 150 NaCl, 6 CsCl, 10 glucose, 
10 HEPES and pH adjusted to 7.4 using NaOH. The pipette solution comprised (in mM): 
140 NaCl, 10 EGTA, 10 HEPES and pH adjusted to 7.2 using NaOH (23). Single channel 
activity was monitored upon a 10s step to -80 mV from a holding potential 0 mV. All 
experiments were performed at room temperature. The analysis and display of whole-
cell recordings were performed using Igor Pro software (WaveMetrics, Lake Oswego, 
USA). Single-channel recordings were analyzed using the Qub software package (24). 
Cell surface biotinylation assay 
HEK293 cells were transiently transfected with TRPV5, the indicated mutants, or the 
empty pCINeo/IRES-GFP vector. One day after transfection, cells were reseeded on 
poly-L-lysine-coated (0.1 mg/ml) culture dishes. Subsequently, cells were biotinylated 
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as described previously (25) and disrupted in 1 ml lysis buffer; 1 % (v/v) Triton-X100, 
150 mM NaCl, 5 mM EDTA, 50 mM Tris (pH 7.5 adjusted with HCl), 1 mM PMSF, 10 
µg/ml leupeptin, 10 µg/ml pepstatin A, 5 µg/ml aprotinin. TRPV5 protein expression at 
the cell surface and in total cell lysate was determined as described previously (25).
CaM binding assay 
HEK293 cells were transiently transfected with TRPV5D542A, S698X, TRPV5D542A, S698X, W583L, 
TRPV5D542A, S698X, W583F in pCINeo/IRES-GFP or the empty pCINeo/IRES-GFP vector. Two 
days after transfection, cells were washed twice with ice-cold PBS pH 7.4 and disrupted in 
0.5 ml lysis buffer; 0.5 % (v/v) Triton-X100, 150 mM NaCl, 50 mM Tris (pH 7.5 adjusted with 
HCl), 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml pepstatin A, 5 µg/ml aprotinin, enriched with 
CaCl2 (1 mM) or EGTA (2.5 mM, Sigma). Following, the cells were centrifuged for 10 min 
at 14,000 g at 4°C. For input samples, 30 µl supernatant was treated with Leammli buffer, 
enriched with 100 mM dithiothreitol (DTT), for 30 min at 37°C. Remaining supernatant was 
added to 200 µL CaM agarose beads (Sigma, St. Louis, MO, USA) and rotated overnight 
at 4°C. The beads were washed 6 times with wash buffer; 0.1 % (v/v) Triton-X100, 150 
mM NaCl, 50 mM Tris (pH 7.5 adjusted with HCl), 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/
ml pepstatin A, 5 µg/ml aprotinin, enriched with either CaCl2 (1 mM) or EGTA (2.5 mM). 
Finally, proteins were eluted by incubation with Leammli buffer, enriched with 100 mM DTT, 
for 30 min at 37°C and the TRPV5 protein was assessed by immunoblotting as described.
Statistical analysis 
All data are shown as mean ± standard error of the mean (SEM). Statistical signiﬁ cance 
(p < 0.05) was determined by analysis of variance and a Dunn post-hoc test. For 
electrophysiological data, unpaired student t-test was used to assess statistical 
signiﬁ cance.   
Results
TRPV5 homology model
A TRPV5 homology model was generated using the recently determined structure of 
rat TRPV1 (16) (Fig 1A). The Sander-Schneider plot indicates that 29% amino acid 
identity between rabbit TRPV5 and rat TRPV1 is sufﬁ cient for homology modelling 
(17). To validate the TRPV5 homology model, some regulatory motifs of TRPV5, 
including the aspartic acid D542, asparagine N358 and the ankyrin repeats, were 
inspected (7,25,26). First, the localization and orientation of the D542 Ca2+-selectivity 
ﬁ lter in the homology model was assessed (7,9,27) and appeared correctly localized 
and oriented, forming a negatively charged ring at the entry of the channel (Fig 1B). 
Ankyrin repeats were detected on the intracellular side as small α-helices, with the 
expected twist between the 4th and 5th ankyrin repeat (26). Based on these known amino 
acid residues and the overall validity of the homology model, the TRPV5 structure 
was further examined for amino acids that might critically affect the channel gating.
 A visual inspection outlined the W583 residue situated at the intracellular 
end of TM six, with its side chain pointing towards the ion permeation pathway (Fig 
1C). Given the hydrophobic nature of the tryptophan side chain, this conformation 
appears energetically unfavourable. The W583 residue is localized in a region that 
is highly conserved among different species (Table 1). It is conserved in TRPV6, but 
not in other members of the TRPV family (Table 2). The side chain of a tryptophan 
can convert to different rotameric positions. One of these rotamers constituted a 
95
The TRPV5 gate is composed of a W-gate and G-hinge
conformation prohibiting Ca2+ permeation (Fig 1D, E). Dehydrated Ca2+ ions have a 
diameter of 0.99 Å. Passage of Ca2+ ions is prohibited when the W583 side chains are 
facing each other. The estimated distance between the centers of the side chains is 
~3.1 Å, and therefore, the passage size will be ~0.8 Å. This is too small for dehydrated 
Ca2+ to pass the channel pore (28) (Fig 1E). However, the absolute values of these 
measurements should be handled with care as this data is based on a homology model. 
Table 1: Sequence alignment between TRPV5 of different species. The region containing the W583 
residue is conserved between the different species (* = exact match).
Table 2: Sequence alignment of TRPV channels. W583 is only conserved in the highly homologous 
TRPV6 channel (* = exact match; : = strongly similar properties; . = weakly similar properties). 
  
Gain of function in TRPV5 upon W583 mutation
To investigate the involvement of W583 in TRPV5 channel gating, site-directed 
mutagenesis was applied to substitute W583 into different amino acids (aromatic: 
TRPV5W583Y and TRPV5W583F; non aromatic: TRPV5W583Q, TRPV5W583L and TRPV5W583A). 
The activity of the mutated channels was assessed using 45Ca2+ uptake assays. The 
TRPV5 blocker ruthenium red was applied to determine the magnitude of the TRPV5-
mediated 45Ca2+ inﬂ ux (29). The 45Ca2+ uptake was similar between mutant and wild type 
TRPV5 (Fig 2A). However, the TRPV5 protein expression was signiﬁ cantly reduced in 
cells expressing mutants compared to wild type TRPV5 (Fig 2A). After correcting for 
expressional differences, a signiﬁ cant increase in 45Ca2+ uptake was detected for all 
mutants (Fig 2B). In general, non-aromatic W583 mutants (TRPV5W583Q, TRPV5W583L 
and TRPV5W583A) yielded poor expression and a ~25 to 43-fold enhancement in 
Ca2+ uptake, while both aromatic TRPV5W583Y and TRPV5W583F mutants showed 
intermediate Ca2+ inﬂ ux (~7 to 10-fold increase). Of note, partial but signiﬁ cant 
inhibition by ruthenium red treatment was observed in all TRPV5 mutants (Fig 2C). 
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Figure 1. Homology model of TRPV5.
A) Side, top and bottom view of the tetrameric TRPV5 channel. Each subunit is displayed in a different 
color. B) Localization of the selectivity ﬁ lter, composed of four D542 residues that are depicted in green. 
These residues are located at the top of the channel, at the bottom are presented the W583 residues in 
yellow. C) Side view of the W583 residue (yellow), presented at the interface of the lipid membrane layer 
and the cytosol. The hydrophobic side chains stick into the solvent. D) All possible rotameric positions 
for the W583 side chains. Three main rotameric positions are detected; with the side chains sticking up, 
pointing down or pointing towards each other. E) Distance between the W583 side chains based on the 
TRPV5 homology model in the main rotameric positions.
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Figure 2. W583 mutation increases the Ca2+ uptake, resulting in cell death. 
A) 45Ca2+ uptake assay and the protein expression of HEK293 cells transfected with TRPV5, TRPV5W583L, 
TRPV5W583F, TRPV5W583Q, TRPV5W583A or TRPV5W583Y (n=9, from three independent experiments). Ruthenium 
red (RR) was used as a negative control. B) 45Ca2+ uptake assay of HEK293 cells transfected with TRPV5, 
TRPV5W583Y, TRPV5W583F, TRPV5W583Q, TRPV5W583A or TRPV5W583L corrected for protein expression. C) 
45Ca2+ uptake of the W583 mutants can be blocked by treatment with the TRPV5 inhibitor RR (10 µM) (n=9-
12, from three independent experiments). D) Cell viability assay of HEK293 cells expressing TRPV5 or any 
of the W583 mutants. Modulation of the W583 residue results in cell mortality (n=6, from three independent 
experiments). E) The basal intracellular Ca2+ levels, as measured by fura-2-AM, are signiﬁ cantly increased 
for all W583 mutants compared to TRPV5 expressing cells (n>30, from two independent experiments). 
Data shown are mean ± SEM, statistical signiﬁ cance is reﬂ ected by * (p<0.05). 
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In line with the reduced protein expression, we observed a decrease in cell survival 
upon transfection with the TRPV5 mutants, which was conﬁ rmed by a trypan blue assay 
demonstrating enhanced cell mortality for all TRPV5 mutants, compared to wild type 
TRPV5 (Fig 2D). To support the link between enhanced TRPV5 Ca2+ uptake and reduced 
cell survival, the basal intracellular Ca2+ levels were assessed using fura-2-AM, a cell-
permeant ratiometric ﬂ uorescent Ca2+ indicator. Compared to a basal Ca2+ level of 0.7 
arbitrary units (a.u.) in wild type TRPV5, the basal levels of the W583 mutants were 
approximately 3-fold enhanced (1.8 - 2.3 a.u.) (Fig 2E). These high intracellular Ca2+ 
levels might cause the observed cell death.
TRPV5 W583 mutants are functional at the plasma membrane
Next, a non-aromatic and aromatic mutant TRPV5 channel (TRPV5W583L and TRPV5W583F) 
were subjected to whole-cell patch clamp recording to examine the channel characteristics. 
Figure 3A shows representative traces of TRPV5, TRPV5W583L and TRPV5W583F that are 
recorded using a voltage step protocol (from -100 to 40 mV). Importantly, the mutant 
channels exhibited the characteristic Na+ inward-rectifying current in nominally divalent-
free (nDVF) bath solution, which were enhanced upon extracellular addition of EGTA 
(DVF) (Fig 3A). Of note, the absolute currents of both TRPV5 mutants were 3-4 fold smaller 
than wild type TRPV5. To conﬁ rm channel expression at the plasma cell membrane, a 
cell surface biotinylation was performed on HEK293 cells expressing TRPV5, TRPV5W583L 
and TRPV5W583F. Even though the overall protein expression was reduced, the relative 
plasma membrane abundance of both TRPV5W583L and TRPV5W583F was not altered (Fig 
3B). 
Figure 3. TRPV5 W mutants are functional at whole-cell level and expressed at the plasma membrane.
A) Representative traces of the whole-cell Na+ currents of TRPV5, TRPV5W583L and TRPV5W583F are 
measured from a step protocol (-100 to +40 mV) in nominally DVF (nDVF) and divalent-free (EGTA) 
solutions. B) Cell surface biotinylation of TRPV5, TRPV5W583L and TRPV5W583F. Top panel displays the 
total protein expression, while the bottom panel displays the fraction of TRPV5 present on the plasma 
membrane. Representative immunoblot of three independent experiments is depicted. 
Mutation of W583 increases the open probability of TRPV5
In order to assess putative changes in the intrinsic properties of the mutant TRPV5 
channels, cells expressing wild type TRPV5, TRPV5W583F, TRPV5W583L, TRPV5W583Y, 
TRPV5W583A and TRPV5W583Q were subjected to cell-attached patch clamp. Brieﬂ y, TRPV5 
activity was measured by applying a series of 10 s voltage steps to -80 mV from a holding 
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voltage of 0 mV, using Na+ as the charge carrier. By applying this protocol, frequent patches 
containing one to three channels were obtained and analyzed for amplitude of openings 
and open probability. Representative channel openings and amplitude histograms are 
depicted in Figure 4. While TRPV5W583F showed no difference in openings compared 
to wild type TRPV5, the TRPV5W583L, TRPV5W583Y, TRPV5W583A and TRPV5W583Q mutants 
presented altered single-channel activity with shorter closing and opening times (Fig 
4A-F). Analysis of these recordings revealed a ~2-fold increase in the open probability 
of TRPV5W583Q, TRPV5W583L, TRPV5W583Y, and TRPV5W583A compared to TRPV5 (Fig 4G). 
On the other hand, the open probability of TRPV5W583F was decreased compared to the 
wild type channel (Fig 4C, G). The amplitude of opening at -80 mV was not signiﬁ cantly 
different between wild type and the mutants (Fig 4H). 
Figure 4. Single channel activity is increased in the TRPV5 W583 mutants. 
Cell-attached single channel recordings were measured during a 10 s step to -80 mV (holding potential 0 
mV) in A) wild type TRPV5, B) TRPV5W583Y, C) TRPV5W583F, D) TRPV5W583Q, E) TRPV5W583A, F) TRPV5W583L. 
Representative amplitude histograms are shown with a Gaussian ﬁ t function corresponding to the closed 
and open states. G) The average open probability and H) amplitude are plotted for wild type and mutant 
TRPV5 (n>7 per condition). Data shown are mean ± SEM, statistical signiﬁ cance is reﬂ ected by * (p<0.05).
W583 does not participate in CaM binding
To address the role of the TRPV5 W583 residue in CaM binding and its involvement on 
TRPV5 activity, a CaM binding assay was performed for wild type TRPV5, TRPV5W583F and 
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TRPV5W583L. It has previously been demonstrated that CaM binds to or near the intracellular 
C-terminal region of TRPV5, involving the W702 residue (12). Mutation of this residue or 
deletion of the TRPV5 C-terminal region (TRPV5S689X) signiﬁ cantly enhanced Ca2+ inﬂ ux 
and cell death. Since CaM can bind at different positions in TRPV5, we hypothesized that 
W583 could also be involved in CaM binding. Hence, the TRPV5S689X mutant was used to 
prevent CaM from binding to the C-terminal region. In order to enhance the cell survival of 
TRPV5S689X, an additional D542A pore mutation (7) was incorporated as mutation of 
this residue is known to block the Ca2+ inﬂ ux (7). The resulting TRPV5D542A, S698X double 
mutant was used to assess whether W583 may form or participate in an additional 
binding site(s) of CaM (12). Calmodulin immobilized on agarose beads was used to 
precipitate TRPV5D542A, S698X in the absence (EGTA) or presence of Ca2+. Clear binding 
of TRPV5D542A, S698X was observed in the presence of Ca2+, and a weak background CaM 
binding under Ca2+-free conditions (Fig 5A). The precipitation of the TRPV5D542A, W583F, S698X 
and TRPV5D542A, W583L, S698X mutants by CaM was similar compared to wild type TRPV5, 
implying that W583 is not involved in CaM binding (Fig 5B). Patch clamp analysis 
revealed that co-transfection with CaM signiﬁ cantly increases the open probability 
for TRPV5, but decreased the elevated open probability of TRPV5W583Q (Fig 5C). 
Figure 5. W583 is not involved in CaM binding. 
A) TRPV5D542, S698X binds CaM in the presence of Ca2+. The top panel displays the total channel expression 
and the bottom panel illustrates the CaM bound TRPV5 fraction. B) Both TRPV5D542, S698X, W583F and 
TRPV5D542, S698X, W583L bind CaM in the presence of Ca2+. Quantiﬁ cation is performed over three independent 
experiments. C) The average open probability of TRPV5 and TRPV5W583Q without or with CaM co-
expression. Black bars represent control; white bars represent co-expression with CaM. Data shown are 
mean ± SEM, statistical signiﬁ cance is reﬂ ected by * (p<0.05).
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Figure 6. TRPV5G579A mutation blocks TRPV5-mediated Ca2+ uptake and channel activity. 
A) 45Ca2+ uptake assay of the TRPV5G579A mutant. The protein expression level is not altered (n=9, from 
three independent experiments). B) TRPV5G579A protein expression at the plasma membrane. The top 
panel displays the total channel expression, and the bottom panel illustrates the plasma membrane 
fraction. Representative immunoblot of three independent experiments is depicted. C) The I-V relation 
of mock, wild type TRPV5 and TRPV5G579A is extracted through a voltage step protocol in DVF solution 
(left). Averaged Na+ current densities at -80 mV are presented in the right panel. D) The open probability 
at -80 mV is assessed using cell-attached patch clamp in cells expressing the TRPV5G579A mutant. Typical 
single-channel behaviour is shown for TRPV5G579A. The average open probability is determined (n>7 per 
condition). Data shown are mean ± SEM, statistical signiﬁ cance is reﬂ ected by * (p<0.05).
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G579 forms the inner pore helix hinge
In addition to the identiﬁ cation of W583, we detected a ﬂ exible hinge point one α-helical 
turn above the aromatic gate. This G579 residue could form a structural hinge point, 
allowing the W583 residues to change position. In order to test this hypothesis, G579 was 
mutated into the more rigid alanine. Radioactive Ca2+ uptake experiments demonstrated 
that TRPV5G579A function is signiﬁ cantly reduced (41 ± 3% vs 100 ± 2%) and comparable 
to ruthenium red-inhibited uptake levels (36 ± 2%). Total protein expression was not 
altered (Fig 6A). Cell surface biotinylation assays showed that TRPV5G579A is present at 
the plasma membrane, although at slightly reduced levels (100 ± 4% vs. 72 ± 16%) (Fig 
6B). Whole-cell patch clamp recording demonstrated a signiﬁ cantly diminished current 
density for TRPV5G579A, with no difference in the current/voltage relationship (Fig 6C). 
Cell-attached single channel analysis of the TRPV5G579A mutant revealed a decreased 
open probability of 3 ± 0.6% compared of 21 ± 4% for wild type (Fig 6D). Of note, the 
amplitude of opening is not changed (Fig 6D).
Discussion
This study presents a new model for TRPV5 channel gating in which the channel is 
mediated by an aromatic gate (W583) in combination with a gating hinge (G579) (Fig 
7). This conclusion is based on the following observations: i) 45Ca2+ uptake is increased 
for all W583 mutants; ii) basal intracellular Ca2+ levels are higher in all W583 mutants; 
iii) the open probability of the W583 mutants, except for TRPV5W583F, is increased, 
and iv) 45Ca2+ inﬂ ux and the open probability of the TRPV5G579A mutant is decreased. 
Figure 7. Proposed gating mechanism of TRPV5. 
The gate of TRPV5 is composed of a glycine hinge and a tryptophan gating residue at the end of TM 
domain six (blue). A currently unknown stimulus induces the bending of the inner pore helix, changing the 
relative position of the tryptophan residues resulting in channel opening (red). 
A TRPV5 homology model was developed based on the recently solved TRPV1 
structure. The rotameric conformations of W583 were analyzed and three major side 
chain positions were detected: pointing down, pointing up or facing each other. Unless 
Ca2+ is protein bound, the ion is surrounded by a hydration shell of nine to ten water 
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molecules (30). The passage of Ca2+ with a hydration shell requires 2.95 Å, while 
dehydrated Ca2+ ions only have a diameter of 0.99 Å (28). Passage of Ca2+ with a 
hydration shell is likely to be impeded, independent of the rotameric position of W583. 
When the W583 side chains are facing each other, passage of dehydrated Ca2+ ions 
will be hampered since the estimated distance between the centers of the side chains 
is ~3.1 Å, implying that the size for passage is ~0.8 Å (Fig 1E). Both other rotameric 
positions are not likely to hinder the dehydrated Ca2+ ﬂ ow, as the gate radius is ~11.2 Å. 
 Often, aromatic residues anchor proteins into the cell membrane through 
interactions with the lipid head groups (31). These residues are then localized at the 
interfacial regions of a TM α-helix and the solvent, acting to anchor the helix into the 
cell membrane (31). Tryptophan residues generally localize to the extracellular face 
in α-helical membrane proteins (32), in contradiction to what is observed here for 
TRPV5. In addition, the current homology model suggests that W583 is pointing 
in opposite direction from the lipids. These observations, together with the present 
ﬁ ndings suggest that W583 may not participate in the interaction of the α-helix with 
lipids, but has a role in channel gating. As a result of their size and oblateness, a small 
rotation in the aromatic residue can lead to a large change in width of the gate (14).
 It was demonstrated that substitution of W583 with a non-aromatic residue 
(TRPV5W583Q, TRPV5W583L, TRPV5W583A) results in massive 45Ca2+ inﬂ ux and cell death, 
while change to an aromatic residue (TRPV5W583F, TRPV5W583Y) seems to have a 
more intermediate phenotype. The open probability of TRPV5W583F is even decreased 
compared to wild type TRPV5. Possibly, TRPV5W583F is leaky towards Ca2+, but can still 
close the channel to some extent as a result of its hydrophobic aromatic characteristics.
The reduced cell viability of the W583 mutants is likely a result of high intracellular 
Ca2+ concentration, as evidenced using ratiometric fura-2-AM imaging. The overall 
deleterious effect and scarcity of suitable cells did not allow for accurate quantiﬁ cation 
and comparison of current densities between the TRPV5 W583 mutants and wild type 
TRPV5. A similar effect on the cell viability was observed for the overactive TRPV5M490P 
and TRPV5S698X mutants (22,33). The observed ruthenium red-mediated inhibition of the 
W583 mutants was smaller compared to TRPV5. Ruthenium red blocks TRPV5 function 
in a voltage-dependent manner, by binding to the extracellular side of the channel (29). 
A possible explanation for the partial ruthenium red inhibition is that cells expressing 
W583 mutants might not have an intact transmembrane voltage, given their poor viability. 
 CaM is previously described as the mediator of Ca2+-dependent TRPV5 inhibition 
(12). The high intracellular Ca2+ levels in cells expressing the W583 mutants might 
imply that W583 is involved in the TRPV5 interaction with CaM. However, our TRPV5 
homology model implies that CaM (PDB: 3CLN) cannot reach W583, as a result of 
steric hindrance. Furthermore, there was no difference in CaM binding observed for 
the tested TRPV5 D542A, S698X, W583L and TRPV5 D542A, S698X, W583F. Based on these indirect 
data it is not likely that CaM is involved int his regulation pathway, however it cannot 
be excluded.  Interestingly, co-expression of TRPV5 with CaM increased the single-
channel open probability, an effect that appears counter-intuitive based on the previously 
described inhibitory role of CaM (12). A likely explanation is that over-expressed CaM 
is sufﬁ cient to buffer intracellular Ca2+ and thereby increases the TRPV5 channel open 
probability. This effect would be absent in TRPV5W583Q due to the high basal intracellular 
Ca2+ concentration. Further experiments will be needed to address this question. 
 A gating function for aromatic residues has been observed previously for other 
ion channels. The proton-selective inﬂ uenza virus M2 channel is regulated by a so-called 
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tryptophan gate (34). This tryptophan gate is stabilized by aspartate residues through a 
network of hydrogen bonds, which support the closed state conformation of the channel 
(35). Upon lowering the outside pH, four histidine residues in this network are protonated, 
leading to a change in conformation of the tryptophan gate. Moreover, the prokaryotic K+ 
channel KcsA is regulated by a phenylalanine gate and mutations at this position have 
a size-dependent effect on gating kinetics (36). Small side-chain substitution results in 
impaired inactivation kinetics, while substitution with larger side chain residues has minor 
effects on channel characteristics. The prokaryotic K+ inwardly rectifying KirBac 1.1 channel 
functions in a similar manner through four phenylalanine residues at the cytoplasmic end 
of the pore (37). These residues are displaced by bending a so-called gating hinge (a 
glycine) in the inner pore helices, thereby allowing channel opening (14,38). A similar 
gating mechanism has been proposed for the closely related KirBac 3.1 channel, using 
a tyrosine residue (39). The TRPV5 homology model reveals a highly conserved glycine 
(G579), located one α-helical turn above the aromatic gate that may cause such a helix 
kink. Mutation of G579 into an alanine completely blocked the 45Ca2+ uptake by reducing 
the open probability, leading to the hypothesis that G579 is essential for proper channel 
gating. Substitution of this residue confers the channel pore into a rigid closed state. 
 Future work aims at studying the stimulus for this conformational change. The 
TRPV5 TM six α-helix is known to change its conformation upon extracellular acidiﬁ cation 
(40). In addition, the pore helix is rotated along its axis as a result of intra- or extracellular 
acidiﬁ cation (41). A pH sensitive histidine (582) is located directly above the tryptophan gate. 
Protonation of the histidine residue might cause the hinge to change the relative positions 
of the tryptophan residues, thereby opening or closing the channel. In addition, external 
factors such as phosphatidylinositol 4,5-bisphosphate (PIP2) can potentially regulate the 
TRPV5 gating mechanism. PIP2 stabilizes TRPV5 in its open conformation (42). The 
TRP domain, located directly below the tryptophan gate, is involved in the PIP2-mediated 
stimulation (43). Interestingly, TRPV5, TRPV6 and the K+ channels displaying a similar 
type of gating are all stimulated by PIP2 (14,44). In contrast, TRPV1 shows no conservation 
of the tryptophan gate and is inhibited by PIP2 (43). Future studies should determine the 
stimulus underlying the conformational changes that result in TRPV5 channel gating.
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Introduction
Glycosylation of a protein is the most complex and diverse form of posttranslational 
modiﬁ cation. Moreover, it is highly abundant as more than 50% of the total proteome 
is modiﬁ ed with a glycan (1). The composition of a glycan can inﬂ uence protein activity, 
membrane trafﬁ cking and many other processes (2). However, due to the  high degree of 
variability in glycan structure, it is difﬁ cult to investigate regulatory pathways in detail. In 
addition, only few labeling methods enable direct detection of glycans in vitro and in vivo (3).
 The Transient Receptor Potential Vanilloid type 5 (TRPV5) Ca2+ channel is an 
example of a protein whose activity is regulated via a glycan located at an extracellular 
asparagine (N) side chain (therefore called N-glycan). The TRPV5 channel facilitates the 
gatekeeper function to regulate renal Ca2+ handling and determines the ﬁ ne-tuning of 
Ca2+ excretion via the urine (4). This active transcellular Ca2+ reabsorption takes place in 
the late distal convoluted tubule (DCT2) and connecting tubule (CNT). Here, Ca2+ enters 
the epithelial cells via the constitutively active and Ca2+-selective TRPV5 channel. The 
intrinsic activity, expression and plasma membrane abundance of the channel regulates 
the total amount of TRPV5-mediated Ca2+ inﬂ ux, as illustrated in chapter 1. Control of 
TRPV5 function via the N-glycan is poorly understood as a result of the high complexity 
of glycan regulation and inadequate glycan labeling tools. This thesis elucidated the 
role of the N-glycan of TRPV5 in the physiological process of renal Ca2+ handling. 
Glycan labeling via click chemistry
There is a need for glycan detection methods that do not interfere with the cell dynamics, 
are easy to use and have high labeling speciﬁ city. To this end, it is essential that the 
particular chemical reaction, which visualizes a glycan, takes place at a high rate and with 
low substrate concentration. Bioorthogonal reactions meet these criteria; with the most 
prominent glycan labeling method used nowadays being the copper-catalyzed azide–
alkyne (3+2) cycloaddition, also known as the click reaction. The click reaction quickly and 
reliably joins two small molecules together, thereby enabling speciﬁ c saccharide labeling. 
The attractiveness of this reaction can be attributed to its high biocompatibility and simplicity. 
Besides the popular copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC), a copper-
free version of the click reaction, known as strain-promoted azide–alkyne cycloaddition 
(SPAAC), has gained signiﬁ cant recognition (5). However, SPAAC is hampered by 
low speciﬁ city in vitro and in vivo (6,7). Reaction rate and selectivity are the two key 
factors determining the suitability of particular chemical reaction for bioconjugation (8). 
 As described in chapter 1, the chemical reporter strategy used for glycan 
labeling involves two steps, ﬁ rst the introduction of an abiotic molecular tag, followed 
by bioorthogonal conjugation with a molecule of choice with designed complementary 
reactivity. To date, the azide group (–N3) is the most utilized bioorthogonal tag, as it is small 
and inert towards most components. In chapter 2, an azide-functionalized saccharide, 
N-azido-acetylmannosamine (ManNAz), was metabolically incorporated into proteins 
expressed in Human embryonic Kidney 293 (HEK293) cells at the position of the sialic 
acids. To ensure a good reactivity of SPAAC, optimal conditions for ManNAz incorporation 
were determined. The incorporation of ManNAz can differ between several cell lines, and 
the use of Chinese hamster ovarian (CHO) cells instead of HEK293 cells might improve 
labeling efﬁ ciency as a result of difference in metabolic incorporation and glycosylation 
patterns (9). In addition, ManNAz is also highly incorporated in gangliolipids, glycosylated 
lipids in the plasma membrane, which compose 75% of the total signal (10). Therefore, 
blocking the synthesis of gangliolipids can increase the labeling speciﬁ city for protein 
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N-glycans. ManNAz compete with the natural saccharide (N-acetylmannosamine) and 
has a lower afﬁ nity to metabolic enzymes compared to endogenous sugars, therefore 
only a fraction of proteins have the non-natural glycan incorporated. It remains to be 
elucidated if the non-natural sugar distribution reﬂ ects the in vivo glycan distribution. 
Cyclooctynes, their strengths and weaknesses
The second step in the chemical reporter strategy involves the bioorthogonal conjugation. 
In chapter 2, the SPAAC reaction is used to label sialic acids in HEK293 cells with speciﬁ c 
developed conjugating molecules, cyclooctynes. The past few years, the effectiveness of 
cyclooctynes used for SPAAC is greatly enhanced by structural modiﬁ cations. The rate of 
most cyclooctynes used in SPAAC is high enough for in vitro and in vivo use (0.012 – 0.96 
Μ-1s-1) (8). Biarylazacyclooctynone (BARAC) is the cyclooctyne with the highest reactivity, 
however broad application is hampered by its lengthy synthesis and low stability (11,12). As 
a result of their good reactivity, stability and accessibility, dibenzoazacyclooctyne (DIBAC)
(13) and bicyclo[6.1.0]nonyne (BCN) (14) are the most commonly used cyclooctynes.
 SPAAC is limited by its selectivity, as thiol-yne additions and unspeciﬁ c hydrophobic 
interactions are common side reactions in vitro and in vivo (6,7). Thiol-yne additions, 
the reaction between a cyclooctyne and a free thiol, takes place at a relatively low 
rate compared to the SPAAC reaction (15). Though, once the cyclooctyne is residing 
intracellular or internalized by the animal, it cannot be removed that quickly, allowing 
thiol-yne additions. In vitro, free thiols can be blocked with iodoacetamide (IAM) prior 
to addition of a cyclooctyne, thereby preventing unspeciﬁ c thiol-yne additions (6,16). 
However, administration of IAM is not suitable for living systems and, therefore, its 
use is restrained. In vivo, unspeciﬁ c thiol-yne additions also limit speciﬁ c detection, as 
cyclooctynes injected in mice react in an azide-independent manner with the free thiol 
group in serum albumin (17). Recently, a cyclooctyne displaying only low unspeciﬁ c thiol-
yne additions was developed (18). However, this might be attributed to the cell line used 
for these experiments and future studies should indicate the use of this cyclooctyne (19). 
 The hydrophobicity of cyclooctynes does not only result in poorly water-soluble 
compounds, but also in potential unspeciﬁ c hydrophobic interactions with proteins or with 
the cell lipid bilayer. The calculated partition-coefﬁ cient (clogP) indicates the distribution 
of a compound between two solutions, typically n-octanol and water, and is a measure 
of lipophilicity. Most cyclooctynes have a calculated clog P value between 0.8 and 4.8 (8) 
(Table 1). One can hypothesize that more polar cyclooctynes display a higher labeling 
speciﬁ city in vitro and in vivo. Leeper et al. developed a more polar variant of DIBO (20), 
called tetramethoxydibenzocyclooctyne (TMDIBO), with a reaction rate of ~ 9.8 × 10-2 
M -1s-1 in the (3+2) cycloaddition with benzyl azide. The signal-to-noise ratio was greatly 
improved for this probe compared to DIFO3, a 3rd generation variant of diﬂ uorocyclooctyne 
(DIFO). Based on the clog P value, this improvement was unforeseen as the hydrophobicity 
for TMDIBO is higher than for DIFO3 (clog P 3.7 vs. 3.3) (18). No direct correlation was 
detected between the labeling speciﬁ city and hydrophilicity of the cyclooctynes (Table 
1 and Table 2), and therefore it can be assumed that unspeciﬁ c signaling is caused 
by a combination of hydrophobic interactions and thiol-yne additions. Hence, the ‘ideal’ 
cyclooctyne will display low unspeciﬁ c thiol-yne additions and hydrophobic interactions, 
which can be achieved by preventing intracellular accumulation of the cyclooctynes. The 
cyclooctyne can be easily removed when it is restricted to the outside of the cell, limiting 
its reaction time and thereby preventing the slow thiol-yne additions. This method is 
only valuable if extracellular labeling is requested. One way this can be accomplished, 
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is by implementing a charge which will also restrict unspeciﬁ c hydrophobic interactions. 
 Chapter 2 describes the development of three polar derivatives of BCN, which 
were analyzed for their speciﬁ city. BCN and its derivatives have a similar reaction rate of 
~ 2 M -1s-1 in the (3+2) cycloaddition with azidocoumarin. The reaction rates were almost 
10 times higher than earlier determined for BCN, via (3+2) cycloaddition with benzyl azide 
(14 × 10-2 M -1s-1) (14) (chapter 2) (Table 2). A phenomenon that can be explained by the 
ﬁ nding that BCN reacts much faster with aromatic azides than with aliphatic azides, as a 
result of the inverse electron demand mechanism that is operative when reacting with an 
aliphatic cyclooctyne such as BCN (21). The newly developed probes were functionalized 
with a biotin tag and have calculated clog P values between 0.3-2.1 in their anionic 
state. To compare the clog P values with other cyclooctynes, the value of the N-methyl 
carbamate derivative of alcohols or acetyl derivative of the amine was calculated (Table 1). 
Table 1: Overview of commonly used cyclooctynes. 
BARAC = biarylazacyclooctynone, BCN = bicyclo[6.1.0]nonyne, DIBAC = dibenzoazacyclooctyne, DIBO 
= dibenzocyclooctyne, DIFO = diﬂ uorocyclooctyne, DIMAC = dimethoxyazacyclooctyne, TMDIBO = 
tetramethoxydibenzocyclooctyne. Reaction rate is determined by reaction with benzyl azide, unless stated 
otherwise. N.D. is not determined. a Calculated for the N-methylamide derivatives of carboxylic acids, the 
N-methyl carbamate derivatives of alcohols and the acetyl derivative of primary and secondary amines.
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As expected, the hydrophobicity is lower than for most other cyclooctynes. 
Charged cyclooctynes displayed a higher labeling speciﬁ city in vitro as 
illustrated in chapter 2. However, solely increasing the hydrophilicity, 
as shown for BHM-BCN, did not improve the labeling speciﬁ city. 
 Importantly, speciﬁ c Golgi-staining with SPAAC via A-BCN was presented in chapter 
2. Since glycans are matured with sialic acids in the trans-Golgi, this signal seems rather 
speciﬁ c. So far, only few cyclooctynes were found to exhibit speciﬁ c intracellular labeling 
(22). It would be interesting to make a panel of cis-, medial-, endo- and trans-Golgi stainings 
in combination with a sialic acid labeling using A-BCN to fully determine the speciﬁ city of this 
staining. As the role of glycosylation in diseases such as infection, inﬂ ammation and cancer 
metastasis is now widely recognized, A-BCN can potentially aid in developing a method to 
identify abnormal localization and accumulation of glycoproteins in these diseases (22). 
Table 2: overview of developed BCN derivatives.
 a Measured in (MeCN:H2O, 1:2) by reaction with azidocoumarin. 
b Calculated for the N-methylamide 
derivatives of carboxylic acids, the N-methyl carbamate derivatives of alcohols and the acetyl derivative of 
primary and secondary amines. c Calculated for the neutral compound.
Overall, the BCN derivatives synthesized in chapter 2 can assist in future studies aiming at 
optimizing in vivo use of SPAAC. So far, only few studies were performed to compare the two 
most popular (3+2) cycloaddition reactions, SPAAC and CuAAC (23,25). SPAAC displays 
shorter reaction times and needs only low equivalents of reagents, both beneﬁ cial for the 
cell viability. Moreover, there is no need for accessory reagents such as a ligand and thus 
no extensive optimization is required. The labeling efﬁ ciency of SPAAC, using BARAC, was 
compared with several ligand-enriched CuAAC reactions, via application of the chemical 
reporter strategy with ManNAz in living cells and zebraﬁ sh. This study implies that the 
use of CuAAC in combination with a ligand results in more speciﬁ c glycan labeling in cell 
lysates compared to SPAAC (23). As BARAC is rather hydrophobic and instable, it would 
be interesting to perform a similar study with a different cyclooctyne such as BCN or DIBAC.
Dual labeling of the protein and the glycan
At present, the cycloaddition reactions used for glycan labeling are saccharide- but 
not protein-speciﬁ c. Cellular protein-speciﬁ c glycan labeling can aid in the study of 
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glycosylation patterns and their involvement in protein regulation and trafﬁ cking pathways. 
Dual labeling with a Förster resonance energy transfer (FRET) donor-acceptor pair can 
be used to accomplish in vitro dual labeling of protein and glycan. The glycan of a chosen 
protein can be visualized, as close proximity between a FRET donor-acceptor pair (~ 
10 nm) results in a speciﬁ c excitation wavelength. Cell surface glycans of determined 
proteins can be labeled by combining CuAAC on the N-glycan with an amino(N)-terminal 
protein label. By labeling the protein and the N-glycan positions with a FRET donor-
acceptor pair, the glycan of the speciﬁ c protein can be visualized (32,33). Unfortunately, 
only cell membrane proteins with an extracellular N-terminus can be visualized using this 
method, as the extracellular N-glycan has to be in close proximity. Alternatively, genetic 
encoding can be used to tag the protein, which in principle allows the incorporation 
of a non-natural amino acid at any chosen position in the protein. In short, the mRNA 
sequence is altered such that an unnatural amino acid (UAA) gets incorporated at 
the location of an introduced amber stop codon. To this end, the cell is provided with 
additional machinery: 1) a tRNA molecule that will recognise the amber stop codon 
and the UAA and 2) an aminoacyl-tRNA synthetase for in vivo assembly of tRNA-UAA. 
Following, the UAA will be incorporated at the position of the amber stop codon. This 
technique has previously been used to incorporate an azido group into a G protein-
coupled receptor (34), but can also function for the incorporation of cyclooctynes (35-37).
 For dual labeling of the protein and the N-glycan, two successive, mutually 
orthogonal reactions have to be performed. For example, the Diels–Alder reaction with 
inverse electron-demand (IEDDA), a reaction between a terminal alkene and a tetrazine, 
can be used in concert with SPAAC (38) (Fig 1). Thus, an alkene can be incorporated into 
the protein via genetic encoding (39), followed by implementation of an azide into the glycan 
as described in chapter 2. Next, the alkene can react with a tetrazine via the IEDDA, and 
the azide can react with a cyclooctyne as indicated previously (38). In addition, a similar 
system can be developed using strain-promoted inverse-electron-demand Diels-Alder 
cycloaddition (SPIEDAC) between a trans-cyclooctyne and a tetrazine in combination 
with SPAAC (37). In this way, a trans-cyclooctyne will be built into the protein via genetic 
encoding, after which it is allowed to react with a tetrazine. The azide can be metabolically 
incorporated in the glycan and react with a strained cyclooctyne as described in chapter 2.
 Labeling TRPV5 in a dual manner via both its N-glycan and the protein can provide 
information on how TRPV5 is regulated and localized by its N-glycan. Moreover, direct 
evidence that klotho does or does not cleave sialic acids from the TRPV5 N-glycan can 
be provided via such a method. In addition, the effect of sialic acids on internalization 
or plasma membrane stabilization of TRPV5 can be investigated. The study can be 
easily expended to other saccharides such as glucosamine, galactosamine and fucose 
analogs (3,40). To develop such a method, the incorporation of an azido-saccharide 
into the N-glycan of TRPV5, as developed in chapter 2, is necessary. In addition, an 
alkene moiety should be implemented into the channel protein via genetic encoding 
(39). Finally, both moieties can react via the SPAAC and IEDDA with their bioorthognal 
partners that are tagged with a FRET donor or acceptor. However, there are some 
concerns one should consider when developing this method. First, the alkene has to 
reside extracellularly, as the distance between the FRET donor-acceptor pair should 
be small. Since, both the N- and C- terminal regions of TRPV5 reside intracellular, the 
amber stop codon should be positioned in the small region between two membrane-
spanning domains, which may cause difﬁ culties in protein folding. Second, as the 
incorporation of the UAA at the amber stop codon is in competition with the endogenous 
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system, TRPV5 expression will be suppressed. The expression of membrane 
proteins is rather low, applying genetic encoding may cause detection problems. 
Figure 1. Dual labeling allows speciﬁ c TRPV5 glycan detection. 
The glycan can be labeled with an azide and detected via the SPAAC reaction as described previously. 
In addition, the TRPV5 protein should be labeled speciﬁ cally. This can be done by genetic encoding. A 
speciﬁ c amino acid with an alkene can be incorporated in TRPV5 speciﬁ cally. Subsequently, the Diels–Alder 
reaction with inverse electron-demand can performed and a label can be added this linker. Subsequently, 
FRET can take place between these two dyes, only if they are in close proximity.     
Another interesting experiment would be to implement an artiﬁ cial glycan at the 
N358 position of TRPV5. This would allow us to study the effect of different (tetra) 
saccharides on TRPV5 localization and activity. Genetic encoding with the amber 
stop codon positioned at the N358 position and a cyclooctyne labeled UAA may allow 
the  implementation of a reactive moiety. (36,37). Following, azide-functionalized 
saccharides can react via SPAAC with the UAA, allowing the incorporation of 
a speciﬁ c chosen saccharide on TRPV5. Functionality of the channel can be 
tested via patch-clamp and radioactive Ca2+ assays, while total internal reﬂ ection 
ﬂ uorescence microscopy (TIRF-M) can be used to detect the protein trafﬁ cking. 
Klotho glycosidase activity remains elusive
Klotho is a type-1 transmembrane protein that is predominantly expressed in the 
kidney, parathyroid glands and epithelial cells of the choroid plexus in the brain (41). 
The protein consists of one transmembrane and two similar extracellular domains, 
KL1 and KL2 (~ 440 amino acids) (41). The extracellular domains can be cleaved 
at two different positions by A Disintegrin and Metalloprotease (ADAM) 10 or 
ADAM17 (42), resulting in three fragments; KL1, KL2 and KL1-KL2. Soluble klotho 
(KL1, KL2 or KL1-KL2) is detected in the blood, urine and cerebrospinal ﬂ uid (43).
 In 2005, soluble klotho has been found to stimulate TRPV5-mediated Ca2+ inﬂ ux 
via a mechanism dependent on the TRPV5 N-glycan (44). To understand the molecular 
mechanism of klotho-mediated TRPV5 regulation, it is important to determine the 
enzymatic activity of klotho. Based on homology studies, it was suggested that klotho
has glycosidase activity, as the KL1 and KL2 domains have an amino acid sequence 
identity of 20–40% with family 1 glycosidases (41,45). Interestingly, two glutamate 
(E) residues, critical for enzymatic activity, are not conserved between klotho and the 
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family 1 glycosidases (Table 3). Since the discovery of klotho as a potential glycosidase, 
much effort has been made to determine its speciﬁ c activity. Klotho was shown to 
possess β-glucuronidase activity towards β-glucuronic acids from 4-methylumbelliferyl 
β-D-glucuronide, though this activity was 26 times lower than the control bovine 
β-glucuronidase activity (46). Furthermore, glucuronic acids are uncommon moieties in 
N-glycans, therefore it is unlikely that TRPV5 is regulated by β-glucuronidase activity (47). 
 In 2008, Cha et al. hypothesized that klotho exerts sialidase activity (48). Removal 
of the end-standing sialic acids from the TRPV5 N-glycan by klotho will then expose 
an N-acetyllactosamine (LacNAc) repeat, a region composed of repeating disaccharide 
Gal-(β1-4)-GlcNAc units. Galectin-1 is a glycan binding protein that was found to bind 
this repeat and thereby stabilize the channel on the plasma membrane (48) (Fig 2A). 
They showed that blocking of sialyltransferase ST6-gal1, which catalyses the transfer 
of sialic acids via α2-6-linkage to galactose residues of Gal-(β1-4)-GlcNAc, abolished 
the klotho-mediated stimulation (48), indicating that klotho needs α2-6-linked sialic acids 
for its function. In addition, the klotho-mediated effect was absent in the presence of the 
sialidase inhibitor, N-acetyl-2,3-dehydro-2-deoxyneuraminic acid (DANA) (48). However, 
this compound inhibits speciﬁ cally the sialic acid hydrolysis of glycosphingolipids 
(49), implying that the effect might be independent of the TRPV5 N-glycan. 
 In chapter 3, the effect of sialidase treatment on the non-glycosylated 
TRPV5N358Q mutant was further investigated. Cha et al. described that the non-
glycosylated TRPV5N358Q mutant is insensitive to sialidase treatment (48). In contrast 
to literature (48), sialidase stimulated TRPV5 channel activity independent of the 
TRPV5 N-glycan. Our data suggests that sialidase-mediated TRPV5 stimulation is not 
speciﬁ c via the TRPV5 N-glycan, as opposed to klotho-mediated TRPV5 stimulation.
 Previously, sialidase was reported to prevent microdomain clustering and lipid 
raft formation by hydrolyzing sialic acids from glycosphingolipids, glycosylated lipids 
highly expressed in lipid rafts (50). Lipid rafts are involved in caveolae-dependent 
endocytosis and, hence, disruption of these lipid membrane compositions via sialidase 
may reduce endocytosis. Chapter 3 conﬁ rmed that the sialidase-mediated TRPV5 
stimulation is caused by reduced caveolae-dependent endocytosis (Fig 2B), resulting 
from disturbed lipid raft formation (50). Interruption of the lipid rafts via ﬁ lipin, a 
compound known to dislocate these microdomains, eliminated the effect of sialidase 
on TRPV5. In contrast, ﬁ lipin did not inﬂ uence the klotho-mediated stimulation on 
TRPV5, implying that klotho acts independent of caveolae-mediated endocytosis. 
Additionally, sialidase hydrolysed the sialic acids of the model glycoprotein 
transferrin that contains end-standing α2-6-linked sialic acids, while 
klotho did not alter the glycan structure as described in chapter 3.
Table 3: Alignment of mouse KL1 and KL2 domains with family 1 glycosidases.
ClustalW alignment of mouse KL1, mouse KL2, guinea pig cystosolic β-glucosidase 
(GpcBGL) and rat lactase-phlorizin hydrolase (rLPH). The conserved glutamate residues 
are indicated in gray. mKL1 has an N at the ﬁ rst conserved E position, while the mKL2 
domain has an alanine (A) at the second conserved E site. Adapted from Ito et al. (45).
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However, one could hypothesize that klotho does not show sialidase activity on 
transferrin because it needs a particular ‘glycan signature’ for cleavage, which is absent 
in transferrin. Based on the data illustrated in chapter 3, it cannot be excluded that klotho 
has sialidase activity, although no evidence is found demonstrating this enzymatic activity. 
Klotho controls TRPV5 membrane expression 
The enhanced TRPV5 function after klotho treatment results from higher plasma 
membrane abundance as shown in previous studies (44,48). Biotinylation 
assays demonstrated that the amount of TRPV5 channels reaching the plasma 
membrane is increased upon klotho treatment. However, this method was not 
able to differentiate between increased trafﬁ cking to the cell surface or a decreased 
protein turnover at the membrane. Therefore, TIRF-M was combined with a 
photoswitchable TRPV5-Dendra-2 protein in chapter 3. Using this technique, it 
was demonstrated that klotho increases the plasma membrane stability of TRPV5. 
The plasma membrane without any treatment. Interestingly, N-glycans are known
to allow the localization of proteins towards clathrin-enriched regions. Non-glycosylated 
proteins are no longer localized to clathrin-enriched areas, resulting in diminished 
endocytosis (51). TRPV5 can be endocytosed via the clathrin- and caveolae-
mediated pathways (52,53), and ablation of the N-glycan reduces clathrin-mediated 
endocytosis resulting in the observed membrane stabilization (51) (chapter 3). 
 Other ion channels, such as Transient Receptor Potential Vanilloid type 6 (TRPV6), 
the renal outer medullary K+ channel (ROMK), and the Na+-K+-ATPase pump are also 
regulated by klotho (54-56). TRPV6 is a Ca2+ channel closely related to TRPV5 (75% 
amino acid identity). It contains a similar N-glycosylation site situated at the extracellular 
loop between transmembrane (TM) domain 1 and 2, and channel function can be activated 
upon klotho treatment (55). However, klotho is not expressed in the intestine where 
TRPV6 is located. The physiological relevance of klotho-mediated TRPV6 regulation 
remains elusive, but soluble klotho may be transported towards the intestine (57). More 
distant channels such as TRPV4 (29% amino acid identity) and TRPM6 (19% amino acid 
identity) are not stimulated by klotho (55). Similar to TRPV5, klotho treatment increases 
ROMK plasma membrane expression (54) in an N-glycan-dependent manner (Fig 3). 
However, the stabilization pathway through which klotho regulates ROMK and TRPV5 
is different. Klotho-mediated ROMK stimulation results from reduced clathrin-mediated 
endocytosis (54), while the TRPV5 plasma membrane stabilization was proposed to be 
caveolae-dependent (48). It seems striking that klotho inﬂ uences different endocytosis 
pathways for these channels, while the ﬁ nal outcome is similar. Chapter 3 illustrated that 
disruption of lipid rafts, and thereby caveolae-mediated endocytosis, does not inﬂ uence 
TRPV5 stimulation by klotho. This data suggests that the membrane stabilization of 
TRPV5 by klotho is actually clathrin-dependent. Interestingly, the N-glycan is also often 
involved in the localization of proteins towards clathrin-enriched regions, connecting 
klotho to glycan-mediated regulation pathways (51). Finally, klotho stimulated the 
recruitment of the Na+-K+-ATPase pump to the plasma membrane, via binding to the 
Na+-K+-ATPase α1 subunit (56) (Fig 3). A subset of Na+-K+-ATPase proteins appeared 
to trafﬁ c from the ER to the cell surface in conjunction with klotho (56). Recently, klotho 
was shown to stimulate the Na+,K+-ATPase pump activity in Xenopus laevis oocytes (58).
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Figure 2. Molecular mechanisms involved in klotho-mediated TRPV5 regulation. 
A) Klotho hydrolyses sialic acids from the TRPV5 N-glycan, exposing a terminal LacNAc 
region. To this region, galectin-1 can bind, stabilizing TRPV5 at the plasma membrane (48). 
B) 1. The activity of Kloto remains to be elucidated. 2. Sialidase hydrolyses the sialic acids 
of both the TRPV5 N-glycan and glycosphingolipids (GSL). By hydrolyzing sialic acids from 
glycosphingolipids, lipids rafts are disturbed and TRPV5 is stabilized at the plasma membrane. 
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Literature described that the membrane stabilization involves galectin-1 binding to 
the TRPV5 N-glycan (48). An antibody against galectin-1, but not against galectin-8, 
abolished klotho-dependent TRPV5 stimulation in CHO cells (48). In addition, this group 
isolated galectin-1 via a co-immunoprecipitation with TRPV5 after cross-linking the cell 
membrane (48). In contrast, our group could not detect galectin-1 expression in HEK293 
cells, as explained in chapter 3. Therefore the expression pattern of galectin-1 in the 
kidney was further elucidated. Galectin-3, but not galectin-1, mRNA was enriched in 
isolated mouse DCT2/CNT cells. Moreover, TRPV5 co-localized with galectin-3 in the 
kidney, but not with galectin-1. It has been demonstrated that galectin-3 is essential for 
apical targeting of proteins (59) and protein stability regulation (60). Extracellular galectin-3 
treatment increased TRPV5 activity only in the presence of the TRPV5 N-glycan, since 
the TRPV5N358Q mutant was not regulated. Though, galectin-3 in combination with klotho 
did not further increase TRPV5-mediated Ca2+ inﬂ ux (chapter 3), suggesting that klotho-
mediated channel stabilization does not involve galectin-3 binding. Next to the stimulating 
effect of extracellular klotho on TRPV5, a recent study described that intracellular klotho 
can also stabilize the channel on the plasma membrane (61). However, future research 
should determine the physiological relevance of this recent ﬁ nding. 
The mystery of klotho, the molecular basis for TRPV5 activation. 
The concept that klotho has sialidase activity is improbable based on the data depicted 
in chapter 3. Moreover, β-glucuronidase activity is doubtful, as β-glucuronic acids 
are only scarcely expressed in N-glycans. It is interesting to address the question if 
klotho could be a lectin-like protein that binds glycans without altering the glycan 
structure (Fig 4A). An example of such action by klotho can be found in the FGF23-
bone-kidney axis. Binding of klotho to the ﬁ broblast growth factor receptor (FGFR) 
down-regulates the 1,25(OH)2D3 production, as outlined in chapter 1. Membrane-
Figure 3. Klotho regulates several ion 
channels. 
1. ROMK is stimulated by klotho in a similar manner 
as previously proposed for TRPV5 (Fig 1A) 
(54). 2. The Na+,K+-ATPase channel is recruited 
towards the plasma membrane by klotho. It 
remains unknown how klotho binds this channel 
and which type of klotho (membrane bound 
or soluble) is involved in this mechanism (56).
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bound klotho converts the canonical FGFR to a speciﬁ c receptor for ﬁ broblast growth 
factor 23 (FGF23), enabling high-afﬁ nity binding of FGF23 and thereby inhibition of 
the 1,25(OH)2D3 production (62). Klotho has no enzymatic activity towards the FGFR, 
probably the protein regulates the FGFR solely via binding (Fig 4B). It should be noted 
that membrane-bound klotho binds the receptor, while soluble klotho regulates TRPV5. 
Chapter 3 demonstrated that simultaneous treatment with galectin-3 and klotho did 
not additively stimulate TRPV5 activity. This could imply that klotho and galectin-3 
stimulate TRPV5 in a similar manner, indicating that klotho functions as a lectin that 
recognizes the TRPV5 N-glycan. One can speculate that klotho competes with regular 
galectins, but has a higher afﬁ nity for speciﬁ c saccharide repeats. Thereby klotho can 
either stabilize the protein on the plasma membrane or prevent localization to clathrin-
enriched regions. Both pathways will result in increased expression of the channel at 
the plasma membrane. Interestingly, the hypothesis of klotho being a binding protein 
would be in line with the homology of the protein, since residues presented in the active 
site of glycosidases are not conserved in klotho. Moreover, homology has been found 
with the lactase-like protein (21% amino acid sequence identity), a protein that lacks 
glycosidase activity (45). However no homology was detected with any type of lectin. 
 To investigate the exact mechanism via which klotho stimulates TRPV5 activity, 
the glycan sequence to which klotho binds needs to be determined. This can be studied 
via a highly sensitive glycan microarray using klotho with a tag (63). The deﬁ ned glycan 
array available from the Consortium for Functional Glycomics (CFG) is the easiest 
method to use. Klotho can be tagged with NHS-activated biotin, a compound that reacts 
with primary amine groups in proteins. Following, klotho can be detected by binding of 
ﬂ uorescent streptavidin to the biotin. After determining the sequence of the glycan that 
binds klotho, assays can be performed to elucidate if the presence of klotho results 
in modiﬁ cation of the glycan. Future research should be performed to analyse the 
glycan sequence that binds klotho, and determine its activity on this glycan sequence. 
Figure 4. Klotho has no enzymatic activity. 
A) One could hypothesize that klotho has only binding properties. Binding of soluble klotho will stabilize 
the channel at the plasma membrane, either by stabilizing the protein at the plasma membrane (as 
depicted) or by localizing the protein away from the clathrin-enriched regions. B) Klotho regulates the 
speciﬁ city of FGFR for FGF23, by binding to the FGFR. Full-length klotho is involved in this system (62).
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β-galactosidase stimulates TRPV5 activity
Glycosidases play important roles in protein localization, stabilization and activity 
(2). β-galactosidase (β-gal) is a glycosidase that catalyses the hydrolysis of terminal β(1,3), 
β(1,4) or β(1,6) linked galactose saccharides in di- and oligosaccharides such as lactose 
and galactobiose, but also in glycoproteins or glycosaminoglycans (64). 
β-gal is mainly expressed in the lysosomes, where it is responsible for the 
degradation of sialylated glucoconjugates. β-gal activity from lysosomal β-D-
galactosidase (active at pH 4.5) is the most extensively used biomarker for 
cell senescence (65-67). Many glycosidases are detected in the urine, such as 
β-glucosidase, β-glucuronidase and N-acetyl-D-glucosaminodase (NAG) (68). 
Since β-gal activity can be measured in the urine of humans (0.45-1.4 mU/µmol creatinin) 
(69), the physiological relevance of β-gal-mediated stimulation is investigated (69). 
Urinary β-gal, is relatively unstable at low pH values and has an optimum at neutral pH 
(70). Interestingly, β-gal is excreted into the pro-urine in the proximal tubule, located 
upstream of the DCT2/CNT where TRPV5 is expressed. Chapter 4 demonstrated 
that β-gal stimulates TRPV5-mediated Ca2+ inﬂ ux, only in the presence of the TRPV5 
N-glycan. Close evaluation indicated that β(1,4)-gal activity is responsible for this effect. 
TIRF-M revealed that the plasma membrane expression of the channel is increased upon 
β(1,4)-gal treatment. In addition, isolated primary mouse DCT2/CNT cells display an 
increased Ca2+ transport upon apical β(1,4)-gal treatment. This excludes that the detected 
effect is due to the overexpression system used for this study. The study described in 
this thesis highlights a physiological regulatory mechanism of the TRPV5 N-glycan. 
 Deﬁ ciencies of β-gal cause human metabolic disorders with heterogeneous 
clinical phenotypes, such as GM1 gangliosidosis (OMIM nr. 230500) and Morquio type B 
disease (OMIM nr. 253010). GM1 gangliosidosis is associated with a highly vacuolated 
cytoplasm containing GM1 ganglioside as storage substance (71). GM1 ganglioside is a 
glycosphingolipid, capped with a β-galactose subunit. Neurodegeneration and skeletal 
abnormalities characterize GM1 patients (71). Morquio type B disease is also caused by 
deﬁ ciencies in β-gal, therefore the clinical lines between GM1 and Morquio disease are 
rather vague. Mutation of TRPV4, a TRPV5 homologue, is known to cause a pseudo-
Morquio syndrome (72). Another connection between TRPV5 and β-gal can be found 
in diabetes mellitus patients, as illustrated in chapter 4. Diabetes mellitus type 1 is 
associated with renal Ca2+ wasting, although the molecular mechanism for this remains 
unknown. Moreover, these patients show elevated β-gal levels in blood and urine, which 
may represent a mechanism of compensation to prevent renal Ca2+ wasting (73,74). 
 Future research should reveal whether differences in the urinary excretion of 
glycosidases are linked to disturbances in the Ca2+ balance or other electrolyte abnormalities.
TRPV5 regulation by glycosidases
Interestingly, several similarities can be found between β-gal and klotho. Serum klotho 
expression and urinary β-gal activity both decline with increasing age (69,75). In addition, 
klotho shares 39% amino acid sequence identity with lactase-phlorizin hydrolase, a 
member of the β-gal family that is responsible for cleavage of lactose (76). Although β-gal 
and klotho both stimulate the plasma membrane expression of TRPV5, as demonstrated 
in chapter 3 and chapter 4, klotho is not likely to possess galactosidase activity. A 
β-gal enzyme assay, in which the colorimetric o-nitrophenyl-β-D-galactopyranoside 
becomes UV-active upon cleavage into o-nitrophenol and galactose, was used to study 
potential β-gal activity for klotho. Lysates of klotho- and β-gal-expressing HEK293 cells 
were tested for β-gal activity. Activity was detected in the β-gal lysate (3.2 arbitrary 
units (au)), but not in the klotho lysate (0.07 au). However, it cannot be excluded 
that klotho needs a ‘glycan signature’ to exert its function, as discussed previously. 
Cleavage of Gal-(β-1,4) by β(1,4)-gal, as well as treatment with other glycosidases 
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(chapter 3), can increase TRPV5 channel function. Therefore, it seems that any type of 
alteration to the TRPV5 N-glycan increases Ca2+ inﬂ ux via TRPV5. Possibly, the N-glycan 
binds a protein that blocks the channel pore via steric hindrance, but this is not likely 
as the N-glycan-deﬁ cient mutant TRPV5N358Q has similar channel characteristics as wild 
type TRPV5. Removal of the TRPV5 N-glycan does not inﬂ uence the open probability or 
the conductance of the channel as described in chapter 4. This implies that the N-glycan 
is not involved in the intrinsic function of the TRPV5 channel, and this is in accordance 
with the idea that the N-glycan mediates membrane expression of the channel.
Stabilization by galectins
Galectins bind speciﬁ cally to LacNAc repeats, composed of repeating Gal-(β-1,4)-GlcNAc 
units. β(1,4)-gal will modify the end-standing LacNAc unit by hydrolysing the Gal-(β-1,4) 
saccharide. Since galectins are often involved in membrane stability of glycoproteins, it is 
likely that these proteins are involved in the glycan-mediated 
regulation of the TRPV5 cell surface expression. Galectin-1, -3, 
-7, -8 and -9 are expressed in human and mice kidney (77,78). 
 Galectin-1 induces anti-inﬂ ammatory cytokines and inhibits the 
production of pro-inﬂ ammatory cytokines (2). The protein is expressed in 
tubular epithelial cells, but not in the progenitor cells of the collecting duct 
(79). Moreover, TRPV5 does not co-localize with galectin-1 (chapter 3).
 Galectin-3 is expressed in mice DCT2/CNT, where it co-localizes with TRPV5 
as described in chapter 3. Moreover, extracellular galectin-3 was shown to increase 
the TRPV5 channel activity dependent on the TRPV5 N-glycan (chapter 3). Based 
on this ﬁ nding, ablation of galectin-3 binding by β(1,4)-gal treatment would decrease 
the TRPV5 activity, in contrast to what is demonstrated in chapter 4. Interestingly, 
capping with sialic acids only slightly inﬂ uences galectin-3 binding to LacNAc repeats, 
as galectin-3 does not need an end-standing LacNAc repeat for binding (80). β(1,4)-gal 
treatment will not modify LacNAc repeats if capped with sialic acids, therefore β(1,4)-
gal treatment may not affect galectin-3 binding. Of note, galectin-3 expression in adult 
kidney is low and appears to be conﬁ ned to the cytoplasm of collecting duct cells (81).
 Galectin-7 is selectively expressed in the cilia of the kidney. Cilia are membrane 
protuberances that sense changes in the ﬂ uid ﬂ ow (82). Here, galectin-7 plays a key role 
in plasma membrane stabilization of glycoproteins, involved in epithelial wound healing 
(77). Up until now, TRPV5 expression in cilia has not been properly investigated. Galectin-7 
might be involved in TRPV5 regulation in the cilia, but, only unciliated kidney cells were 
used for the above-described experiments, therefore galectin-7 is probably not involved 
for TRPV5 regulation via klotho or β(1,4)-gal. Next, galectin-8 has a strong afﬁ nity for 
α2,3 sialylated Galβ(1,3)GalNAc (83), which are not cleaved by β(1,4)-gal treatment, 
thereby omitting a role for galectin-8 in the regulation of TRPV5 activity via β(1,4)-gal. 
 Galectin-9 serves a variety of functions and is mostly expressed in the lysosomal/
endosomal compartments along the renal tubule (84,85). Galectin-9, in contrast to 
galectin-3, is highly expressed in adult kidney (78). This galectin has a high afﬁ nity 
for end-standing LacNac repeats in N-glycans and Frossman pentasaccharides 
present on apical residing glycolipids (86). The protein functions as an urate channel/
transporter (87), a regulator of thymocyte-epithelial cell interactions (88), a tumor 
antigen (89) and a mediator of apoptosis (88). Furthermore, galectin-9 is involved 
in the polarization of epithelial cells and facilitates the apical sorting of proteins and 
lipids (85,90). Knockdown of this protein leads to loss of epithelial polarity in renal 
Madin-Darby Canine Kidney (MDCK) cells (90). Finally, galectin-9 binding stabilizes 
glycoproteins in clathrin-enriched domains, thereby increasing their endocytosis (51). 
Hence, removal of the Gal-(β-1,4) saccharide from the TRPV5 N-glycan may inhibit 
galectin-9 binding, thereby reducing endocytosis (Fig 5). It would be interesting to 
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investigate the effect of extracellular galectin-9 on TRPV5 plasma membrane expression. 
Figure 5. TRPV5 activity is stimulated by β-gal, possibly via galectin-9 interaction. 
TRPV5 is endocytosed via the clathrin-dependent pathway. Galectin-9 binding to the LacNAc region will 
translocate TRPV5 into clathrin-enriched regions, thereby stimulating endocytosis. Upon β-gal treatment, 
the galectin-9 interaction is lost and the channel is located into regions with low clathrin expression, 
reducing endocytosis.
TRPV5 homology model
Chapter 5 outlined the construction and investigations of a TRPV5 homology model, 
based on the recently resolved rat TRPV1 structure (91). This structure was solved 
by electron cryo-microscopy, at ~ 3.4 Å resolution for the TM domains and ~ 4.8 Å 
resolution for the cytoplasmic domains (91). The structure of TRPV1 is solved in a close 
state conformation from residue leucine 111 to alanine 719 (total TRPV1 is composed 
of 838 amino acids), excluding a small and highly divergent region (605-626). This 
region was removed to increase the biochemical stability of the TRPV1 channel. With 
an amino acid sequence identity of 29% between rabbit TRPV5 and rat TRPV1, a 
rabbit TRPV5 homology structure from methionine 1 to valine 644 was modeled (total 
rabbit TRPV5 is composed of 729 amino acids). The amino acid sequence identity 
in combination with the size of the protein was sufﬁ cient to develop a valid homology 
model (92). The structures revealed that both TRPV1 and TRPV5 contain four-fold 
symmetry around the central ion pathway, which is formed by TM 5, 6 and the pore loop. 
 To validate the model, several aspects were highlighted as described in chapter 
5. Previously, the N-terminal ankyrin repeat domain (ARD) of TRPV6 was elucidated by 
crystallization at a resolution of 1.7 Å (93). Since the ARD of TRPV5 and TRPV6 share 
an amino acid sequence identity of 88%, it is likely that the tertiary structures are similar. 
The TRPV6 ARD contains anti-parallel inner and outer α-helices, with a ﬁ nger loop to 
link the helical layers together. The large twist between ankyrin 4 and 5 is characteristic 
for the ARD of TRPV6 and is also detected in the TRPV5 homology model (Fig 7A), 
implying that the model correctly represents the TRPV5 N-terminal domain. Next, the 
N-glycosylation position is expected to be located at the extracellular site of the channel, 
as urinary glycosidases can inﬂ uence TRPV5 channel activity. In agreement, N358 is 
located at the extracellular side with the side chain pointing into the extracellular solvent 
in the homology model (Fig 7B). The glycosylation site of TRPV1 is not present in the 
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electron cryo-microscopy-solved structure, as it is situated in the excluded region (amino 
acid 604) (91). The aspartic acid (D) 542 residue, which is responsible for selective Ca2+ 
gating, is located directly above the pore, as displayed in chapter 5 (94). However, the 
distance between the four D542 residues in the model is rather large to form a selectivity 
gate (~ 9.5 Å). The selectivity ﬁ lter of the TRPV1 channel was only ~ 4.6 Å (91). On the 
other hand, TRPV5 displays a different selectivity ﬁ lter sequence compared to TRPV1, 
as it has a more pronounced selectivity for Ca2+ over monovalent cations (95). Moreover, 
intracellular acidiﬁ cation decreases the size of the ﬁ lter gate from 10.3 Å at pH 9.0 to 
5.6 Å at pH 6.0, as estimated by electrophysiological analysis (96). Even though, the 
physiological pH varies only from 6.8 to 8.4 (63), these data suggests a noticeable ﬂ exibility 
of the pore. Finally, the highly conserved TRP domain, located after TM 6, is a key feature 
in TRP ion channels (97-99). Similar to TRPV1 (91), the TRPV5 homology model reveals 
that the TRP domain interacts with the loop between TM 4, TM 5 and the pre-TM 1 α-helix 
via hydrogen bonds. This domain is involved in phosphatidylinositol 4,5-bisphosphate 
(PIP2) binding, which is shown to stimulate TRPV5 channel activity (100). Taken 
together, the homology model appears a reliable structure based on known structural 
characteristics of TRPV5. However, it should be considered that the presented structure 
is a model and, therefore, may not fully represent the authentic TRPV5 conformation.
Figure 6. Key features of the TRPV5 homology model. 
A) TRPV5 ARD (left) presented in the homology model is similar to the previously crystallized TRPV6 
ARD (93) (right, PDB = 2RFA). Both, the model and the crystal structure, show a characteristic 
twist between ankyrin 4 and ankyrin 5. B) The TRPV5 homology model displays the N358 
glycosylation sites at the top of the tetrameric channel (red), pointing towards the extracellular matrix. 
TRPV5 regulation by an aromatic gate and a glycine hinge 
The TRPV5 homology model improves our understanding of the channel function by 
studying the process of channel opening and closing. Three main gating movements 
are known to regulate K+ and related ion channels; i) rotation of the inner pore α-helices 
around the pore; ii) kinking of the inner pore α-helix in the middle or iii) kinking at the 
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bottom of the inner pore α-helix in combination with an aromatic gate (101). Evaluation 
of the TRPV5 model led to the identiﬁ cation of the aromatic tryptophan (W) 583 residue 
located at the bottom of the pore mouth helix. Modiﬁ cation of W583 resulted in an 
over-active TRPV5 channel and provoked cell death as explained in chapter 5. This 
indicates that the four W583 residues together form a so-called W-gate, essential for 
channel function. Many prokaryotic K+ channels are regulated by the concerted action 
of an aromatic gate with α-helical bending via a glycine hinge (102). Interestingly, 
TRPV5 contains a glycine (G579) approximately one α-helical turn above W583 (Fig 
7B). Chapter 5 delineates that mutation of the ﬂ exible glycine residue into a more 
restrained alanine nearly completely ablates TRPV5-mediated Ca2+ transport. These 
gating residues are highly conserved amongst species and also in the homologous 
TRPV6 channel. Taken together, the data suggest that TRPV5 is regulated by kinking 
of the pore α-helix (G579) in combination with an aromatic gate (W583) (Fig 6A). 
Importantly, the other TRPV family members (TRPV1-4) do not display such an aromatic 
residue in the pore, suggesting that they are regulated via a different mechanism.
 Stimuli causing bending of the TRPV5 α-helix at the G579 position have not 
been elucidated. Interestingly, a conserved histidine (H) 582 residue is located in close 
proximity to the W-gate as described in chapter 5. This residue is conserved among 
different species and in TRPV6. Histidine residues are pH sensitive, and therefore it can 
be speculated that H582 causes the α-helix to bend upon pH changes. Low extracellular 
pH inhibits for example the proton-selective inﬂ uenza virus M2 channel via histidine 
residues (103). These residues are located four amino acids above the W-gate, situating 
the side chains of the tryptophan and histidine residues on top of each other in the 
3D structure. Protonation of the histidine residue initiates bending or rotation of the 
tryptophan side chains, thereby closing the channel (103). Extracellular and intracellular 
pH changes regulate TRPV5, as acidiﬁ cation at either side decreases channel activity 
(96). In the TRPV5 model, the side chains of the W583and H582 residues are sticking in 
opposite directions (Fig 7C), indicating that a proton-selective inﬂ uenza virus M2 channel-
like mechanism is likely not involved in channel regulation. However, a positively charged 
lysine (K) at position 484 is located at only ~ 7 Å distance from H582. Protonation of 
H582 may repel K484, causing the helix to bend (Fig 6D). In contrast, the model displays 
a methionine (M) 485 residue that stabilizes the H582 side chain via a hydrogen bond. 
The value of the hypothesis that the protonated H582 will repel the positively charged 
K484, causing the W583 to change position needs to be determined. This can be studied 
by mutation of the H582 in the positively charged arginine or in a non-charged tyrosine. 
Following, differences in TRPV5 activity should be studied and will indicate whether H582 
is a factor inﬂ uencing the W-gate. Another signaling molecule that could be involved in 
the TRPV5 gating mechanism is PIP2, a membrane phospholipid that binds the positively 
charged TRP domain located directly below the W-gate. Binding of PIP2 stabilizes TRPV5 
in its open conformation (100). In addition, the slow Mg2+-mediated TRPV5 inhibition is 
counteracted by PIP2, even though activation of TRPV5 via PIP2 is independent of Mg
2+ 
(104). Interestingly, both TRPV5 and TRPV6 contain the W-gate and are stimulated by 
PIP2. In contrast, TRPV1 is inhibited by PIP2 and shows no conservation of the G-hinge 
and the W-gate (100). K+ channels that display a similar type of gating, as postulated for 
TRPV5, are also stimulated by PIP2 (101,105). As all channels regulated via a G-hinge 
and W-gate are stimulated by PIP2, this factor might be the stimulus in this system. 
The importance of PIP2 in TRPV5 gating can be studied in more detail by investigating 
the effect of additional PIP2 on wild type TRPV5, TRPV5
G579A and TRPV5W583Y. If the 
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stimulating effect of exogenous PIP2 is no longer detected on the TRPV5
G579A and 
TRPV5W583Y mutant, it is likely that PIP2 is involved. However, a direct connection cannot 
be determined via this method as PIP2 is involved in many different processes (105). 
 Finally, the selectivity ﬁ lter might be able to communicate with the 
closing gate, as described for the KcsA channel (106,107). In this system, 
the gate and selectivity ﬁ lter are able to communicate bi-directionally, thereby 
regulating channel opening and closing. Future research should determine 
mechanistic principles underlying a possible conformational coupling. 
Figure 7. The TRPV5 gate is composed of a W-gate in combination with a G-hinge. 
A) Schematic representation of the TRPV5 gating mechanism. The W583 residues are indicated in yellow, 
and the G579 bending point is indicated in pink. B) The ﬂ exible G579 (red) is located approximately one 
turn above W583, which is proposed to function as a W-gate (yellow). C) The W-gate (yellow) is placed at 
the end of TM domain 6 (blue), a H (red) residue is located directly above the gate. The sensitive H side 
chain is pointing towards TM domain 5. D) An increase in pH will result in protonation of H582 (pink), which 
may repel the positively charged K484 (yellow). H582 forms a hydrogen bond with M485 (yellow) of TM 
domain 5. 
Outlook
The aim of this thesis was to investigate how glycosylation regulates the Ca2+ channel 
TRPV5. It is important that speciﬁ c research methods are developed to accurately 
investigate this type of complex posttranslational modiﬁ cation. The origin of many 
glycosylation disorders is not determined yet. Therefore, mechanistic insights in the 
glycosylation processes will support the design of new diagnostical methods and 
eventually contribute to the development of therapeutics. Nevertheless, many questions 
remain to be answered. Implementing charge in BCN increases the membrane labeling 
speciﬁ city, but will this work for other cyclooctynes as well? This thesis provided a basis 
for future studies in which genetic encoding can be used to insert one of the tags on 
the protein, followed by metabolic incorporation of a saccharide analog to implement a 
different tag. Would it also be possible to develop a dual labeling system through which 
126
GENERAL DISCUSSION AND SUMMARY
we can label TRPV5 with one tag and the N-glycan with another? Next, we demonstrated 
that klotho stimulates the TRPV5 channel activity via the N-glycan, by stabilizing the 
protein at the plasma membrane. However, what is the exact enzymatic activity of 
klotho, if there is any? Analogously, β-gal inﬂ uences TRPV5 activity by stabilizing the 
channel at the cell surface. Are galectins involved in this stabilization process? What is 
the physiological importance of β-gal in regulation of the Ca2+ homeostasis? Moreover, 
animal experiments should validate if β-gal also regulates TRPV5 activity in vivo. Finally, 
the TRPV5 homology model provides signiﬁ cant new insights in understanding channel 
regulation on the molecular level. We identiﬁ ed important residues in channel functioning 
and thereby propose a gating model composed of a W-gate and a G-hinge. However, 
which factors regulate this gating mechanism? Is TRPV5 a voltage-gated channel, such 
as the resembling K+ channels? Future research could provide more information on the 
stimulus for conformational changes in the pore structure. In addition, the TRPV5 gating 
mechanism might be extended to TRPV6 and possibly other channels. The molecular 
revelations described in this thesis will contribute to further understanding of TRPV5 
regulation and the Ca2+ handling in the human body.
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Chapter 7
In onderzoek worden DNA, RNA en eiwitten vaak gezien als de belangrijkste onderdelen 
van een cel. Deze drie bestandsdelen kunnen echter niet ten volle zorgdragen voor de 
totale opmaak en complexiteit van een cel. Hoewel het belang van vetten en suikers 
(sacchariden) vaak onderbelicht blijft, zijn deze eveneens essentieel voor het verloop 
van de noodzakelijke biologische processen. 
Glycosylering is een proces waarbij een aantal saccharide-eenheden aan een 
eiwit- of vetstructuur gekoppeld worden, zoals uitvoerig beschreven in hoofdstuk 1. 
Bij meerdere gekoppelde saccharide-eenheden spreken we dan van glycanen. Deze 
glycanen zijn noodzakelijk voor het complexe functioneren van een cel. Het glycaan kan 
deze functie vervullen door op verschillende niveaus te variëren, door de samenstelling 
van de sacchariden, de chemische verbindingen, het type polymeer formatie (lineair 
of vertakt) en eventuele chemische modiﬁ caties zoals acetylering. Ongeveer 50% 
van alle eiwitten in het menselijk lichaam is geglycosyleerd. Een klein defect in het 
glycosyleringssysteem heeft vaak grote gevolgen voor het functioneren van het gehele 
organisme. Echter, de huidige kennis over eiwitglycosylering is beperkt in vergelijking 
met onze kennis over DNA en eiwitten. Een van de belangrijkste redenen hiervoor is de 
complexiteit van de glycanen en het gebrek aan goede detectiemethoden. 
 Dit proefschrift richt zich speciﬁ ek op de N-glycosylering. Dit is de koppeling van 
een glycaan aan het amine van het aminozuur asparagine in een eiwit. Het glycaan 
verzorgt bindingsplaatsen voor een scala aan eiwitten. Daarnaast kan het glycaan 
ingekort worden door een glycosidase, een enzym dat een speciﬁ ek saccharide van 
het glycaan kan verwijderen. Door deze modiﬁ catie verandert de bindingsplaats voor 
eiwitten en kunnen de activiteit, de membraan lokalisatie en vele andere processen van 
een eiwit beïnvloed worden. Het transient receptor potential vanilloid type 5 (TRPV5) 
is een gespecialiseerd eiwit, dat calcium (Ca2+) ionen door het plasmamembraan kan 
transporteren, een Ca2+-selectief ionkanaal. TRPV5 bevindt zich in het distale deel 
van de nierbuis, waar vier dezelfde TRPV5 eiwitten samen het kanaal (een tunnel) 
vormen, dat speciﬁ ek de Ca2+ ionen doorlaat. In de nier is het kanaal betrokken bij de 
Ca2+ opname vanuit de voorurine terug naar de bloedbaan. Dit gebeurt via een actief 
transcellulair transport, dat zorgdraagt voor de nauwe regulatie van de Ca2+ balans in 
ons lichaam. Aangezien Ca2+ een belangrijke rol speelt bij vele fysiologische processen, 
zoals de productie van hormonen, botmineralisatie en spiercontracties, is het van groot 
belang om een goede Ca2+ balans te handhaven. Verstoringen in deze balans als gevolg 
van een defect in TRPV5 resulteren in botafwijkingen en in verhoogde Ca2+ excretie 
via de urine. Kennis omtrent de regulatie van TRPV5, is van essentieel belang om het 
moleculaire mechanisme van de renale Ca2+ huishouding te begrijpen. De mate van Ca2+ 
transport door TRPV5 wordt bepaald door de intrinsieke activiteit van het kanaal en de 
hoeveelheid aanwezige kanalen op het plasmamembraan, zoals uitvoerig beschreven in 
hoofdstuk 1. Deze processen blijken gereguleerd te worden via het N-glycaan dat zich 
bevindt op TRPV5. Dit proefschrift levert nieuwe inzichten in de rol van het N-glycaan ten 
aanzien van de TRPV5 activiteit. 
 Om inzicht te krijgen in N-glycaan afhankelijke regulatieprocessen is de detectie van 
het N-glycaan essentieel. De diversiteit van glycanen maakt de ontwikkeling van goede 
technieken voor de detectie van het glycaan tot een moeilijke zaak. De meest gebruikte 
methode om glycanen te labelen is de zogenaamde azide-alkyn [2+3] cycloadditie, ook 
wel bekend als de klikreactie. Een erg populaire klikreactie is de spanning-gemedieerde 
azide-alkyn cycloadditie (SPAAC). Normaliter is een alkyn-groep recht en reageert deze 
alleen in de aanwezigheid van een katalysator zoals koper met een azide. In het geval 
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van de SPAAC is de alkyn gebogen, de buiging geeft spanning op het alkyn. Dit is gedaan 
door deze te plaatsen in een achtring. Dit maakt dat het alkyn reactiever is, waardoor de 
reactie met een azide kan plaatsvinden in afwezigheid van een katalysator. SPAAC is de 
reactie tussen een gebogen en dus gespannen alkyn, vaak een cyclooctyn, en een azide 
functionaliteit waarbij een stabiele triazool-ring gevormd wordt. Om glycanen te kunnen 
labelen met behulp van deze reactie worden cellen behandeld met een azide-bevattend 
saccharide-analogon. In dit proefschrift is ManNAz gebruikt, een analoge saccharide 
welke wordt opgenomen door de cel en op de positie van een eindstandig siaalzuur-
saccharide wordt ingebouwd. Dit resulteert in de expositie van een azidegroep op de 
positie van het siaalzuur in het glycaan (Fig 1). Vervolgens vindt er een reactie plaats met 
een cyclooctyn, welk gebonden is aan een ﬂ uorescent label. Een van de meest gebruikte 
cyclooctynen is bicyclo[6.1.0]nonyne (BCN) (Fig 1). De toepassing van deze reactie en 
andere SPAAC reacties op cellulaire en dierlijke systemen wordt vaak bemoeilijkt door 
aspeciﬁ eke interacties. Aspeciﬁ citeit ontstaat in de SPAAC reactie vooral als gevolg van 
hydrofobe interacties en aspeciﬁ eke thiol-yn addities. Een thiol-yn additie is de reactie 
tussen een thiol - welk bijvoorbeeld voorkomt in het aminozuur cysteine en dus ook in 
veel eiwitten - en de cyclooctyn, in ons geval BCN. 
Om de chemische gereedschapskist voor het biologische onderzoek naar 
glycanen uit te breiden zijn in hoofstuk 2 nieuwe varianten van BCN bedacht, ontwikkeld 
en getest met als doel de reactiespeciﬁ citeit in cellulaire glycaan-labeling te verhogen. 
Hierbij zijn drie verschillende afgeleiden van het cyclooctyn BCN ontwikkeld, die ieder 
enigszins verschillen in chemische structuur. De eerste bevat een extra hydroxylgroep 
(BHM-BCN), de tweede een glutaryl-aminogroep (GA-BCN) en de derde een aminogroep 
(A-BCN). Deze veranderingen verhogen allen het hydroﬁ ele karakter van het cyclooctyn. 
De lading van een molecuul heeft een grote invloed op het hydroﬁ ele karakter van 
een stof. Verwacht wordt dat A-BCN en GA-BCN een lading, respectievelijk positief en 
negatief, laten zien bij neutrale pH. In vergelijking tot het al bestaande BCN lieten A-BCN 
en GA-BCN een verhoogde speciﬁ citeit zien in het labelen van glycanen. Toevoeging 
van een extra hydroxylgroep (BHM-BCN) liet daarentegen geen verbetering in de 
speciﬁ citeit zien. Daarnaast kon de aanwezigheid van A-BCN worden aangetoond in het 
Golgi-apparaat van de cel, de locatie waar glycanen aan een eiwit gebonden worden. 
Tot slot zijn deze nieuw ontwikkelde cyclooctynen gebruikt om TRPV5 te detecteren 
op het plasmamembraan. Dit onderzoek geeft aan dat een lading in het cyclooctyn 
de speciﬁ citeit van glycaan detectie door middel van de klikreactie kan verhogen. De 
belangrijkste factoren hierin zijn hoogst waarschijnlijk verminderde aspeciﬁ eke hydrofobe 
interacties en een daling in de hoeveelheid intracellulair cyclooctyn waardoor minder 
thiol-yn addities plaats kunnen vinden.    
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Figuur 1. De metabole incorporatie van een azido-saccharide en de SPAAC reactie met BCN. Als 
eerste wordt een azide-bevattend saccharide-analogon door de cel opgenomen en gebruikt voor de bouw 
van N-glycanen. Vervolgens wordt de azidegroep gebruikt voor de SPAAC reactie met gelabelde BCN. 
Middels deze techniek is het eiwit dat de gelabelde N-glycaan bevat zichtbaar op het plasmamembraan. 
Er zijn verschillende enzymen en hormonen geïdentiﬁ ceerd die een belangrijke rol spelen 
bij de Ca2+ balans via regulatie van TRPV5. Een van de eiwitten die speciﬁ ek aangrijpt 
op het N-glycaan van TRPV5 is klotho. Klotho is een antiverouderingshormoon, dat in 
de nieren voorkomt en vervolgens via de urine wordt uitgescheiden. Klotho stimuleert de 
hoeveelheid TRPV5 kanalen op het plasmamembraan, afhankelijk van de aanwezigheid 
van het N-glycaan. De enzymatische activiteit van klotho blijft echter onbekend. Zo is er 
beschreven dat klotho sialidase activiteit heeft. Dit betekent dat klotho siaalzuren van 
het N-glycaan kan verwijderen. Door deze verandering in saccharidesamenstelling kan 
er een saccharidebindend eiwit, het galectine-1, aan het TRPV5 N-glycaan binden en 
daarmee het kanaal op het plasmamembraan stabiliseren. Uit het onderzoek beschreven 
in hoofdstuk 3 blijkt echter dat sialidase een stimulerend effect heeft op de activiteit van 
zowel het wild type TRPV5 kanaal als de ongeglycosyleerde TRPV5 mutant (TRPV5N358Q). 
Dit impliceert dat het effect van sialidase onafhankelijk is van het TRPV5 N-glycaan. 
De stimulatie door sialidase is toe te schrijven aan een verminderde internalisatie van 
het kanaal vanuit het plasmamembraan. Deze internalisatie wordt gemedieerd door 
dynamische vetstructuren in het membraan, bekend als lipid rafts. Lipid rafts zijn onder 
andere opgebouwd uit geglycosyleerde vetten, welke een siaalzuur bevatten. Deze 
siaalzuren zullen ook door sialidase verwijderd worden en daarmee wordt de structuur 
van de dynamische lipid rafts verstoord. Deze verstoring zal de internalisatie van TRPV5 
verminderen (Fig 2). Door de formatie van lipid rafts te hinderen via een chemische 
remmer wordt inderdaad de sialidase-gemedieerde stimulatie op de TRPV5 functie 
belemmerd. 
 Dezelfde verstoring heeft daarentegen geen effect op TRPV5 stimulatie via 
klotho, wat doet vermoeden dat klotho anders functioneert dan sialidase. Verder is er 
aangetoond, dat sialidase het siaalzuur van een geglycosyleerd modeleiwit (transferrine) 
kan verwijderen, terwijl klotho geen verandering geeft in de transferrine glycosylering. 
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Deze bevindingen leiden tot de conclusie dat sialidase TRPV5 reguleert op een 
N-glycaan-onafhankelijke wijze. Dit in tegenstelling tot klotho, dat het N-glycaan nodig 
heeft voor stimulatie van de TRPV5 functie. Verder hebben we aangetoond dat het 
niet waarschijnlijk is, dat galectine-1 het kanaal stabiliseert op het membraan na klotho 
behandeling. Galectine-3 is een ander glycaan-bindend eiwit dat zich in de nier bevindt. 
Dit eiwit zou de functie van galectine-1 kunnen overnemen. Behandeling met galectine-3 
stimuleert inderdaad de TRPV5 activiteit. Een combinatiebehandeling met galectine-3 en 
klotho geeft daarentegen geen extra stimulans voor het kanaal. 
Figuur 2. Sialidase reguleert TRPV5 via geglycosyleerde vetten in de lipid rafts. Sialidase verwijdert 
de siaalzuren van het N-glycaan van TRPV5, maar ook van de vetten in de dynamische lipid rafts (LP). 
Deze dynamische vetstructuren in het plasmamembraan zijn verantwoordelijk voor de internalisatie van 
TRPV5. Door de siaalzuren van deze vetten te verwijderen blijft TRPV5 stabiel op het plasmamembraan. 
Klotho reguleert TRPV5 speciﬁ ek via het N-glycaan. Het regulatiemechanisme blijft vooralsnog onbekend.
Om de fysiologische regulatie via het TRPV5 N-glycaan verder te ontrafelen is er tevens 
onderzoek gedaan naar verscheidene glycosidases, welke ieder een andere saccharide 
van het glycaan afknippen en daarmee van invloed kunnen zijn op TRPV5. Het 
β-galactosidase verwijdert eindstandige β-galactose sacchariden van een glycaanstructuur 
en is in enzymatisch actieve vorm aanwezig in de urine. De TRPV5 kanaalactiviteit wordt 
gestimuleerd door β-galactosidase en dit effect was alleen zichtbaar in de aanwezigheid 
van het TRPV5 N-glycaan zoals beschreven in hoofdstuk 4. Afbraak van een speciﬁ ek 
β1,4-gebonden galactose door β1,4-galactosidase (β1,4-gal) stimuleert de TRPV5-
gemedieerde Ca2+ opname door het kanaal te stabiliseren op het plasmamembraan. 
Gezien de aanwezigheid van actieve β-galactosidase in de urine zou dit enzym van 
belang kunnen zijn voor de Ca2+ balans. Om de fysiologische relevantie te bestuderen 
hebben we primaire distale nierbuiscellen geïsoleerd uit de muis. Net als in de nier zijn 
deze cellen gepolariseerd. Dit betekent dat ze twee verschillende kanten hebben, een 
apicale (voorurine) zijde waar TRPV5 aanwezig is en een basolaterale (bloed) kant. In 
deze cellen kan het Ca2+ transport ook gestimuleerd worden door behandeling met β1,4-
gal vanaf de voorurine kant (apicaal). Dit impliceert dat β-galactosidase, aanwezig in de 
voorurine, TRPV5 kan stimuleren en daarmee invloed heeft op de Ca2+ balans.
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Tot slot wordt in hoofdstuk 5 een mechanisme besproken dat verantwoordelijk is voor het 
functioneren van het TRPV5 kanaal op moleculair niveau. Een kanaal werkt als een soort 
poort die kan openen en sluiten door verandering in de eiwitstructuur. Er is een model 
van de TRPV5 eiwitstructuur ontwikkeld aan de hand van een opgehelderde TRPV1 
structuur. Gedetailleerd inzicht in de TRPV5 structuur heeft tot nieuwe bevindingen 
geleid. Zoals verwacht, is aan de bovenkant van het kanaal het N-glycaan gepositioneerd 
in het model. De porie van het kanaal, ook wel gezien als een tunnel, heeft aan de 
bovenkant een selectiviteitsﬁ lter, bestaande uit vier asparaginezuren die samen ervoor 
zorgen dat het kanaal alleen Ca2+ doorlaat. Tot onze verbazing is aan het einde van 
de tunnel een groot aromatisch, hydrofoob aminozuur, tryptofaan, gelokaliseerd. De 
locatie is onverwacht, aangezien de zijketen van dit aminozuur het kanaal insteekt en de 
doorgang deels blokkeert. Ook energetisch gezien is dit een ongunstige positie voor het 
betreffend aminozuur. Vervanging van dit tryptofaan door een ander aminozuur resulteert 
in extreem hoge intracellulaire Ca2+ niveaus en daarmee gepaard gaande celdood. De 
intrinsieke activiteit van het kanaal blijkt sterk verhoogd, waardoor er meer Ca2+ ionen 
doorgelaten worden. Uit deze data kan worden opgemaakt, dat de tryptofaanresiduen 
als een soort poort aan het einde van de tunnel fungeren. Vervolgens is onderzocht wat 
maakt dat de tryptofaanresiduen zich verplaatsen opdat de poort zich kan openen. In 
de directe nabijheid van deze tryptofaan-poort blijkt een ﬂ exibel glycine gelokaliseerd. 
Glycine is het kleinste aminozuur en fungeert vaak als een buigpunt binnen eiwitten. Als 
dit glycine wordt vervangen door het meer rigide alanine, blijkt Ca2+ transport niet meer 
mogelijk. Hieruit kan geconcludeerd worden dat sluiting van het TRPV5 kanaal geregeld 
wordt door een glycine buigpunt in combinatie met een tryptofaan-poort. 
In hoofdstuk 6 worden de conclusies van het beschreven onderzoek op een rij 
gezet. Daarnaast worden er enkele mogelijkheden voor toekomstig onderzoek op het 
gebied van TRPV5 glycosylering beschreven. De nieuw ontwikkelde BCN derivaten 
worden geplaatst in het licht van de reeds bekende cyclooctynen. Tevens worden 
mogelijke mechanismen besproken voor de N-glycaan afhankelijke TRPV5 regulatie 
door klotho. Een louter bindende functie voor klotho zou een verklaring kunnen geven 
voor de stimulatie via klotho. Dit zou betekenen dat klotho geen enzymatische, maar 
uitsluitend een bindende functie heeft. Daarnaast wordt een moleculair mechanisme 
besproken als mogelijke verklaring voor de β1,4-gal-gemedieerde TRPV5 stimulatie. De 
verwijdering van β1,4-galactose zou binding van galectin-9 kunnen voorkomen, hetgeen 
de internalisatie van TRPV5 zou kunnen verminderen. Tot slot worden verschillende 
factoren belicht, die verantwoordelijk kunnen zijn voor de buiging van de eiwitstructuur 
middels glycine en het daarmee gepaard gaande openen en sluiten van de tryptofaan-
poort. 
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CHAPTER 8: LIST OF ABBREVIATIONS
List of abbreviations
1α-OHase 25-hydroxyvitamin D3-1α-hydroxylase
17β-E2 17β-estradiol
1,25(OH)2D3 1,25-dihydroxy-vitamin D3
80K-H  protein kinase C substrate 80K-H
A-BCN amino-bicyclo[6.1.0]nonyne
ADAM  a disintegrin and metalloprotease
ANK  ankyrin
ANOVA analysis of variance
ARD  ankyrin repeat domain
AU  arbitrary units
ß-gal  ß-galactosidase
ß(1-3)-gal ß(1-3)-galactosidase
ß(1-4)-gal ß(1-4)-galactosidase
BAPTA-AM 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
tetrakis(acetoxymethyl ester)
BARAC bisarylazacyclooctynone
BCN  bicyclo[6.1.0]nonyne
BCRP  breast cancer resistant protein
BHM-BCN bis(hydroxymethyl)-bicyclo[6.1.0]nonyne
BSA  bovine serum albumin
BTTAA bis[(tert-butyltriazoyl)methyl]-[(2carboxymethyltriazoyl)methyl]amine 
BTTES tris(triazolylmethyl) amine-based ligand
45Ca2+  radioactive calcium isotope
Ca2+  calcium ion
CaM  calmodulin
CaSR  calcium-sensing receptor
CD  collecting duct
CFG  consortium for functional glycomics
CHO   chinese hamster ovarian 
CNT  connecting tubule
COPAS complex object parametric analyzer and sorter
CRD  carbohydrate recognition domain
Cu  copper ion
CuAAC copper catalyzed azide-alkyne cycloadditon
DCM  dichloromethane
DCT  distal convoluted tubule
DIBAC/DBCOdibenzoazacyclooctyne
DIBO  dibenzocyclooctyne
DIFO   diﬂ uorocyclooctyne
DIMAC dimethoxyazacyclooctyne
DMAP  4-dimethylaminopyridine
DMEM dulbecco’s Modiﬁ ed Eagle’s Medium
DMF  dimethylformamide
DMP  Dess-Martin periodinane
DNA  deoxyribonucleic Acid
DTT  dithiothreitol
DVF  divalent-free
EBP  elastin/laminin-binding protein
EDEM  endoplasmic reticulum degradation-enhancing α-mannosidase like protein
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EDTA  Ethylenediaminetetraacetic acid
Endo-F endoglycosidase-F
EGF  epidermal growth factor
eGFP  enhanced green ﬂ uorescent protein
EGFR  epidermal growth factor receptor
EGTA  ethylene glycol tetraacetic acid
ER  endoplasmic reticulum
ERK1/2 extracellular signal-regulating kinase 1/2
FACS  ﬂ uorescence activated cell sorting
FGF23 ﬁ broblast growth factor 23
FGFR  ﬁ broblast growth factor receptor
FRET   förster resonance energy transfer 
Fura-2-AM fura-2-acetoxymethyl ester
GA-BCN glutarylamino-bicyclo[6.1.0]nonyne
GFP  green ﬂ uorescent protein
GSDB  goat serum dilution buffer
GSL  glycosphingolipids
GST  glutathione S-transferases
H+  proton
HEK293 human embryonic kidney 293
IAM  iodoacetamide
IC50  half maximal inhibitory concentration
IEDDA Diels-Alder reaction with inverse electron-demand
IEF  isoelectric focusing
IRES  interinal ribosome entry site
Kl   klotho 
KO  knockout
LacNAc N-acetyllactosamine
ManLev N-levulinoylmannosamine
ManNAz N-azidoacetyl-mannosamine 
MDCK madin darby canine kidney
MeCN  acetonitrile
Mw  molecular weight
Na+  sodium ion
NAG  N-acetyl-D-glucosaminodase
NCX1  sodium-calcium exchanger
nDVF  nominally divalent-free
NeuAc N-acetylneuraminic acid, sialic acid
NHERF2 sodium-hydrogen exchange regulatory cofactor 2
PBS  phosphate buffered saline
PCR  polymerase chain reaction
PDB  protein databank
PFA  paraformaldehyde
PIP2  phosphatidylinositol 4,5-bisphosphate
PKA  protein kinase A
PKC  protein kinase C
PLC  phospholipase C
PMCA  plasma membrane calcium-ATPase
PMSF  phenylmethanesulfonylﬂ uoride
Po  open probability
PSS  physiological salt solution
PT  proximal tubule
146
CHAPTER 8: LIST OF ABBREVIATIONS
PTH  parathyroid hormone
Rab11a ras-related protein 11a
ROMK renal outer medullary K+
RP-HPLC reversed-phase HPLC 
RR  ruthenium red
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEM  standard error of the mean
SGK1  serum and glucocorticoid-regulated kinase 1
SNR  signal-to-noise ratio
SPAAC strain-promoted alkyne-azide cycloaddition 
SPIEDAC strain-promoted inverse-electron-demand Diels-Alder cycloaddition
TAL  thick ascending limb of Henle’s loop
THPTA tris(hydroxypropyltriazolyl)-methylamine
TIRF-M total internal reﬂ ection ﬂ uorescent microscopy
TK  tissue kallikrein
TM  transmembrane segment / domain
TMDIBO tetramethoxydibenzocyclooctyne
TRPV  transient receptor potential channel, subfamily vanilloid
tTG  tissue transglutaminase
UAA  unnatural amino acid
UMOD uromodulin
WNK4  with-no-lysine kinase 4
WT  wild type
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Floris, bedankt voor je wetenschappelijke input en begeleiding tijdens deze periode. Je zat 
altijd vol ideeën en ik vind jouw enthousiasme over het onderzoek bewonderenswaardig. 
Ik waardeer je enorme kennis over Organisch Chemie. Ik wil je het allerbeste toewensen 
voor de toekomst en met SynAfﬁ x! 
Jenny, als laatste toegevoegd aan mijn lijst met promotoren. In de laatste maanden heb 
je mij ontzettend geholpen met het schrijven van dit proefschrift. Daarnaast heb je ook nog 
hard meegedacht en gewerkt aan hoofdstuk 5, bedankt voor je waardevolle suggesties. 
Ik wens je alle succes met je onderzoek carrière, en wie weet ooit als professor...
Tijdens mijn 4-jarig traject heb ik zowel op de afdeling Fysiologie als op de afdeling 
Organische Chemie gewerkt. Ik wil dus ook graag mensen bedanken van beide 
afdelingen. Te beginnen met de afdeling Fysiologie, waar ik uiteindelijk de meeste tijd 
heb doorgebracht. 
René Bindels, als hoofd van het RIMLS ben je een druk bezette man. Desondanks heb 
je nog steeds tijd om je met het reilen en zeilen van afdeling bezig te houden, dat vind ik 
heel knap. Bedankt voor het meedenken met mijn onderzoek. 
Ellen, jou zal ik het meeste missen. De jaren met jou in de unit waren gezellig en jij was 
degene die mij weer op wist te beuren wanneer het iets minder goed ging. Je grappige 
zelfbedachte liedjes en vrolijke ‘goedemorgen collega’s’ op de vroege ochtend werden 
altijd goed ontvangen. Ik heb veel geleerd van jouw visie op verschillende aspecten in 
het onderzoek en in het leven. Het is dan ook voor mij niet meer dan logisch dat jij op 
deze belangrijke dag naast me zal staan. Nog even en dan ben jij ook aan de beurt!  
Sjoerd, onze eeuwige optimist. Bedankt voor je wetenschappelijke en strategische input 
tijdens de afgelopen vier jaar. Ze waren heel waardevol voor mij en ik heb er een hoop 
van geleerd. Jouw onverbeterlijke enthousiasme is erg belangrijk voor het lab. Gelukkig 
wist je toch tijd vrij te maken om me te wijzen op mijn interessante woordkeuze, misschien 
toch een beetje jaloers op mijn uitgebreide woordenschat?
Wilco, je kwam ons kleine Ca2+-groepje, helaas maar tijdelijk, aanvullen als post-doc. 
Je was een gezellige en nuchtere unit-genoot, dat kon ik erg waarderen. Je sarcasme 
en nuchtere kijk op het leven zette mij bij tijd en wijle weer met twee benen op de grond. 
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Ik weet zeker dat we je aan het zingen hadden gekregen als we nog een jaartje de tijd 
hadden gehad. Veel geluk met de kleine!
Anke, bedankt voor de adviezen en de gezelligheid op het lab. Ik weet zeker dat het je 
goed zal gaan in de toekomst!
Eline, ik bewonder je kritische blik op het onderzoek. Met vragen kon ik altijd bij jou 
terecht en ik waardeer je eerlijkheid. Ik wens je heel veel succes als klinisch chemicus.
Mark, bedankt voor je luisterend oor. Jouw kalme karakter binnen deze hectische afdeling 
heb ik altijd als prettig ervaren. Jij bent er bijna, nog even doorbijten!   
Maxime, thank you for your wise advices and support with the papers. I liked working 
with you and I believe you are one of the best researchers I know.
Lauriane, it was nice to work with you at the lab. I am sorry I did not improve my French 
more, but it was too difﬁ cult. I wish you all the best for the future! 
Femke, AnneMiete en Marla, bedankt voor jullie hulp met de verschillende experimenten. 
Femke, het was altijd gezellig tijdens de pauzes en ik wens jou veel geluk toe met de 
kleine. AnneMiete, jij was de hoeder van het lab. Ik heb jou inbreng gemist de laatste 
jaren. Marla, jouw grappige verhalen waren vaak een welkome aﬂ eiding. Ik wens je veel 
succes in de toekomst!
Kukiat, I loved working with you on the lab as you were always calm and relaxed. 
Moreover, you were the only one who appreciated my singing. Thank you and good luck 
at Harvard!
Irene, voor jou geen exotische bestelling meer. Ondanks dat niet iedereen altijd even 
blij is als er weer iets gedaan moet worden (ik), zien we uiteindelijk allemaal in dat jij van 
onschatbare waarde bent voor het lab. Bedankt. 
Naast het werken op het fysiologie lab heb ik met geweldige mensen mogen samenwerken 
op het Organisch Chemische lab. Ik wil graag allereerst alle mensen in vleugel 1 
bedanken, jullie waren behulpzaam en vriendelijk. Ik heb me altijd welkom gevoeld, en 
jullie hebben mijn talloze (en soms nutteloze) vragen altijd met geduld beantwoord. Dit 
vind ik heel bijzonder en is iets om trots op te zijn, jullie zijn een top afdeling(en)!
Olumide, I would like to thank you for your guidance at the Organic Chemistry department 
in the beginning. You are a wonderful person and I enjoyed our discussions. I wish you 
all the best for the future!
Jorge, bedankt voor je hulp met het BCN manuscript! Daarnaast wil ik graag heel SynAfﬁ x 
bedanken voor hun gezelligheid en ondersteuning. Ik heb ontelbaar veel vragen gesteld, 
en jullie waren altijd bereid om mij hiermee te helpen. Bedankt!
Jan, dankjewel voor je hulp en uitleg wanneer ik het even niet meer kon volgen! 
Lab 03.118 bedankt voor de gezelligheid (thanks for the nice time) en in het bijzonder wil 
ik graag Willem-Jan Karstens bedanken voor zijn wetenschappelijke raad. 
Daarnaast wil ik nog mijn studenten bedanken voor hun hulp bij het onderzoek Mandy en 
Dennis. Mandy, de publicatie die uit jou onderzoek volgde was niet meer dan verdiend. 
Dennis, ook al liep het project wat moeilijk, het was ﬁ jn om met jou samen te werken. 
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Ook wil ik graag Dr. Dirk Lefeber bedanken voor zijn adviezen. Naast de waardevolle 
wetenschappelijke input die jij mij gaf, was jij ook een goede mentor.
Tot slot wil ik graag mijn familie, de familie Gommans en al mijn vrienden bedanken. 
De vriendengroep uit Nijmegen, de meiden van Sintermeerten, Joyce en de groep 
uit Grubbenvorst bedanken voor hun gezelligheid en steun tijdens de afgelopen jaren. 
Deze lijst is te lang om op te noemen, maar ik wil speciaal mijn familie en Jos bedanken.
Te beginnen met mijn zussen, die tevens ook mijn beste vriendinnen zijn. Nina en Lotte, 
bedankt voor jullie onvoorwaardelijk vertrouwen, liefde en gezelligheid. Het was ﬁ jn om 
te weten dat jullie altijd achter me stonden, ik altijd mocht bellen en ik (af en toe) mocht 
klagen over de gang van zaken. Jullie hielden mij met beide benen op de grond en 
hielpen mij er regelmatig aan herinneren dat er ook andere dingen in het leven zijn dan 
promotieonderzoek. Natuurlijk hebben ook de “ex-buitenlanders” bijgedragen hieraan, 
Pim en Armand! Bedankt voor jullie gezelligheid en adviezen tijdens deze periode. 
Armand, ik ben heel blij met de mooie voorkant! Tijdens mijn promotie zijn er nog twee 
mensen bijgekomen die ik wil toevoegen aan dit rijtje, Lara en Sam. Jullie hielpen mij 
herinneren aan de belangrijke dingen in het leven en het is natuurlijk altijd leuk om jullie 
vrolijke gezichtjes te zien. En we verwelkomen van harte mijn nieuwe neefje Roan.
Lieve Mam en Pap, ongeacht wat er is, jullie staan altijd voor me klaar. Dankzij jullie 
hulp, steun en liefde heb ik het tot hier gebracht. De gezellige avonden, goede adviezen 
en rustgevende weekendjes in het zonnige zuiden waren belangrijke momenten voor 
mij in deze hectische periode. Bedankt voor de geweldige ouders die jullie zijn en jullie 
oneindige vertrouwen in mij. 
Lieve Jos, bedankt voor alles. Als ik alle elementen apart ging benoemen had ik nog wel 
twee pagina’s nodig. We weten beide dat ik hier zonder jou nooit had gestaan. Dankjewel 
voor je support, liefde en vooral je eeuwige geduld. Ik kijk uit naar de nieuwe avonturen 
die we samen gaan beleven, want ik weet, met jou naast mij komt alles altijd goed.
Veel liefs,
Liz
153
Chapter 8
